GAF-Tandem Signal Transduktion in Chimeren mit der CyaB1 Adenylat Cyclase als Reporter by Mansi, Iman
 
GAF-Tandem Signal Transduktion in Chimeren mit der CyaB1 
Adenylat Cyclase als Reporter 
 
 
 
 
Interdomain Signal Transduction in GAF Tandem Chimeras 
Using the CyaB1 Adenylyl Cyclase as a Reporter 
 
 
 
DISSERTATION 
 
 
der Fakultät für Chemie und Pharmazie  
der Eberhard-Karls-Universität Tübingen 
 
 
 
zur Erlangung des Grades eines Doktors 
der Naturwissenschaften 
 
 
 
 
2008 
 
 
vorgelegt von 
 
Iman Mansi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tag der mündlichen Prüfung: 18. Juli 2008 
Dekan:    Prof. Dr.L.Wesemann  
Erster Berichterstatter:  Prof. Dr. J.E. Schultz 
Zweiter Berichterstatter:  Prof.Dr. P. Ruth 
Allah sagte: 
’’ihr Menschen! Wir erschufen euch aus einem Mann und einer Frau und machten 
euch zu Völkern und Stämmen, damit ihr einander kennenlernt. Doch der vor Allah 
am meisten Geehrte von euch ist der Gottesfürchtigste unter euch. Allah ist fürwahr 
wissend, kundig’’ 
          (Quran, 49:13) 
 
 
 
۞۞۞۞  
 
All thanks goes to Allah who created me, send me my living, guided me to the right 
path and gave me power and good health to finish this work. 
 
۞۞۞۞ 
 
 
Acknowledgment 
 
The experimental part of this work was performed within the period from August 2004 to 
September 2007 under the supervision of Prof. Dr. J.E.Schultz. 
I would like to thank prof. Schultz for accepting me in his lab., for the beneficial scientific 
discussions and the different subjects he gave. 
I am so grateful to prof. Ruth for taking part in the evaluation of my thesis. 
Prof. Werz and prof. Laufer, I do appreciate your participation in the thesis examination. 
I express my gratitude to Jost Weber and Jürgen Linder for the great help and interest they 
showed at the beginning of my work in the lab and for training me on the handling of the 
different kits and methods. Special thanks to J.Linder for the beneficial discussions, support 
and interest and for providing some of the constructs and templates. Anita Schultz, thanks a 
lot for providing some of the templates and your help in the cloning of three of my constructs. 
And not to forget to thank Gottlieb Daimler und Karl Benz Foundation represented by the 
company managers Prof. Putlitz and Dr. Schade, the manager of the foundation, Dr. Klein and 
his secretary Mrs. Jung and all other employees in the foundation for providing my personal 
finance for two years and for the annual nice meetings with beneficial lectures and interesting 
journeys.  
I am so thankful to Dr. I.Tews and his four-week diploma student, F.Voigts-Hoffmann from 
Heidelberg University, for the efforts they spent to solve the crystal structure of CyaB1 PAS 
domain and from the department of Biochemistry (Tübingen University), Dr. C.Schal for 
measuring the crystals of CyaB2 GAF (∆253-A255) and J.Romer for his help in operating the 
crystallization robot. 
 ‘Meine Deutsch Lehrerin, Frau. Voegt, Ich danke ihnen sehr für ihre Bemühung und Geduld 
während Deutsch Unterrichte’  
My Lab colleagues, my friends in Germany and in Jordan, my family in Germany and in 
Jordan, thank you all, without your love, encouragement and prayers, I will never be able to 
finish this work. 
  
  
 
Content 
 I
Content 
 
Content…………………………………………………………………………… 
 
List of Constructs………………………………………………………………... 
 
Abbreviations…………………………………………………………………….. 
 
Amino acid abbreviations……………………………………………………….. 
 
I 
 
IX 
 
XII 
 
XIV 
1. Introduction………………………………………………………………….. 
Signal transduction………...………………………………………………….. 
 
1.1. Small molecule binding domains……………………………….………... 
1.1.1. GAF domains…...……….……………………………………….. 
1.1.2. PAS domains...………………………………….………………... 
 
1.2. Phosphodiesterases…………………………............................................. 
1.2.1. PDE regulatory domain..………………………………………….. 
1.2.2. PDE catalytic domain...………………………….………………... 
 
1.3. Class III adenylyl cyclase……………………………………………....... 
 
1.4. Cyanobacterium anabaena sp. PCC 7120 Adenylyl cyclases, CyaB1 and 
CyaB2……………………………………………………………………. 
 
1.5. Aim of work…………………………………………………….………... 
 
1 
1 
 
2 
3 
5 
 
6 
8 
10 
 
12 
 
 
12 
 
14 
 
2. Materials and equipments…..………………………………………………. 
 
2.1. Chemicals and Materials…………...…………………………………….. 
 
2.2. Equipments………………………………………………………………. 
 
2.3. Bacterial strains.....……………………………………………………….. 
 
2.4. Plasmids………………………………………………………………….. 
17 
 
17 
 
19 
 
20 
 
21 
Content 
 II 
2.5. Oligonucleotides…………………………………………………………. 
2.5.1. Sequencing primers……………………………………………….. 
2.5.2. Cloning primers………………………………….………………... 
2.5.2.1.CyaB1 holoenzyme…………………………………………… 
2.5.2.2.CyaB2 holoenzyme and mutants..…………………………….. 
2.5.2.3.hPDE5 GAF domain………………………………………….. 
2.5.2.4.rPDE2 GAF domain………………………………………….. 
2.5.2.5.hPDE2 GAF domain………………………………………….. 
 
2.6. Buffers and solutions………..…………………………………………… 
2.6.1. Molecular biology...………………………………………………. 
2.6.1.1.solutions for DNA treatment…...……………………………... 
2.6.1.2.Solutions for bacterial culture media.………………………… 
2.6.1.3.Solutions for blue/white screening....…………………………. 
2.6.2. Protein chemistry…...…………………………….………………. 
2.6.2.1.Protein purification with Ni+2 –NTA- Agarose…….………... 
2.6.2.2.SDS-Polyacrylamide gel electrophoresis...…………………… 
2.6.2.3.Western blot……………………......…………………………. 
2.6.2.4.Cyclase enzyme Assay……………………………………….. 
2.6.2.5.Dimerization buffers………………………………………….. 
2.6.2.6.Other solutions……………………………………………….. 
 
21 
22 
23 
23 
24 
26 
27 
28 
 
29 
29 
29 
29 
29 
30 
30 
30 
31 
31 
32 
33 
3. Methods………………………………………………………………………. 
 
3.1. Bioinformatics and databases……………………………………………. 
 
3.2. Molecular biology methods…………………............................................ 
3.2.1. Polymerase chain reaction………………………………………... 
3.2.2. Isolation of DNA by agarose gel electrophoresis………………… 
3.2.3. Purification of DNA fragment from agarose gel…………………. 
3.2.3.1.Use of DNA purification kit………………………………….. 
3.2.3.2.Use of squeeze-freeze method………………………………... 
3.2.4. Generation of blunt ends…………………………………………. 
3.2.5. 5’-phosphorylation of the PCR product………………………….. 
3.2.6. Dephosphorylation of the plasmid vector………………………… 
3.2.7. Photometric determination of the DNA concentration…………… 
3.2.8. Ligation of the DNA fragments…………………………………... 
3.2.9. Transformation of the recombinant DNA………………………… 
3.2.9.1.Preparation of competent cells………………………………... 
33 
 
33 
 
33 
33 
35 
36 
36 
36 
36 
36 
37 
37 
37 
37 
37 
Content 
 III
3.2.9.2.Transformation of DNA plasmid into competent cells...……... 
3.2.10. White-blue colony screen…………………………………………. 
3.2.11. Isolation of DNA………………………………………………….. 
3.2.11.1. Isolation and purification of DNA from bacterial cultures 
(minipreps)…………………………………………………….. 
3.2.11.2. Phenol/chloroform extraction……………………………... 
3.2.11.3. Ethanol precipitation……………………………....……..... 
3.2.12. Enzymatic digestion………………………………………………. 
3.2.13. Sequencing………………………………………………………... 
3.2.13.1. Chain terminating sequencing…………………………….. 
3.2.13.2. Capillary DNA sequencing….…………………………….. 
3.2.14. Glycerol stock…………………………………………………….. 
 
3.3. Protein chemistry………………………………………………………… 
3.3.1. Preculture…………………………………………………………. 
3.3.2. Expression………………………………………………………… 
3.3.3. Cell harvesting and washing……………………………………… 
3.3.4. Purification of soluble protein from E.coli……………………….. 
3.3.5. Protein dialysis……………...…………………………………….. 
3.3.6. Bio-Rad protein determination……………………………………. 
3.3.7. Sample concentration……………………………………………... 
3.3.8. SDS-PAGE………………………………………………………... 
3.3.9. Western blot………………………………………………………. 
3.3.10. Adenylyl cyclase enzyme assay…………………………………... 
3.3.11. Crystallization…………………………………………………….. 
3.3.11.1. Hanging-drop vapour diffusion method…………………... 
3.3.11.2. Sitting-drop vapour diffusion method...…………………... 
3.3.12. Size exclusion chromatography (Gel filtration)…………………... 
3.3.13. Dimerization studies…………………………………………….... 
 
3.4. Cloning…………………………………………………………………… 
3.4.1. Cloning of hPDE2 constructs……………………………………... 
3.4.1.1. Cloning of hPDE2NGAF/CyaB1 chimera…………………… 
3.4.1.2. Cloning of ΔN-hPDE2GAF/CyaB1 chimera………………… 
3.4.1.3. Cloning of hPDE5N-hPDE2GAF/CyaB1 chimera…………... 
3.4.1.4. Cloning of rPDE2GAF/CyaB1………………………………. 
3.4.2. Cloning of CyaB2 constructs and mutants………………………... 
3.4.2.1. Cloning of (Δaa or + aa)/CyaB1……………………………... 
3.4.2.2.Cloning of CyaB2 (ΔR253-A254)/CyaB1……………………. 
38 
38 
38 
 
38 
38 
39 
39 
39 
39 
40 
41 
 
41 
41 
41 
42 
42 
42 
42 
42 
43 
44 
45 
46 
46 
46 
47 
49 
 
50 
53 
53 
54 
55 
57 
58 
58 
60 
Content 
 IV 
3.4.2.3.Cloning of CyaB2 (ΔR253-A255) GAFcr for crystallization… 
3.4.2.4.Cloning of CyaB2 (256 + NAA)cr, CyaB2 
(M258L/M259L)GAF and CyaB2 (M258S/M259T)GAF…….. 
3.4.2.5.Cloning of CyaB2 (M74G/L75G)/CyaB1 and CyaB2 
(M74S/L75T)/CyaB1………………………………………….. 
3.4.2.6.Cloning of CyaB2 α2-mutants (CyaB2 (M87S)/CyaB1, 
CyaB2 (L88S)/CyaB1 and CyaB2(M87A/L88S)/CyaB1)…….. 
3.4.2.7.Cloning of CyaB2 connecting helix-mutants (CyaB2 
(M258A/M259A)/CyaB1, CyaB2 (M258L/M259L)/CyaB1, 
CyaB2 (M258G/M259G)/CyaB1and CyaB2 (M258S/M259T)/ 
CyaB1………………………………………………………….. 
3.4.2.8.Cloning of CyaB2 (M74S/L75T/M258S/M259T)/CyaB1……. 
3.4.2.9.Cloning of CyaB2 (M258T)/CyaB1………………………….. 
3.4.2.10. Cloning of CyaB2 (GAFlinker1)/CyaB1………………….. 
3.4.3. Cloning of hPDE2 mutants……………………………………….. 
3.4.3.1.Cloning of hPDE2NGAF/CyaB1 α1-helix mutants …………. 
3.4.3.2.Cloning of hPDE2NGAF/CyaB1 –connecting helix mutants... 
3.4.3.3.Cloning of Cloning of the quadruple mutant of 
hPDE2GAF/CyaB1………………………………………….… 
3.4.3.4.Cloning of hPDE2NGAFcr…………………………………… 
3.4.3.5.Cloning of ΔN-hPDE2GAFcr………………………………… 
3.4.3.6.Cloning of ΔN-hPDE2GAF (L396A/L397A)cr………………. 
3.4.3.7.Cloning of hPDE2NGAF (L396A/L397A)cr………………… 
3.4.3.8.Cloning of ΔN-hPDE2GAF (I230A/L231A/L396A/L397A)cr. 
3.4.4. Cloning of hPDE5 mutants……………………………………….. 
3.4.4.1.Cloning of hPDE5NGAF(L152A/L153A)/CyaB1 …………... 
3.4.4.2.Cloning of hPDE5NGAF (L333A/L334A)/CyaB1 and 
hPDE5NGAF (L152A/L153A/L396A/L397A)/CyaB1….……. 
3.4.4.3.Cloning of hPDE5NGAF and mutants………………………... 
3.4.4.4.Cloning of ΔN-hPDE5GAF (L333A/L334A)………………… 
3.4.4.5.Cloning of ΔN-hPDE5GAF (L152A/L153A/L333A/L334A)... 
3.4.5. Cloning of CyaB1 constructs……………………………………... 
3.4.5.1.Displacement of CyaB1 PAS by hPDE5 catalytic linker…….. 
3.4.5.2.Cloning of Constructs IA and IB…………………………….. 
3.4.5.3.Cloning of CyaB1(PAS2)/CyaB1…………………………...... 
3.4.5.4.Cloning of CyaB1 (571+L)…………………………………… 
3.4.5.5.Cloning of CyaB1 PAS and CyaB1 PAS/catalytic for 
crystallization purposes……………………………………….. 
3.4.5.6.Cloning of CyaB1 GAFcr for crystallization purposes………. 
61 
 
62 
 
63 
 
65 
 
 
 
66 
67 
68 
70 
73 
73 
75 
 
77 
78 
79 
79 
80 
80 
 
81 
 
83 
84 
85 
85 
87 
87 
89 
91 
93 
 
95 
96 
Content 
 V
3.4.5.7.Cloning of CyaB2 PAS and CyaB2 catalytic domain for 
crystallization purposes……………………………………….. 
3.4.5.8.Cloning of CyaB2 PAS/catalytic domain for crystallization 
purposes………………………………………………………. 
 
 
97 
 
98 
4. Results………………………………………………………………………. 
 
4.1. The effect of the N-terminal domain on signaling in the PDE2 GAF 
tandem/CyaB1 chimera………………………………………………….. 
4.1.1. Biochemical characterization of hPDE2NGAF/CyaB1 chimera … 
4.1.1.1.Expression and purification of hPDE2NGAF /CyaB1 chimera. 
4.1.1.2.Protein dependence …………………………………………... 
4.1.1.3.Dose response study of hPDE2NGAF/CyaB1 Chimera……… 
4.1.1.4.Time dependence……………………………………………... 
4.1.1.5.Temperature dependence…………………………………….. 
4.1.1.6.pH dependence……………………………………………….. 
4.1.1.7.ATP kinetics………………………………………………….. 
4.1.2. Effect of N-terminus on CyaB1 AC activity……………………… 
4.1.2.1.Expression and purification of the protein……………………. 
4.1.2.2.Protein dependence …………………………………………... 
4.1.2.3.Dose response study…………………………………..………. 
4.1.2.4.Time dependence……………………………………………… 
4.1.2.5.Substrate kinetics……………………………………………... 
4.1.2.6.Crystallization of ∆ N1-227-hPDE2GAF/CyaB1………………. 
4.1.3. Exchange by hPDE5 N-terminus…………………………………. 
4.1.3.1.Protein dependence …………………………………………... 
4.1.3.2.Dose response study…………………………………..………. 
4.1.4. Truncation of rat PDE2GAF.CyaB1 N-terminus…………………. 
 
4.2. Role of the connecting helix of the GAF-tandem……………………….. 
4.2.1. CyaB2 GAF tandem………………………………………………. 
4.2.1.1.Biochemical characterization of CyaB2 GAF/CyaB1 AC 
chimera………………………………………………………… 
4.2.1.2.Role of the connecting helix length…………….…………….. 
4.2.1.2.1. Shortening of the connecting helix…….……………... 
4.2.1.2.2. Elongation of the connecting helix………..………...... 
4.2.1.2.3. Exchange of the connecting helix…………………….. 
4.2.1.3.Crystallization of CyaB2 (∆ R253-A255) and CyaB2 
(256+NAA)……………………………………………………. 
99 
 
 
99 
99 
100 
101 
101 
102 
103 
104 
104 
105 
106 
106 
107 
107 
108 
109 
110 
111 
111 
112 
 
114 
114 
 
114 
115 
116 
118 
120 
 
122 
Content 
 VI 
4.2.1.3.1. CyaB2GAF (∆ R253-A255)……………….………….. 
4.2.1.3.2. CyaB2GAF (256 + NAA)cr ………………..……….... 
4.2.1.4.Mutation of GAFa α – helices………………………………… 
4.2.1.4.1. α1-helix………………………………..……………… 
4.2.1.4.2. α2-helix……………………………………………….. 
4.2.1.5.Mutation of connecting helix of CyaB2 GAF………………… 
4.2.1.6.Dimerization study and gel filtration…………………………. 
4.2.1.7.Crystallization of CyaB2 PAS (444-568), catalytic (569-860 
and PAS/catalytic (444-860) domains…………………………. 
4.2.2. hPDE2 GAF tandem……………………………………………… 
4.2.2.1.Mutation of GAFa α1– helix...……………………………....... 
4.2.2.2.Mutation of the connecting helix of hPDE2NGAF/CyaB1…... 
4.2.2.3.Quadruple mutation of both helices…………………………... 
4.2.2.4.Crystallization of hPDE2GAF ± N-terminus………………..... 
4.2.2.4.1. hPDE2NGAFcr……………….………………………. 
4.2.2.4.2. ∆ N-hPDE2 GAF ………………..……….................... 
4.2.2.5.Glutaraldehyde dimerization and gel filtration of hPDE2GAF 
and mutants …………………………………………………… 
4.2.3. hPDE5 GAF tandem……………………………………………… 
4.2.3.1.hPDE5/CyaB1 mutants...……………………………............... 
4.2.3.2.Dimerization by Glutaraldehyde and gel filtration of hPDE5 
and mutants……………………………………………………. 
 
4.3. Signal transduction through the PAS domain of CyaB1………………… 
4.3.1. Exchange of CyaB1 PAS domain by the PDE5 linker…………… 
4.3.1.1.Control (truncated catalytic domains)………............................ 
4.3.1.2.Category A ……………………………………..….................. 
4.3.1.3.Category B……………………………………………………. 
4.3.2. Exchange of CyaB1 PAS domain by CyaB2 PAS domain……….. 
4.3.3. Insertion of tetradekapeptide linker between PAS and catalytic 
domains of CyaB1…………………………………………………... 
4.3.4. Crystallization trials of the CyaB1 domains……………………… 
4.3.4.1. Crystallization of CyaB1 GAF domain..................................... 
4.3.4.2.Crystallization of CyaB1 PAS domain…...…........................... 
4.3.4.3.Crystallization of Catalytic and PAS/catalytic domains of 
CyaB1………………………………………………………….. 
 
122 
125 
126 
126 
128 
130 
135 
 
136 
137 
137 
140 
142 
144 
144 
145 
 
146 
150 
151 
 
154 
 
159 
159 
160 
164 
165 
167 
 
170 
172 
172 
175 
 
179 
 
 
 
 
Content 
 VII
5. Discussion……………………………………………………………………. 
 
5.1. Biochemical characterization of hPDE2NGAF/CyaB1 chimera………… 
5.1.1. hPDE2NGAF/CyaB1 chimera had a 5-fold stimulation upon 
binding of cGMP ……………………….…………………………... 
 
5.2. Role of the N-terminal domain on the activity and regulation of 
PDE2/CyaB1 chimera……………………………………………………. 
5.2.1. Effect of the hPDE2 N-terminus….................................................. 
5.2.2. Effect of hPDE5 N-terminus on the regulation and activity of 
hPDE2/CyaB1 AC chimera................................................................. 
5.2.3. The CyaB1 N-terminus reduced the fold stimulation by cGMP of 
rat PDE2 GAF……………………………………………………….. 
 
5.3. Role of the connecting helix in the signal transduction………………….. 
5.3.1. Shortening and elongation of the connecting helix of CyaB2GAF 
disturb dimerization and signaling……………………....................... 
5.3.2. The effect of CyaB1 connecting helix on the signaling of CyaB2 
GAF……………………..………………………………………….. 
5.3.3. The role of the two hydrophobic residues (ML) in α1 and α2 
helices of CyaB2 GAF………………………………………………. 
5.3.4. The role of two methionines in the connecting helix on 
dimerization and signaling…………………………………………... 
5.3.5. Mutation of two hydrophobic aa residues in the α1-helix and 
another in the connecting helix disturbed the dimerization of hPDE2 
and hPDE5 GAF domain……………………………...…………….. 
 
5.4. Signal transduction through CyaB1 PAS domain……………………….. 
5.4.1. Is it determined by the binding of a divalent cation to the PAS 
domain?…………………………….…………………....................... 
5.4.2. CyaB1 catalytic domain utilizes only one ATP catalytic core 
depends on the truncation…………………………………………… 
5.4.3. The linker of hPDE5 can transduce the signal between GAF and 
catalytic domains of CyaB1 but with less efficiency……………….. 
5.4.4. Exchange of the PAS domain by that of CyaB2 is still able to 
transduce the signal but with less efficiency………………………... 
5.4.5. The insertion of a flexible linker between the catalytic linker and 
the catalytic domain of CyaB1 completely destroyed signaling to 
the catalytic domain…………………………………………………. 
183 
 
183 
 
183 
 
 
185 
185 
 
186 
 
186 
 
187 
 
187 
 
189 
 
189 
 
191 
 
 
192 
 
194 
 
194 
 
195 
 
197 
 
199 
 
 
199 
Content 
 VIII
5.4.6. Crystallization of CyaB1 PAS domain…………………………… 
5.4.7. Discovering of metal ligand for the CayB1 PAS…………………. 
5.4.8. Importance of this work…………………………………………... 
5.4.9. Open questions and outlook………………………………………. 
200 
201 
201 
201 
6. Conclusion…………………………………………………………………… 
 
7. Appendix…………………………………………………………………….. 
 
8. References…………………………………………………………………… 
 
203 
 
205 
 
225 
 
 
 
 
  
 
  
 
List of constructs   
 IX
List of constructs 
 
1. hPDE2 constructs 
 
Construct  Description 
1. hPDE2NGAF/CyaB1 hPDE21-558-CyaB1386-859 
2. ∆N-hPDE2GAF/CyaB1 hPDE2228-558-CyaB1386-859 
3. hPDE5N-PDE2GAF/CyaB1 hPDE51-150- hPDE2228-558-CyaB1386-859 
4. ∆N-rPDE2GAF/CyaB1 rPDE2207-546-CyaB1386-859 
5. hPDE2 (I230S)/CyaB1 hPDE21-558 (I230S)-CyaB1386-859 
6. hPDE2 (L231S)/CyaB1 hPDE21-558 (L231S)-CyaB1386-859 
7. hPDE2 (C393S)/CyaB1 hPDE21-558 (C393S)-CyaB1386-859 
8. hPDE2 (L396A/L397A)/CyaB1  hPDE21-558 (L396A/L397A)-CyaB1386-859 
9. hPDE2 (C393S/L396A/L397A)/CyaB1 hPDE21-558 (C393S/L396A/L397A)-CyaB1386-859 
10. ∆N-hPDE2 (I230A/L231A/L396A/ 
L397A)/CyaB1 
hPDE2228-558 (I230A/L231A/L396A/L397A)/ CyaB1386-
859 
11.hPDE2NGAFcr hPDE2 1-562 for crystallization 
12. ∆N-hPDE2cr hPDE2 228-562 for crystallization 
13. hPDE2NGAF (L396A/L397A) hPDE2 1-562 (L396A/L397A) 
14. ∆N-hPDE2GAF (L396A/L397A) hPDE2 228-562 (L396A/L397A) 
15. ∆N-hPDE2GAF (I230A/L231A/L396A 
/L397A) 
hPDE2GAF 228-562 (I230A/L231A/L396A/ L397A) 
 
2. CyaB2 constructs 
 
Construct Description 
1. CyaB2(∆R253)/CyaB1 CyaB21-252-CyaB2254-441-CyaB1386-859 
2. CyaB2(∆R253-A254)/CyaB1 CyaB21-252-CyaB2255-441-CyaB1386-859 
3. CyaB2(∆R253-A255)/CyaB1 CyaB21-252-CyaB2256-441-CyaB1386-859 
4. CyaB2(∆R253-A256)/CyaB1 CyaB21-252-CyaB2257-441-CyaB1386-859 
5. CyaB2(256+NAA)/CyaB1 CyaB21-256-NAA-CyaB2257-441-CyaB1386-859 
6. CyaB2(256+NAAI)/CyaB1 CyaB21-256-NAAI-CyaB2257-441-CyaB1386-859 
7. CyaB2(M74G/L75G)/CyaB1 CyaB21-441 (M74G/L75G)-CyaB1386-859 
8. CyaB2(M74S/L75T)/CyaB1 CyaB21-441 (M74S/L75T)-CyaB1386-859 
9. CyaB2(M87S)/CyaB1 CyaB21-441 (M87S)-CyaB1386-859 
10. CyaB2(L88S)/CyaB1 CyaB21-441 (L88S)-CyaB1386-859 
11. CyaB2(M87A/L88S)/CyaB1 CyaB21-441 (M87A/L88S)-CyaB1386-859 
12. CyaB2(M258T)/CyaB1 CyaB21-441 (M258T)-CyaB1386-859 
List of constructs   
 X 
13. CyaB2(M258L/M259L)/CyaB1 CyaB21-441 (M258L/M259L)-CyaB1386-859 
14. CyaB2(M258G/M259G)/CyaB1 CyaB21-441 (M258G/M259G)-CyaB1386-859 
15. CyaB2(M258A/M259A)/CyaB1 CyaB21-441 (M258A/M259A)-CyaB1386-859 
16. CyaB2(M258S/M259T)/CyaB1 CyaB21-441 (M258S/M259T)-CyaB1386-859 
17. CyaB2(M74S/L75T/M258S/M259T)/ 
CyaB1 
CyaB21-441 (M74S/L75T/M258S/M259T)-CyaB1386-859 
18. CyaB2(GAFlinker1)/CyaB1 CyaB21-230-CyaB1197-229-CyaB2264-441-CyaB1386-859 
19. CyaB2 ((∆R253-A255)cr CyaB258-252-CyaB2256-445 for crystallization 
20. CyaB2(256+NAA)cr CyaB258-256-NAA-CyaB2257-445 for crystallization 
21. CyaB2(M258L/M259L) CyaB258-445 (M258L/M259L) 
22. CyaB2 (M258S/M259T) CyaB258-445 (M258S/M259T) 
23. CyaB2PAS/Cat CyaB2444-860 for crystallization 
24. CyaB2PAS CyaB2444-568 for crystallization 
25. CyaB2Catalytic CyaB2569-860 for crystallization 
 
3. hPDE5 constructs 
 
Construct Description 
1. hPDE5(L152A/L153A)/CyaB1 hPDE51-513(L152A/L153A)-CyaB1386-859 
2. hPDE5(L333A/L334A)/CyaB1 hPDE51-513(L333A/L334A)-CyaB1386-859 
3. hPDE5(L152A/L153A/L333A/L334A)/ 
CyaB1 
hPDE51-513(L152A/L153A/L333A/L334A)-CyaB1386-
859 
4. hPDE5NGAF hPDE51-517 
5. hPDE5(L152A/L153A) hPDE51-517(L152A/L153A) 
6. hPDE5(L333A/L334A) hPDE51-517(L333A/L334A) 
7. hPDE5(L152A/L153A/L333A/L334) hPDE51-517(L152A/L153A/L333A/L334A) 
8. ∆N-hPDE5cr (from Ana Banjac) hPDE5136-517 
9. ∆N-hPDE5(L333A/L334A) hPDE5136-517(L333A/L334A) 
10. ∆N-hPDE5(L152A/L153A/L333A/ 
L334A) 
hPDE5136-517(L152A/L153A/L333A/ L334A) 
 
4. CyaB1 constructs 
 
Construct Description 
1. Construct IA CyaB11-387 –hPDE5513-537 –CyaB1595-859 
2. Construct IIA CyaB11-387 –hPDE5513-537 –CyaB1589-859 
3. Construct IIIA CyaB11-387 –hPDE5513-537 –CyaB1572-859 
4. Construct IVA CyaB11-387 –hPDE5513-537 –CyaB1560-859 
List of constructs   
 XI
5. Construct IB CyaB11-387 –hPDE5513-548 –CyaB1595-859 
6. Construct IIB CyaB11-387 –hPDE5513-548 –CyaB1589-859 
7. Construct IIIB CyaB11-387 –hPDE5513-548 –CyaB1572-859 
8. Construct IVB CyaB11-387 –hPDE5513-548 –CyaB1560-859 
9.Construct I (from T.Kanacher) CyaB1595-859 
10.Construct II (from J.Linder) CyaB1589-859 
11.Construct III (from J.Linder) CyaB1572-859 
12.Construct IV (from J.Linder CyaB1560-859 
13.CyaB1GAF (from A.Schultz) CyaB142-389 
14.CyaB1PAS CyaB1387-571 
15. CyaB1PAS/catalytic CyaB1387-859 
16. CyaB1(PAS2)/CyaB1 CyaB11-387 –CyaB2444-570 –CyaB1570-859 
17.CyaB1(571 + L) CyaB11-571 –TRAAGGPPAAGGLE-CyaB1572-859 
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Abbreviations 
 
 
Abb. Illustration 
AA/Bis Acrylamide/ Bisacrylamide (37.5:1) 
Amp Ampicillin 
AC Adenylyl cyclase 
aa amino acid 
bp base pair 
bPDE2 Bovine phosphodiesterase 2 
BSA Bovine serum albumine 
cpm counts per minute 
CyaB1/CyaB2 adenylate cyclases CyaB1/CyaB2 from Anabaena sp. PCC 
7120 
CyaB1 AC Catalytic domain of CyaB1 enzyme 
dNTP deoxy nucleoside triphosphate 
ddNTP dideoxy nucleoside triphosphate (for sequencing) 
EtBr Ethidium bromide 
ESRF European Synchrotron Radiation Facility 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hPDE2 human phosphodiesterase 2 
IPTG Isopropyl thiogalactoside 
LB- medium Luria-Bertani culture medium for bacteria 
MCS Multiple cloning site 
MES 2-(N-Morpholino) ethanesulphonic acid 
Min Minute 
Ni+2-NTA agarose Nickel-nitrilotriacetic acid Agarose 
ORF open reading frame 
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PAGE Polyacrylamide gel electrophoresis 
PDE’s  Phosphodiesterase (s) 
PEG Polyethylene Glycol 
rPDE2 rat phosphodiesterase 2 
rpm revolution per minute 
RT room temperature 
Sec Second 
SMBDs small molecules binding domain 
TBS Tris buffered saline 
TEMED N,N,N’,N’-trimethylethylene diamine 
Tris 2-amino-2-hydroxymethyl-propane-1,3-diol 
WT Wild type 
X-Gal  5-bromo-4-chloro-3-indolyl-β-D- Galactopyranoside 
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Abbreviation for aa residues 
 
1 letter code 3-letters code  Full name 
A  Ala  Alanine 
C  Cys  Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe  Phenylalanine  
G Gly  Glycine  
H His  Histidine  
I Ile  Isoleucine  
K Lys  Lysine  
L Leu Leucine  
M Met Methionine  
N Asn Asparagine 
P  Pro Proline  
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine  
V Val Valine 
W Trp Tryptophane 
Y Tyr Tyrosine 
X  Any residue 
aa  Amino acid 
 
Abbreviation of bases 
 
A: Adenine 
T: Thymine 
G: Guanine 
C: Cytosine 
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1 Introduction 
Signal transduction         
Living organisms usually adapt themselves to continuous changes of the environment. The 
control of biological function occurs at the systematic, cellular and molecular level. Cells in 
the pluricellular organisms do not respond only to exterior inputs, but to substances produced 
by other cells of the same organism.  
The availability of complete genome sequences of organisms representing each of the three 
divisions of cellular life (bacteria, archaea and eukaryota) has provided unprecedented 
opportunities for comparative analysis of the relative significance of different regulatory 
processes in these organisms. Regulatory mechanisms can be classified into partially 
overlapping broad categories in the basis of the sites and targets of their action. One of these 
categories is signal transduction (signaling) whereby an extracellular or intracellular stimulus 
leads to a cascade of molecular interactions that affects one or more cellular functions 
resulting in a response to the initial signal [1]. 
From the time of their identification by Rall and Sutherland in 1958 [2-4], the cyclic 
nucleotide second messengers, cAMP and cGMP, were considered to be key molecules for 
transducing the action of extracellular signals such as hormones, neurotransmitters, and light 
into the most diverse cell functions, thus playing an important role in a wide array of 
physiological processes that include vision, cell growth and division, memory, and immune 
responses [5-7]. Cellular activation of adenylate and guanylate cyclases, respectively, results 
in the cyclization of ATP and GTP to 3′-5′ cyclic adenosine monophosphate (cAMP) and 3′-5′ 
cyclic guanosine monophosphate (cGMP) respectively. Each of them activates in addition to 
other enzymes, protein kinases, the protein kinase activated by cAMP (PKA) and the protein 
kinase activated by cGMP. Activated PKA and PKG are able to phosphorylate a number of 
cellular effector proteins (for example ion channels, G-protein-coupled receptors, structural 
proteins). It is possible in this way for the second messengers to control a wide variety of 
physiological processes in a wide variety of organs. However, the cyclic nucleotides are also 
able to act directly on effector molecules. Thus, it is known, for example, that cGMP can act 
directly on ion channels and thus can influence the cellular ion concentration. The 
phosphodiesterases (PDEs) are a control mechanism for controlling the activity of cAMP and 
cGMP. PDEs hydrolyse the cyclic monophosphates to monophosphates AMP and GMP 
(Fig.1.1) [8, 9]. 
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Fig.1.1: cyclic nucleotide signaling and regulation. Localization of fundamental molecules involved in 
cAMP and cGMP signalling is illustrated. Effector molecules of cAMP and cGMP are indicated by 
arrows from each cyclic nucleotide. Phosphorylation of PDEs by PKA and PKG is demonstrated by 
dotted arrows. Modulation by PDE activity by cGMP is shown by thick arrow. Cellular and 
physiological outputs of cyclic nucleotide signaling are shown in gray-coloured boxes. NPs indicate 
natriuretic peptides; NO, nitric oxide; NPRs, natriuretic peptide receptors; sGCs, soluble guanylyl 
cyclases; AC, adenylyl cyclases; Gs, GTP-binding protein α subunit; GPCRs, G protein-coupled 
receptors; Epac, exchange protein directly activated by cAMP; CNG-channel, cyclic nucleotide-gated 
channel. Image taken from [9]. 
 
Until recently, it has been difficult to understand how these simple, small, second messenger 
molecules could provide both the specificity of action and the diversity of function necessary 
for such regulation [10]. 
 
1.1 Small molecule binding domains (SMBD)    
The ability to sense small molecules is the key for every life form and provides information 
about the extracellular environment, monitors intracellular physiological status, or establishes 
cell-cell communication. Sensory signaling proteins are often modular in nature with distinct 
domains for ligand sensing and for output signals. A number of these domains are abundant in 
bacteria and animals [11]. 
SMBDs are compact globular domains distinct from the catalytic domains of the respective 
enzymes, whose principal biochemical role is to exert a regulatory effect and/or to transmit 
signal by binding a small molecule. This can include small molecule-mediated regulation of 
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transcription (kinases), signal transduction (PDEs and phosphatases) and transport (membrane 
associated ABC ATPases) [1, 12] 
Most of the SMBD are relatively small domains, often ~ 100 amino acid residues in length, 
and in general, their sequences do not share high similarities as those of enzymatic domains. 
More than 21 SMBD were identified in the database for example: PAS (PER, ARNT, SIM), 
GAF (cGMP-PDE, Adenylyl cyclase, FhlA), ACT (Aspartokinase, Chorismate mutase, 
TyrA), CBS (Cystothionine β-Synthase), cNMPBD (cyclic Nucleotide MonoPhosphate 
Binding Domain), HAMP domain (Histidine kinases, Adenylyl cyclases, Methyl-accepting 
chemotaxis protein and Phosphatases) and many other domains. Several SMBD were found to 
be fused to enzymatic domains involved in metabolic reactions which suggests the regulation 
of the catalytic activity through small molecule binding [1]. 
 
1.1.1 GAF Domains 
The GAF domain is one of the largest families of small molecule binding regulatory domains 
[13]. Although ligand binding was documented for only few predicted GAFs, ligand binding 
GAF domains have been shown to bind formate, aromatic compounds (e.g. tetrapyrrole and 
photopigments) and cyclic nucleotides. GAF domains are found in many different proteins in 
nearly all phyla, including histidine kinases, phosphotransferases, ATPases, cyclases and 
phosphodiesterases. The acronym GAF is derived from mammalian cGMP-activated PDEs, 
Anabaena Adenylyl cyclases, and E.coli Formate hydrogen lyase transcription activator 
(FhlA), enzymes where they were initially recognized [14, 15]. GAF domains have been 
shown to be associated with gene regulation in bacteria, light-detection and signalling 
pathways in plants and cyanobacterial phytochromes, ethylene detection and signalling in 
plants, nitrogen fixation in bacteria, feed forward control of cyanobacterial ACs by cAMP 
binding and the two component sensor histidine kinase in viruses, bacteria and plants [14, 16]. 
Figure 1.2 shows the abundance of GAF domains in different phyla. 
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Fig.1.2: Domain structures of mammalian GAF and PAS domain-containing phosphodiesterases and 
other representative GAF domain proteins. Image is taken from ref. [17]. 
 
The PDE superfamily is the only group of mammalian proteins known to have GAFs; all 
isoforms of five families (PDEs 2, 5, 6, 10 and 11) contain a tandem GAF (a and b), and in 
PDEs 2, 5, 6, and 11, at least one GAF forms an allosteric site for cGMP binding while the 
GAF domain of PDE10 forms an allosteric binding site for cAMP [13, 18, 19]. In addition to 
cyclic nucleotide binding, GAF domains of mammalian PDEs are involved in protein-protein 
interactions that provide for homologous and heterologous dimerization of PDE catalytic 
monomer as well as for binding of PDE6 catalytic monomers with specific members of the 
family of inhibitory proteins known as Pγ [20]. The dimerization in PDEs may be important 
for regulation, enzyme stability, subcellular localization, or other features. The importance of 
GAF domains and cGMP allosteric interactions in the PDEs is illustrated by the H258D 
mutation in the GAFa domain of human PDE6B, which causes the autosomal dominant 
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congenital stationary night blindness [21]. In addition, recessive mutations in hPDE6B gene 
that cause truncations in the gene product result in retinitis pigmentosa [22]. 
Up to date, four GAF domains have been structurally elucidated. The yeast GAF domain, 
YKG9, resolved at 1.9 Ǻ, was the first GAF domain crystal structure to be elucidated and was 
found to form a homodimer with no ligand binding [17]. Another two are cyclic nucleotide 
binding-GAF tandems. Mouse PDE2 GAF tandem, resolved at 2.9 Ǻ, is a parallel dimer with 
cGMP molecule bound to the GAF b subdomain of each monomer. The tandem GAF domain 
of the CyaB2 AC, resolved at 1.9 Ǻ, which is an antiparallel dimer with four cAMP molecules 
bound to each subdomain, GAF a and b, of both monomers [23, 24]. The last GAF crystal 
structure  was an E.coli fRMsr (methionine-R-sulfoxide reductase), which was resolved at 2.1 
Ǻ and considered to represent a GAF domain with enzymatic activity [25]. 
Even among cGMP-binding PDEs the functions of the respective GAFs are not conserved. 
Many questions remain unclear regarding the structure-function relationships within the 
regulatory domain of these PDEs, the role of GAFs a and b in function and physical 
parameters that provide for cGMP binding and regulation of function by post-translational 
modifications such as phosphorylation [15]. 
The presence of the GAF domains in almost half of the mammalian PDEs families makes 
them particularly attractive therapeutic targets for manipulation of cAMP and cGMP 
signalling [13]. 
 
1.1.2 PAS Domains 
The PAS domain is one of the regulatory modules that can be found in proteins in all 
kingdoms of life (archaea, bacteria and eukarya) [14, 26-28]. The PAS module was first 
identified in the Drosophilla clock protein PER, and the basic helix-loop-helix containing 
transcription factor ARNT (aryl hydrocarbon receptor nuclear translocator) in mammals and 
SIM (single minded protein) in insects [29], and it is considered one of the important 
signaling modules that monitors changes in light, redox potential, oxygen, small ligands, or 
the overall energy level of a cell [26, 30-32], in addition to their role in mediating protein-
protein interactions [1]. 
These domains are sometimes referred to as LOV domains (Light, Oxygen or Voltage 
domains). Unlike many other sensory domains, PAS domains are located in the cytoplasm 
[26] and are found in serine/threonine kinases [33],  histidine kinases [34], photoreceptors and 
chemoreceptors for taxis and tropism [35], cyclic nucleotide phosphodiesterase [36], circadian 
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clock proteins [37, 38], voltage activated ion channels [39], as well as regulators of responses 
to hypoxia [40] and embryological development of the central nervous system [29]. Most 
PAS domains bind cofactors or ligands, which are required for the detection of sensory input 
signals [31]. 
PAS domains convert various input stimuli into signals that propagate to downstream 
components by altering intra- or intermolecular protein-protein interactions. The mechanisms 
whereby PAS domains transmit the input signal into the effector domain are of great current 
interest but are poorly understood [41]. 
The specificity in sensing arises from cofactors that are associated with PAS domains: p-
hydroxycinnamic acid in the bacterial photoactive yellow protein, PYP [42]; a heme in the 
bacterial oxygen sensor FixL [43]; and flavin adenine dinucleotide (FAD) in a bacterial redox 
potential sensor NifL [44]. A plant photoreceptor, NPH1 that also senses redox potential has a 
flavin mononucleotide (FMN) cofactor in its PAS domain [45].  
The PAS domain superfamily is highly diverse in sequence and in length but is suggested to 
share the common conformational flexibility  and the basic three dimensional (3D) structure, 
consisting of a PAS core motif, helical connector and a PAC motif [30, 46]. 
Similar to the GAF domain, mutations in the PAS domain were also found to cause inherited 
diseases. A mutation in the HERG PAS domain (T65P) of K+ channel in the heart causes 
congenital long QT syndrome which manifests itself by a prolonged QT interval on the 
electrocardiogram and by a propensity for tachyarrhythmias causing syncope and sudden 
death [47]. 
 
1.2 Phosphodiesterases        
 Phosphodiesterases split the phosphodiester bond and generate the mononucleotides. PDEs 
are classified by their primary structure similarities into three classes [48]: 
¾ The class I domain: all share a C-terminal catalytic domain of 250 aa’s with the 
invariant motif H(X)3H(X)25-35D/E that forms the two metal ion binding sites in the 
active centre [49].This class includes all mammalian PDEs, as well as several genes 
identified in Drosophila, Caenorhabditis and yeast.  
¾ The class II domain: shares the signature sequence HXHLDH in its catalytic domain 
which may be part of a metal ion binding site. Class II is comprised of a few enzymes 
from Saccharomyces cervesae (PDE gene 1 product), Dictyostelium discoideum, 
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Schizosacchromyces pombe, Candida albicans and a periplasmic PDE from Vibrio 
fischeri. 
¾ Class III PDE domain: cpdA gene of E.coli [48]. 
 
Twenty-one genes encoding PDEs have been identified in the human genome [50, 51], and 
corresponding proteins have been characterized in terms of their physicochemical properties 
and regulatory properties [6, 7]. Based in their sequence relatedness, kinetics, modes of 
regulation and pharmacological properties, the class I mammalian PDEs can be further 
subdivided into 11 families (PDE1 – PDE11)[52]. The different PDEs of the same family are 
functionally related despite the fact that their amino acid sequences show considerable 
divergence. Functional analyses and amino acid sequence comparisons of various PDEs 
indicate that all PDEs are multidomain proteins with different domains functioning in 
catalysis and regulation of activity [53]. Table 1.1 shows the different characteristics of 
different PDEs. 
PDEs affect the cellular levels of cyclic nucleotides. Inhibiting these enzymes is an attractive 
strategy in the development of smooth-muscle relaxants and drugs to treat inflammatory 
diseases, asthma, chronic obstructive pulmonary disease, depression and many other diseases. 
The first selective inhibitor was PDE5-inhibitor, ViagraTM (Sildenafil), which was marketed 
for the treatment of male erectile dysfunction and later for pulmonary hypertension. This was 
followed by developing more selective PDE5-inhibitors and other PDE inhibitors [54-56]. 
Because all PDEs share a high degree of sequence similarity in their catalytic domain, the 
selectivity profile of all inhibitors at least partially overlap [10]. At the time that PDE4 
inhibitors cause nausea and emesis, possibly by inhibiting PDE4D in the brain, sildenafil and 
related PDE5 inhibitors exhibit cross-reactivity with PDE6 and PDE11, which is thought to be 
responsible for side effects such as blue-tinged vision and back and muscle pain. Information 
about the binding mode of PDE inhibitors will therefore be crucial for the design of drugs that 
target these enzymes in a more selective manner [57]. 
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Table 1.1: Biochemical characteristics of human PDE families modified according to [9, 58]: 
Localisation Gene 
Family 
Substrate  
Tissue Intracellular 
Inhibitors 
hPDE1 
A/B 
C 
 
cGMP>cAMP 
cGMP=cAMP 
Brain, smooth 
muscles, heart ,testis 
cytosolic Vinpocetine, ICOS, 
SCH51866 
hPDE2A cGMP=cAMP Adrenal cortex, brain, 
heart 
PDE2A1 is cytosolic 
while PDE2A2 and A3 
are membrane- bound 
EHNA, BDP, BAY 60-
7550, IC933 
hPDE3 
A/B 
 
cGMP<cAMP 
Heart, smooth muscle, 
adipose tissue, 
platelets 
A membrane bound or 
cytosolic but B is 
membrane bound 
Cilostamide, Milrinone, 
Trequinsin, Cilastazol, 
OPC-33540 
hPDE4 
A/B/C/D 
 
cAMP 
Ubiquitous (immune 
system, olfactory 
system, Brain, testis, 
lung and other tissues) 
PDE4A5 is membrane 
bound but other 
splices are 
predominantly 
cytosolic 
Rolipram, Ruflumilast, 
Cilomilat, Ro 20-1724, 
AWD 12-281, V-
11294A, SCH351591 
hPDE5A cGMP Smooth muscle, 
platelets, cerebellum 
cytosolic Zaprinast, Sildenafil, 
Vardinafil, Tadalafil, 
DA-8159 
hPDE6 
A/B/C 
 
cGMP 
Retina cytosolic - 
hPDE7 
A/B 
 
cAMP 
Skeletal muscle, 
immune cells, brain 
cytosolic BRL 50481, IC242 
hPDE8 
A/B 
 
cAMP 
Immune cells, liver, 
kidney, testis, thyroid 
Cytosolic and 
particulate 
- 
hPDE9A cGMP Brain, kidney cytosolic BAY 73-6691 
hPDE10A cAMP>cGMP Brain, testis A1 and A3 are 
cytosolic but A2 is 
particulate 
- 
hPDE11A cGMP=cAMP Prostate, testis, 
skeletal muscle 
cytosolic - 
 
 
1.2.1 PDE regulatory domain 
The PDE N-terminal domains determine several properties such as regulation of enzyme 
activity by posttranslational modifications (e.g. phosphorylation by PKA, PKB, ERK2, 
CaMK and PKG), and binding of other messenger molecules (e.g. cGMP, cAMP, Ca+2, 
calmodulin, and phosphatidic acid) or by specifying the subcellular localization of the 
enzymes by protein-protein interactions and membrane insertion [59, 60].  
PDE1 family, two tandem Ca+2/Calmodulin domains are present N-terminally. The binding of 
both Ca+2 and calmodulin is required for full activation of the enzyme which varies from 3-10 
fold depending on the source, tissue and enzyme preparation [10]. 
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In PDE2, 5, 6, 10, and 11 families, two tandem GAF domains in the regulatory domain were 
found to bind cyclic nucleotide which activates the catalytic domain and enhance 
dimerization. Phosphorylation sites were identified in PDE1, 2, 3, 4, 5, 6, 10 and 11 which 
differ in their effect on the catalytic domain [61-64]. 
A membrane divergent N-terminal region with its membrane associated domain and a 
hydrophilic catalytic domain were identified in PDE3. Studies of different truncated PDE3 
forms revealed that the N-terminal was not required for maintaining full catalytic activity and 
sensitivity to PDE3 specific inhibitors, although it may be important for localization [65]. 
cGMP was found to have an inhibitory effect on PDE3, but the mechanism of inhibition was 
not due to binding to the regulatory domain as the GAF domain, rather by competition with 
cAMP at the catalytic site [10]. 
In the PDE4 N-terminus, two tandem UCR (Upstream Conserved Region) domain and one 
phosphorylation site are regulating the catalytic domain. Different splice variants are 
expressed by PDE4 genes which are distinguished by long forms and short forms. Long forms 
possess both UCR1 and UCR2. The UCR tandem has been shown to be responsible for the 
dimerization of the enzyme. In addition, phosphorylation of serine in UCR1 of PDE4 long 
forms causes the activation of the enzyme by 60-250%[58]. 
At the time a PKA pseudosubstrate site is present in the N terminus of PDE7A subfamily, 
PDE8 contains REC and PAS domains in its N-terminal portion. REC domain functions as a 
receiver of signals from the sensor component in 2-component signal transduction systems in 
lower organisms. PAS domain is involved in the binding of small ligands and protein–protein 
interaction. However, regulation of PDE8 via REC or PAS domain is unknown. Lastly, there 
is no report on the regulation of PDE9A activity or the presence of endogenous PDE9A 
activity in either tissue or cell extracts [9]. Binding of a ligand or phosphorylation in these N-
terminal domains causes a change in the conformation of the catalytic domain with an 
increase in Vmax or decrease in Km toward the cyclic nucleotide substrate and often modifies 
interaction with inhibitors. The changes in conformation of the catalytic domain that follow 
modification at the N-terminus are unknown but may provide a window of opportunity for 
new drug design [62]. Figure 1.3 shows the different N-termini of the 11 PDE families with 
phosphorylation sites. 
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Figure 1.3: Schematic representation of the eleven human PDE families. Representative members 
that constitute the 11 human PDE families are shown here. Each PDE protein is indicated by a thick 
line. protein regions are represented by rectangles with patterns. N-terminal variation of PDE1A 
variants carrying N1, N2, and N3 sequences are boxed. Splice variants of PDE5, PDE10, and PDE11 
families are also shown in boxes. The 3 isoforms in the PDE4 family are illustrated and boxed. PDE3 
enzymes produced by alternative translation initiation are boxed. Reported phosphorylation sites are 
indicated with arrows. ERK phosphorylation site in PDE4A variants is absent. image taken from [9]. 
 
1.2.2 PDE catalytic domain: 
Although PDE families contain a variable N-terminal regulatory domain, they share a similar 
C-terminal catalytic domain. Within each family, sequence similarity in the catalytic domain 
is high (typically 75% or greater) while the catalytic domain similarity between families is 
generally of 20–45% [66]. Crystal structures have been reported for the catalytic domains of 
eight PDE families in the unliganded form, in complex with products or inhibitors: PDE1B 
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[67], PDE2A [53], PDE3B [68], PDE4B/4D [69-71], PDE5A [72], PDE7A [73], PDE9A [74] 
and PDE10A2 [75]. The catalytic domain of PDE4 and probably all other class I PDEs are 
composed of 16 alpha helices consisting of three subdomains that define a deep pocket where 
the substrate binds. The presence of three subdomains likely facilitates the ability for 
conformational changes to occur within the catalytic domain, which may account for different 
apparent conformations detected by substrate or inhibitor binding. Beside the substrate in the 
catalytic pocket, two metals were observed to bind, a tightly bound Zn+2 is coordinated by 
histidine and aspartate residues and another less tightly bound Mg+2 which is considered to be 
important for catalysis [62].  
The PDEs have different substrate specificities: Some are cAMP selective hydrolases (PDE 4, 
7 and 8), others are cGMP selective hydrolases (PDE 5, 6 and 9) and the rest can hydrolyse 
both cAMP and cGMP (PDE1, 2, 3, 10 and 11). Selectivity in this case is commonly defined 
as high substrate preference at physiological concentration [52, 53]. However, how the 
catalytic pocket of the PDE families selectively recognizes cAMP and cGMP is still not clear. 
On the basis of the crystal structure of PDE4-cAMP and PDE5-cGMP, a glutamate switch 
mechanism was proposed for the substrate specificity. However, this mechanism has been 
challenged by mutagenesis experiments. Experiments of the Q817A mutation in PDE5A1 
reduced cGMP affinity by 60-fold but didn’t significantly impact cAMP binding [76]. In 
addition, in dual substrate specific PDE2 and PDE10 crystal structures, presence of hydrogen 
bond between the invariant glutamine and a scaffolding tyrosine will block free rotation of 
glutamine side chain and prohibit gain of two hydrogen bonds with cAMP or cGMP. 
Moreover, in the structure of PDE10A2, the Gln726 forms two hydrogen bonds with cAMP 
but one with cGMP. A structural model shows that Gln726 will retain one hydrogen bond 
with cGMP even after switching the side chain conformation of the invariant glutamine. In 
conclusion, the glutamine appears to be important for substrate affinity but less critical for 
differentiation of substrate. In general, the substrate specificity is determined by multiple 
elements and individual PDE families have characteristic mechanisms and this can be due to 
the variation in the amino acids and the shape/size of nucleotide binding pocket [75, 77].   
Although the crystal structures of many PDE catalytic domains were solved, no high 
resolution structure of any PDE enzyme has been reported. Little is known about the 
molecular details of signal transduction from the regulatory domain to the catalytic domain 
[58].  
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1.3 Class III Adenylyl cyclases       
Adenylyl cyclases are responsible of production of cAMP from ATP in both eukaryotic and 
prokaryotic cells. Class III adenylyl cyclases are universal. They are found in metazoa, 
protozoa, fungi, eubacteria, some archaebacteria and certain green algae. However, neither 
class III ACs nor any other type of ACs has ever been conclusively identified in higher plants. 
Class III class is subdivided into another four subclasses (a-d). In mammals, ACs function as 
pseudoheterodimer with a single catalytic pocket. In bacteria and protozoa, ACs are 
homodimers with two catalytic pockets [78]. 
Six canonical amino acids have been identified in ACs, which serve three principal functions 
in catalysis. Two aspartate residues coordinate two metal cofactors (Mg+2 or Mn+2), a lysine 
and an aspartate pair are responsible for selecting ATP over GTP as substrate and an arginine 
and asparagine couple stabilizes the transition state [78]. 
CyaB1, is a class III adenylate cyclase in which the above amino acid residues correspond to  
D606 and D650 for coordination of the metal cofactor, K646, T721 for adenine binding and 
N728, R 732 for the stabilization of the transition state [79]. To ascertain that these amino 
acids are in agreement with canonical class III catalytic cleft, different mutants have been 
generated. The mutation of T721A lowered the AC activity but did not relax the substrate 
specificity for ATP as GTP was not accepted as substrate [79, 80]. 
 
1.4 Cyanobacterium anabaena sp. Strain 7120 adenylyl cyclases, 
CyaB1 and CyaB2 
Cyanobacteria are a diverse group of prokaryotes known as blue green algae. They are either 
unicellular or filamentous, and perform plant-type oxygen evolving photosynthesis. They are 
known to inhabit a variety of sea and fresh water habitats [81]. In 2001, the entire genome of 
filamentous heterocyst-forming, N2-fixing cyanobacterium, Anabaena sp. PCC 7120 
(Anabaena), was determined [82]. Later, domain analysis revealed that the anabaena genome 
encodes a large number of signal transducing proteins in which the number of signaling 
domains in single protein is extremely large compared with other bacteria. In the total 
genome, 87 GAF domains were detected in 62 putative proteins, while 143 PAS domains 
were detected in 61 proteins [30]. 
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More than ten adenylate cyclase genes have been annotated in cyanobaceria. The deduced 
proteins have structurally related catalytic domains in their carboxyl terminal regions and 
characteristically diverse domains upstream of the catalytic domains [83](see fig. 1.4).  
 
Fig. 1.4: Domain structure of six adenylyl cyclases of Anabaena sp. PCC 7120 identified by 
complementation cloning, including CyaB1 and CyaB2. PAS and GAF are mentioned before, HisKA: 
dimerization and phosphoacceptor domain of Histidine kinases; HATPase_c: ATPase domains of 
Histidine kinase; REC: response regulator receiver domain; CHASE: predicted to be ligand binding 
domain; TM: transmembrane domain. Image taken from [81]. 
 
Among these enzymes, the deduced products of CyaB1 and CyaB2 genes have two distinct 
domains in the amino-terminal half, a GAF domain (GAFa and GAFb), and a PAS domain in 
addition to a C-terminal catalytic domain [83]. The GAF domains show significant similarity 
to cGMP binding tandem GAF domain of the mammalian cyclic nucleotide 
phosphodiesterases (PDEs) and have a regulatory action on the catalytic domain. In CyaB1, 
the binding of cAMP to the GAFb domain increases the Vmax of the AC activity 27–fold, thus 
functioning as an autoactivating switch and a feed forward mechanism. In CyaB2, the 
molecular mechanism of activation shows some differences. The crystal structure of CyaB2 
GAF tandem revealed an antiparallel dimer with four molecules of cAMP binding to each of 
the four GAFs. The exchange of the CyaB1 GAF by those of mammalian PDEs and CyaB2 
has produced functional chimeras regulated by the new GAF which suggests that the GAF 
domains do not bind the catalytic domain, but that the signal is transmitted through the 
intervening PAS domain [84].  
CyaB1 and CyaB2 are the first identified directly Na+-responsive signalling molecules that 
function in sodium homeostasis. The knock out of CyaB1 and CyaB2 from Cyanobacteria 
produced mutant strains that are not able to grow below 0.6M Na+. Mutants lacking CyaB1 
had defects in Na+/H+ antiporter function. The addition of external cAMP has reversed the 
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inhibitory effect of sodium and improved the survival of the mutated cells at low 
concentration of NaCl. This effect was assigned to presence of metal binding pockets in the 
GAF domain [85]. 
 
1.5 Aim of work          
According to experiments performed by Tobias Kanacher by the exchange of GAF domain of 
CyaB1 by rat PDE2 GAF domain, the success of this exchange gave the idea to use the 
CyaB1 PAS/catalytic domain as a reporter to study  the function of different parts of the 
regulatory domain. Because cAMP and cGMP are working concomitantly as allosteric 
activators and substrates in PDEs, it was beneficial to use the CyaB1 PAS/catalytic domain as 
a reporter which utilizes ATP as substrate and cAMP or cGMP (depending on the GAF 
swapped) as an allosteric activator. Chimeras of mammalian GAF domains and the CyaB1 
adenylyl cyclase have been prepared and successfully employed as a tool to study GAF 
tandem domains of mammalian phosphodiesterases with respect to ligand specificity, role of 
N-terminal regions upstream of the GAF tandem, role of phosphorylation sites and 
identification of previously unknown ligands. 
In the first part of this thesis, the effect of the N-terminus of hPDE2 on the activity of the 
enzyme has been studied, so different constructs (±N-terminus, with hPDE5 N-terminus) have 
been cloned and assayed for activity and activation. In addition, rPDE2 GAF was also studied 
(± CyaB1 N-terminus). 
The second aim of this project was to examine the role of the connecting helix of the GAF 
tandem domain in the dimerization of the enzyme and hence signal transduction. Three 
different GAF tandems, two of human phosphodiesterases, PDE2 and PDE5, and one from 
Cyanobacteria anabaena strain PCC 7120, CyaB2, have been selected for this study. The 
crystal structure of two of them (mPDE2 and CyaB2) has been solved [23, 24]. Accordingly, 
the boundaries of the connecting helix and the α1-helix could be exactly determined. In this 
study different approaches have been taken. First, the length of this connecting helix which 
was determined in the two crystal structure to be of thirty three aa’s, and as the stimulation 
factor for CyaB2GAF was much higher than that of PDE2 GAF, CyaB2 was selected for this 
study. The second part was to study the effect of the hydrophobic region in the middle of this 
connecting linker and alpha1-helix preceding GAFa on the transduction of the signal through 
the two motifs GAF tandem using site-directed mutation (fig.1.5). 
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CyaB1A : KINNILCMPVVS-SKDQIVAVVQLANKTG-------------------NIPFNRNDEESFRDFAASIGIILETCQS--------- : 174
CyaB1B : LTRNILCLPVFN-SANELIGVTQLINKQ--------------------QGSFTASDEEFMRAFNIQAGVALENARLFENVLLE-- : 177
CyaB2A : RTYTMLALPLLS-EQGRLVAVVQLLNKLKP-----YSPPDALLAERIDNQGFTSADEQLFQEFAPSIRLILESSRS--------- : 191
CyaB2B : RTCSLLCMPVFN-GDQELIGVTQLVNKKKTGEFPPYNPETWPIAPECFQASFDRNDEEFMEAFNIQAGVALQNAQLFATVKQQEQ : 201
hPDE2A : ELQAMLCVPVISRATDQVVALACAFNKLE-------------------GDLFTDEDEHVIQHCFHYTSTVLTSTLA--------- : 169
hPDE2B : RTRNILCFPIKN-ENQEVIGVAELVNKIN-------------------GPWFSKFDEDLATAFSIYCGISIAHSLLYKKVNEAQY : 180
hPDE5A : KTQSILCMPIKN-HREEVVGVAQAINKKSG-----------------NGGTFTEKDEKDFAAYLAFCGIVLHNAQL--------- : 184
hPDE5B : CIRSLLCTPIKNGKKNKVIGVCQLVNKMEEN-------------TG-KVKPFNRNDEQFLEAFVIFCGLGIQNTQMYEAVERAMA : 198
hPDE6aA: KTKNILASPIMN--GKDVVAIIMAVNKVD-------------------GSHFTKRDEEILLKYLNFANLIMKWYHL--------- : 184
hPDE6aB: MIKNVLSMPIVNKK-EEIVGVATFYNRKDG-------------------KPFDEMDETLMESLTQFLGWSVLNPDTYESMNKLEN : 218
hPDE10A: RIQSVLCLPIVT-AIGDLIGILELY-RHWG------------------KEAFCLSHQEVATANLAWASVAIHQVQV--------- : 177
hPDE10B: TTRNILCMPIVS-RGS-VIGVVQMVNKIS-------------------GSAFSKTDENNFKMFAVFCALALHCANMYHRIRHSEC : 187
hPDE11A: KTKSLLCMPIRS-SDGEIIGVAQAINKIP------------------EGAPFTEDDEKVMQMYLPFCGIAISNAQL--------- : 189
hPDE11B: HIRSVLCVPIWNSN-HQIIGVAQVLNRLDG-------------------KPFDDADQRLFEAFVIFCGLGINNTIMYDQVKKSWA : 197
 
CyaB1A : FVCLLDFITAEFQQFLRAIELIN-NEALEN-------MLEKVLEAITLKIGQILQAEHTAIFLVDYDK---CQLWSKVPQ-DNGQ :  73
CyaB1B : ------F-YVAARNQRGVTALLRATQTLGQS-LD----LEATLQIVMEQARILMQADRSTLFLYRKEM---GELWTKVAA-AADT :  69
CyaB2A : FKQVVTEVEQKLQIVHQTLSMLDSHGFEN--------ILQEMLQSITLKTGELLGADRTTIFLLDEEK---QELWSIVAA-GEGD :  73
CyaB2B : ------F-YIATQKQRAAAAMMKAVKSLSQSSLD----LEDTLKRVMDEAKELMNADRSTLWLIDRDR---HELWTKITQ-DNGS :  70
hPDE2A : ---AEDQKGGAAYTDRDRK-ILQLCGELYD--LD----ASSLQLKVLQYLQQETRASRCCLLLVSEDN---LQLSCKVIG---DK :  69
hPDE2B : ------F-QKEQKLKCECQALLQVAKNLFTHLDD----VSVLLQEIITEARNLSNAEICSVFLLDQN-----ELVAKVFDGGVVD :  69
hPDE5A : -LTPPRF-DHDEGDQCSR--LLELVKDISSH-LD----VTALCHKIFLHIHGLISADRYSLFLVCEDSSNDKFLISRLFDVAEGS :  76
hPDE5B : ------Y-ETSLLENKRNQVLLDLASLIFEEQQS----LEVILKKIAATIISFMQVQKCTIFIVDEDCS--DSFSSVFHMECEEL :  72
hPDE6aA: -VDFSNY--HSPSSMEESEIIFDLLRDFQEN-LQ----TEKCIFNVMKKLCFLLQADRMSLFMYRTRNG-IAELATRLFNVHKDA :  76
hPDE6aB: -----SY--LHNCETRRGQILLWSGSKVFEELTD----IERQFHKALYTVRAFLNCDRYSVGLLDMTKQ--KEFFDVWPVLMGEV :  72
hPDE10A: ---VSRY---QDTNMQGVVYELN---SYIEQRLDTGGDNQLLLYELSSIIKIATKADGFALYFLGECN---NSLCIFTPPGIKEG :  73
hPDE10B: -------CRGLAKQTELNDFLLDVSKTYFDNIVA----IDSLLEHIMIYAKNLVNADRCALFQVDHKN---KELYSDLFDIGEEK :  71
hPDE11A: -PTAIDY-KCHLKKHNERQFFLELVKDISND-LD----LTSLSYKILIFVCLMVDADRCSLFLVEGAAAGKKTLVSKFFDVHAGT :  78
hPDE11B: ------F-AASRKEYERSRALLEVVNDLFEEQTD----LEKIVKKIMHRAQTLLKCERCSVLLLEDIESPVVKFTKSFELMSPKC :  74
 
CyaB1A : KF---------LEIR-------------------------TPITVGIPGHVASTGQYLNISETATHP---LFSPELE---RQMGY : 118
CyaB1B : TQL--------IEIR-------------------------IPANRGIVGYVASTGDALNIS-DAYKDPR--FDPTTD---RKTGY : 115
CyaB2A : RS---------LEIR-------------------------IPADKGIAGEVATFKQVVNIPFDFYHDPRSIFAQKQE---KITGY : 121
CyaB2B : TK----------ELR-------------------------VPIGKGFAGIVAASGQKLNIPFDLYDHPDSATAKQID---QQNGY : 117
hPDE2A : VLG--------EEVS-------------------------FPL-TGCLGQVVEDKKSIQLK-DLTSED----VQQLQ---SMLGC : 112
hPDE2B : D--------ESYEIR-------------------------IPADQGIAGHVATTGQILNIP-DAYAHPL--FYRGVD---DSTGF : 115
hPDE5A : TLEEVSN----NCIR-------------------------LEWNKGIVGHVAALGEPLNIK-DAYEDPR--FNAEVD---QITGY : 126
hPDE5B : EKSSDTLTREHDAN---------------------------KINYMYAQYVKNTMEPLNIP-DVSKDKR--FPWTTENTGNVNQQ : 127
hPDE6aA: VLEDCLVMPD-QEIV-------------------------FPLDMGIVGHVAHSKKIANVP-NTEEDEH--FCDFVD---ILTEY : 129
hPDE6aB: PPYSGPRTPDGREINFYKVIDYILHGKEDIKVIPNPPPDHWALVSGLPAYVAQNGLICNIM-NAPAEDF--FAFQKE-PLDESGW : 153
hPDE10A: KP---------RLIPAG----------------------PITQGTTVSAYVAKSRKTLLVE-DILGDER--FPRGTG---LESGT : 121
hPDE10B: EGKPVFK--KTKEIR-------------------------FSIEKGIAGQVARTGEVLNIP-DAYADPR--FNREVD---LYTGY : 123
hPDE11A: PLLPCSSTENSNEVQ-------------------------VPWGKGIIGYVGEHGETVNIP-DAYQDRR--FNDEID---KLTGY : 132
hPDE11B: SADAENSFKESMEKSSY---------------------SDWLINNSIAELVASTGLPVNIS-DAYQDPR--FDAEAD---QISGF : 132
 
 
Fig.1.5: Alignment prepared by ClustalW method for human PDE GAF domains and cyanobacterial, 
CyaB1 and CyaB2, GAF domains. h is for human, a and b are for GAFa and GAFb. Red: 100% 
similarity, Blue: 60-90% similarity and Black: < 60% similarity. 
And third, I will try to explore the mechanism by which the signal transduced through the 
PAS domain of CyaB1 (from GAF domain to the catalytic domain). A recent mechanism 
suggested that GAF domain activation may be accomplished by movement of rigid domains 
by a fixed angle and distance and hence, the PAS domain has no role in signalling, an 
experiment in which the GAF domain was directly swapped in front of the catalytic domain 
has shown loss of the activation (J.Linder, personal communication). This was performed by 
the exchange of CyaB1 PAS by first hPDE5 catalytic linker and second by the PAS domain of 
CyaB2. Then, a flexible linker (14 aa’s in length) was inserted between the PAS and catalytic 
domain of CyaB1, and lastly I tried to crystallize different PAS domains of CyaB1 and CyaB2 
either alone or attached to their catalytic domain. 
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2 Materials and equipments 
2.1 Chemicals and materials       
Art Robbins Instruments, California (USA): 96 well Intelli-plate polished shelf 
crystallization plates 
AGS, Heidelberg: restriction endonucleases with 10x reaction buffer 
American National Can, Chicago (USA): Parafilm “M” Laboratory film 
AppliChem, Darmstadt: Acrylamide 4K-solution (37.5:1) 30%, HEPES, IPTG 
Applied biosystems, California (USA): BigDye Terminator cycle sequencing kit version 3.1 
Applegene, Heidelberg: Taq DNA-polymerase with 10x reaction buffer 
ASID BONZ GmbH, Herrenberg: ProLine Latex surgical gloves 
Axygen Scientific, Union City (USA): PCR tubes PCR-02-R 
Becton Dickinson (BD), Basel (Schweiz): Falcon tubes 15 and 50 ml, 10 ml-disposable 
syringes 
BIO-RAD, München: BIO-RAD Protein-Assay dye reagent 
Biozym Diagnostik, Hess. Oldendorf: Sequagel XR, Sequagel Complete Buffer Reagent, 
Chill-out 14 liquid Wax 
Dianova, Hamburg: Secondary goat antimouse IgG-Fc horseradish peroxidase conjugated 
antibodies 
Emerald BioStructures, Bainbridge Island, Washington (USA): Wizard I and II reagent 
kits for protein crystallization 
Fluka, Basel: cAMP, glucose, glutaraldehyde (25% in water), PEG 1000, sodium dodecyl 
sulphate (SDS) 
GE Health Care, Freiburg (2,8- 3H)- cAMP (ammonium salt), ECL Plus western Blotting 
detection system, hyperfilm ECL, formamide, thermosequenase fluorescent labeled primer 
cycle sequencing kit 
Fortuna, Wertheim: Pasteur pipettes 
Griener Labortechnik, Nürtingen: Sterile Petri dishes 
Hampton Research, California (USA): Crystal screenTM, Crystal screen 2 and crystal screen 
lite reagent kits for protein crystallization screening, VDX 24-well polystyrene pre-greased 
crystallization plates, 22 mm siliconized cover slides, 100% PEG 400, PEG 3350, PEG 8000 
Hartmann Analytik, Braunschweig: (α-32P)-ATP 
ICN Biomedicals, Eschwege: Ethidium bromide tablets 
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Kimberly-Clark Roswell (USA): Safeskin Satin Plus-Latex- gloves, Kimtechscience Precision 
wipes 
Macherey-Nagel, Düren: Nucleotrap kit, Porablot PDVF- blotting membrane (2µm pore 
size) 
Merck, Darmstadt: Acetic acid 100%, Aluminium oxide 90% active, ammonium sulphate, 
calcium chloride, chloroform, disodium hydrogen phosphate, DMSO, ethanol, imidazole, 
glucose, glycerol 87%, magnesium chloride hexahydrate, 2-mercaptoethanol, methanol, 
sodium acetate, sodium chloride, sodium hydroxide, sodium pyrophosphate 
MWG-Biotech, Ebersberg: Oligonucleotides (PCR and sequencing primers) 
New England Biolabs, Schwalbach/Taunus: BSA for molecular biology, restriction 
endonucleases, T4-Polynucleotide kinase and 10x kinase buffer 
Novagen R&D systems, Wiesbaden: pET16b- Expression vector, E. coli BL21 (DE3)- 
[pREP4] cells 
Pall Corporation, Michigan (USA): NANOSEP 10K OMEGA centrifugal devices. 
Peqlab, Erlangen: PeqGold Protein Marker, dNTPs 
Perkin Elmer, Boston (USA): Ultima Gold XR-LSC- scintillator, super polyethylene vials, 
20 ml 
Promega, Madison (USA): Pfu DNA-polymerase enzyme with 10x buffer, Wizard Plus SV 
Plasmid Purification Kit (Minipreps)  
Qiagene, Hilden: Ni-NTA Agarose, pQE30, pQE60 and pQE82 - expression vectors, purified 
mouse monoclonal RGS-His4 antibody and Tetra-His antibody, Taq-DNA- polymerase 
Roche (Boehringer), Mannheim: alkaline phosphatase, ATP, Combithek® Protein standards 
for chromatography, Complete-EDTA-free protease inhibitor tablets, dNTPs, λ-DNA, 
Restriction endonucleases, Klenow-polymerase with 10x buffer, Rapid DNA ligation Kit 
Roth, Karlsruhe: Aluminium foil, agarose, ampicillin, brilliant blue G250 and R250 
(Coomassie), glacial acetic acid, glycine, isopropanol, kanamycin, LB-Agar, LB-broth 
powder 
Sartorius, Göttingen: Sterile Nalgene syringe filter (0.22 µm), HAWP filter (0.45 µm) 
Vivaspin 500 µl and 2 ml 10k protein concentrator 
Schleicher& Schuell, Dassel: Whatmann Paper 3MM 
Serva, Heidelberg: Visking dialysis tubing 8/32 (diameter: 6 mm) and 27/32 (diameter: 21 
mm), Glass wool 
Sigma-Aldrich: Ethanol, APS, bromophenol blue, BSA, cAMP, cGMP, Corning Spin-X 
Centrifugation filters (0.2 µm), Dowex 50WX4-400, EDTA, Glycerol 99%, IPTG, LB-agar, 
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LB-broth, monothioglycerol, MOPS, sodium citrate, TEMED, tetracycline, tris, tween 20, 
ponceau S, X-gal 
SLG, LP Italiana, Milan (Italy): 10 and 25 ml disposable pipettes 
Stratagene, Heidelberg: pBluescript II SK (-) cloning vector, E.coli XL 1- Blue cells 
TPP, Transadingen (Switzerland): Falcon tubes 15 and 50 ml 
Vetter, Entringen: Eppicups, white, yellow and blue tips 
Whatman International Ltd. Maidstone (UK): Whatman 3 MM paper. 
2.2 Equipments          
Bender & Hobein, Zurich: Vortex Genie 2TM 
Berthold, Wildbad: Hand –Fuss Monitor LB 1043 B, Hand Monitor LB 1210 B 
Biometra, Göttingen: TRIO- thermoblock thermocycler with Trio heated lid 
Biorad, München: Blotting apparatus Trans-Blot SD Semi Dry Transfer Cell 
Branson, Danbury, Connecticut (USA): Sonifier B-12, Ultrasound bath Bransonic B12 
Bühler, Tübingen: KL-15 and KL- 2 shakers 
Carl Zeiss, Göttingen: Microscope Axioskope 40/40 FL with fixed polarisator, Lambda 
plate, Canon powershot G2 high quality digital camera with 4.0 Mpixel, CDD sensor and 3x 
optical zoom 
Eberhard-Karls-Universität, Tübingen: Gel electrophoresis chambers, combs and moulds 
for agarose gel 
Eppendorf, Hamburg: BioPhotometer, Multipipette, Pipettes, Table centrifuges 5414, 5415, 
5402, Thermomixer 5436, Thermostat 5320, Thermomixer Compact 
Förbel, Lindau: Consort microcomputer electrophoresis power supply E411 
GE Health Care, Freiburg: ÄKTA FPLC Instrument,  chromatography column Supradex 
200 HR 10/30, Liquid scintillation counter Rackbeta 1209 (LKB Wallac),  Hoefer Mighty 
small SE245  gel casting apparatus, Mighty small II E250  chamber, Electrophoresis power 
supply EPS 301 
Gilson, Middleton (USA): Pipettes  
Heraeus, Osterode: Megafuge 1.0 R (BS 4402/A) 
Hirschmann Laborgeräte, Eberstadt: Pipetus-Reddot electronic pipette 
H.Saur Laborbedarf, Reutlingen: Vacuum centrifuge type BA-VC.300H 
Infors AG, Bottmingen (Switzerland): Unitron incubator  
Kontron-Hermle, Gosheim: Centrikon H401 & ZK401, Rotors A6.14 (SS34) and A8.24 
(GSA) 
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KSG Sterilisatoren, Olching: Sterilisator KSG 40.2.1 
LTF Labortechnik, Wasserburg: Videoprinter Mitsubishi Video Copy Processor P91 with 
Sony CCD video Camera Modul XC- ST500E, thermopapers K65HM, Software BioCapt 
Version 99.01s 
Metrohm, Herisau (Switzerland): pH- Meter E 512 and 605 
Mettler-Tolido, Steinbach: Balance Mettler PL 200, pH-electrode inlab 423 
Millipore, Eschborn: MilliQ UF Plus apparatus 
MWG-Biotech, Ebersberg: LI-COR DNA Sequencer model 4000, BaseImagIR version 4.0 
software 
Promega, Madison (USA): Vac-Man (vacuum for Wizard plus SV Plasmid Purification Kit), 
wizard minicolumns 
Sartorius, Göttingen: Balance BP 2100 S, Analytical balance Handy  
SLM-AMINCO Instruments, Urbana (USA): French Press FA-078-E1 
WTC Binder, Tuttlingen: Incubators 
 
2.3 Bacterial strains         
Table 2.1: The bacterial strains used in cloning, their Supplier and characteristics: 
Strain Supplier Genotype characteristics 
E. coli XL1 Blue Stratagene 
(Heidelberg) 
recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F´ proAB 
lacIqZΔM15 Tn10 (Tetr)] 
Cloning cells 
(Tetracycline resistant) 
E. coli DH5α Invitrogen 
(Karlsruhe) 
F–, Ф 80dlacZΔM15, Δ(lacZYA-
argF)U169, deoR, recA1, endA1, 
hsdR17(rK–, mK+), phoA, supE44, λ–
, thi-1, gyrA96, relA1 
Cloning cells 
 (No antibiotic) 
E.coli BL21 
(DE3) [pREP4] 
Novagene 
(Wiesbaden) 
F-, ompT, hsdSβ(rβ-mβ-), dcm, gal, 
(DE3) tonA 
Expression cells 
(Kanamycin resistant)  
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2.4 Plasmids           
 
Table 2.2: Plasmids, their supplier and characteristics. 
Plasmid Size (kb) Supplier Characteristics 
pBluescript II SK (-) 2.961 Stratagene 
(Heidelberg) 
Cloning and transcription vector, 
lacZa, AmpR 
pQE30 3.462 Qiagene 
(Hilden) 
Expression vector, AmpR, 6xHis-tag 
(N) 
pQE60 3.431 Qiagene 
(Hilden) 
Expression vector, AmpR, 6xHis-tag 
(C) 
pQE82 4.752 Qiagene 
(Hilden) 
Expression vector, AmpR, 6xHis-tag 
(N) 
pET16b-pQE30 
MCS* 
5.634 Novagene 
(Wiesbaden) 
Expression vector, AmpR, 6xHis-tag 
(N) 
* pET16b was from Novagene and modified by the insertion of the MCS of pQE30 by 
A.Schultz. 
 
 
 
2.5 Oligonucleotides         
 
Restriction sites are UNDERLINED, mutations are in BOLD and inserted bases are in bold 
italic small letters 
s = sense primer  as = antisense primer  o = orientation 
Stop codon = (between parenthesis)  … = deleted bases 
Restriction sites 
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2.5.1 Sequencing primers 
 
Table 2.3: Sequencing primers, their annealing temperatures and positions. 
Name  o Ta 
(oC) 
Sequence (5’ 3’) Position Comment 
T3 as 56 AAT TAA CCC TCA CTA 
AAG GG 
772-791 pBluescript II 
SK (-) 
T7 s 56 TAA TAC GAC TCA CTA 
TAG GG 
626-645 
 
5320-5249 
pBluescript II 
SK (-), 
pET16/pQE30 
MCS 
R-800-pET 
MCS pQE30 
as 56 ACC CCT CAA GAC CCG 
TTT AGA 
5423-5443 pET16b / MCS 
pQE30 
U-pQE-IR s 54 GAA TTC ATT AAA GAG 
GAG AAA 
88-108 pQE30, pQE60 
and pQE82 
R-pQE-IR as 54 CAT TAC TGG ATC TAT 
CAA CAG G 
212-233 pQE30, pQE60 
and pQE82 
U-IR-800 
CyaB1-PAS2 
s 56 GCT TGT CAG ATG CTG 
TAA TTT C 
1190-1211 CyaB1 
holoenzyme 
R-IR-800 
GAFCyaB1 
as 56 ACT TTT ATG ATT AGC 
ATC ACC 
1279-1299 CyaB1 
holoenzyme 
U-IR-800 
KatCyaB1 
s 56 GAT GCC   TTA ATG GTT 
GGT G 
1768-1786 CyaB1 
holoenzyme 
U-IR-800 
CyaB2GAF 
s 56 TCG ATA TTT GCC CAA 
AAA CAA 
484-504 CyaB2 
holoenzyme 
U-IR-800 
hPDE2GAF 
s 56 GAG AAG CAT ACC CTG 
GTC 
541-558 hPDE2 
holoenzyme 
U-IR-800 
PDE5GAF 
s 56 CAT GAT GAA GGG GAC 
CAG TGC T 
427-448 hPDE5 
holoenzyme 
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2.5.2 Cloning primers 
2.5.2.1 CyaB1 holoenzyme 
 
Table 2.4: Cloning primers of CyaB1 holoenzyme 
 
# Name  o position Sequence (5’ 3’) comment 
1 CyaB1GAFlnk spe s s 489-606 AAA ACT AGT gca gat gag caa ttg 
ttt caa gaa TTT GCT GCT TCT 
ATT GGG 
SpeI 
2 CyaB12GAFlnkXba 
as 
as 670-687 AAA TCT AGA tcc aga cta ctt tgg 
ctc aga GAT TGA GTA GCG CGT 
AAA AG  
XbaI 
3 PASCyaB1s-Bam s 1162-1182 AAA GGA TCC AAA CAA TAT 
CAA AAA GAC ATT  
BamHI 
4 PASCyaB1as-Sma as 1696-1713 AAA CCC GGG (CTA) AGT AGT 
TTT GAG GCG CTT  
SmaI 
5 KatCyaB1s-Afl s 1708-1725 AAA CTT AAG ACT ACT ATG 
TAT CGC TAC  
AflII 
6 KatCyaB1as-Kpn as 2563-2580 AAA GGT ACC (CTA) CTT TGT 
GAA AAT TGT  
KpnI 
7 PASCyaB2as-Mlu as 1696-1713 AAA ACG CGT AGT AGT TTT 
GAG GCG CTT  
MluI 
8 KatCyaB1s-Xho s 1714-1731 AAA CTC GAG ATG TAT CGC 
TAC CTT ACA 
XhoI 
9 CyaB1GAFcr s s 124-141 AAA CCA TGG ACT TTA TCA 
CTG CCG AA 
NcoI 
From Anita 
10 CyaB1GAFcr as as 1144-1167 AAA GGA TCC TTG TTT TTC 
TAG TAA TAC ATT TTC 
BamHI 
From Anita 
11 CyaB1-XhoI 
A732(neu) as 
as 2176-2203 AAA TCT CGA GGG CGG AAC 
TTA AAT TCA CAC C 
XhoI 
From Anita 
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2.5.2.2 CyaB2 holoenzyme and mutants 
 
Table 2.5: Cloning primers of CyaB2 holoenzyme 
# Name  o position Sequence (5’ 3’) comment 
Primers for CyaB2 holoenzyme 
12 CyaB2 N-Bam s s 1-18 AAA GGA TCC ATG TCA TTG 
CAA CAG CGT 
BamHI 
From Anita 
13 CyaB2GAFB Xho as as 1306-1323 AAA TCT GAG CTT GAC TGT GGC 
AAA CAA 
Xho I 
From Anita 
14 pasCyaB2s Bam s 1330-1347 AAA GGA TCC GAG CAA ATG 
CAA CGG GAT  
BamHI 
15 pasCyaB2as-Hind as 1687-1704 AAA AAG CTT (CTA) GCG CTT 
CTC ATC GCT AAT  
HinDIII 
16 KatalCyaB2s-Bam s 1705-1722 AAA GGA TCC CTC AAG AGT 
ACG ATG TAT  
BamHI 
17 PASCyaB2s-Xho s 1330-1347 AAA CTC GAG GAG CAA ATG 
CAA CGG GAT 
XhoI 
18 CyaB2GAFcr s s 172-189 AAA CC A TGG TTA CAG AAG 
TCG AGC AA 
NcoI 
From Anita 
19 CyaB2GAFcr as as 1315-1332 AAA GGA TTC CTC TTG TTG CTT 
GAC TGT 
BamHI 
From Anita 
20 PASCyaB2as-Afl as 1687-1704 AAA CTT AAG GCG CTT CTC ATC 
GCT AAT 
Afl II 
21 CyaB2cat sma as as 2567-2583 AAA CCC GGG (TCA) CTT CTC 
CTG AAA CGT  
SmaI 
Primers where aa’s are deleted or inserted 
22 CyaB2GAFlnk Bgl (-
R)s 
s 733-780 AAA AGA TCT TTT TAT ATA GCG 
ACG CAA AAA CAA … GCG GCG 
GCG 
Bgl II 
23 CyaB2GAFln(-
RA)Bgls 
s 733-780 AAA AGA TCT TTT TAT ATA GCG 
ACG CAA AAA CAA … … GCG 
GCG GCG ATG ATG AAG 
Bgl II 
24 CyaB2GAFlnk-
RAABgls 
s 733-780 AAA AGA TCT TTT TAT ATA GCG 
ACG CAA … … … AAA CAA GCG 
GCG ATG ATG AAG 
Bgl II 
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25 CyaB2GAFlnk  
-RAAABgls 
s 733-780 AAA AGA TCT TTT TAT ATA GCG 
ACG CAA AAA CAA … … … … 
GCG ATG ATG AAG GCG GTA 
AAG 
Bgl II 
26 CyaB2GAFlnk 
+NAABgls 
s 733-783 AAA AGA TCT TTT TAT ATA GCG 
ACG CAA AAA CAA AGG GCG 
GCG GCG aac gca gca GCG ATG 
ATG AAG GCG 
Bgl II 
27 CyaB2GAFlnk 
+NAAI 
s 733-783 AAA AGA TCT TTT TAT ATA GCG 
ACG CAA AAA CAA AGG GCG 
GCG GCG aac gca gca att GCG ATG 
ATG AAG GCG 
Bgl II 
28 CyaB2GAFlnk Bgl 
as 
as 709-726 AAA AGA TCT TGA CGA CTC 
CAA AAT CAA 
Bgl II 
29 CyaB2GAF spe as as 646-660 AAA ACT AGT AAA ACC TTG 
ATT ATC 
Spe I 
30 CyaB2-XbaI (s) s 813-837 AAA TCT AGA AGA TAC CCT 
CAA ACG GGT A 
XbaI 
From Sandra 
31 CyaB2-RA as as 739-774 CAT CGC CGC CGC … … TTG TTT 
TTG CGT CGC TAT 
Fusion PCR 
From Anita 
32 CyaB2-RA s s 745-780 ACG CAA AAA CAA … … GCG 
GCG GCG ATG ATG AAG 
Fusion PCR 
From Anita 
Primers for CyaB2 mutants 
33 CyaB2GAFA M74Ss s 250-276 AAA CTG CAG GAG AGC TTG 
CAG TCA ATT ACC 
PstI 
34 CyaB2GAFA L75Ss s 250-276 AAA CTG CAG GAG ATG AGC 
CAG TCA ATT ACC 
PstI 
35 CyaB2GAFA 
ML75ASs 
s 250-279 AAA CTG CAG GAG GCA AGC 
CAG TCA ATT ACC TTA 
PstI 
36 CyaB2N-ter Pst as as 235-255 AAA CTG CAG GAT ATT TTC 
AAA CCC 
PstI 
37 CyaB2GAFB Bgl s 733-768 AAA AGA TCT TTT TAT ATA GCG 
ACG CAA AAA CAA AGG GCG 
GCG GCG 
 
 
BglII  
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38 CyaB2 MM258LL 
Bgl s 
s 733-780 AAA AGA TCT TTT TAT ATA GCG 
ACG CAA AAA CAA AGG GCG 
GCG GCG GCG CTG CTG AAG 
GCG GTA AAG 
BglII  
39 CyaB2 MM258AA 
Bgl s 
s 733-780 AAA AGA TCT TTT TAT ATA GCG 
ACG CAA AAA CAA AGG GCG 
GCG GCG GCG GCG GCG AAG 
GCG GTA AAG 
BglII 
40 CyaB2 MM258GG 
Bgl s 
s 733-780 AAA AGA TCT TTT TAT ATA GCG 
ACG CAA AAA CAA AGG GCG 
GCG GCG GCG GGG GGG AAG 
GCG GTA AAG 
BglII 
41 CyaB2 MM258ST 
Bgl s 
s 733-780 AAA AGA TCT TTT TAT ATA GCG 
ACG CAA AAA CAA AGG GCG 
GCG GCG GCG TCG ACG AAG 
GCG GTA AAG 
BglII 
42 CyaB2GAFA sfu s s 238-261 AAA TTC GAA AAT ATC CTG 
CAA GAG ATG 
SfuI 
43 CyaB2 ML74GG sfu 
as 
as 208-243 AAA TTC GAA CCC GTG AGA 
ATC CCC CCC TGA CAG GGT 
TTG 
SfuI 
44 CyaB2ML74ST sfu 
as 
as 208-243 AAA TTC GAA CCC GTG AGA 
ATC CGT GGA TGA CAG GGT 
TTG 
SfuI 
 
2.5.2.3 hPDE5 GAF domain 
Table 2.6: Cloning primers of hPDE5 
# Name o Position Sequence (5’ 3’) Comment 
45 hPDE5N-ter Bam s s 1-18 AAA GGA TCC ATG GAG CGG 
GCC GGC CCC 
BamHI 
46 hPDE5N-ter Bgl I s s 1-18 AAA AGA TCT ATG GAG CGG 
GCC GGC CCC 
BglII  
From 
J.Weber 
47 hPDE5N-ter Xba as as 430-450 AAA TCT AGA GCA CTG GTC 
CCC TTC ATC 
 
XbaI  
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48 PDE5 5’ Xho s 1537-1554 AAA CTC GAG AGA GCC ATG 
GCC AAG CAA 
XhoI 
49 hPDE5-I-as1 as 1558-1581 AAA AGA TCT TGT TTC TTC 
CTC TGC TGC TGA AGC 
BglII 
50 hPDE5-I-as2 as 1594-1614 AAA AGA TCT CAC CAC AGC 
AGC CGC TAA CGA 
BglII 
51 hPDE5LL152AA s s 444-468 GTG CTC AAG AGC CGC GGA 
ATT AGT G 
Fusion PCR 
52 hPDE5LL152AA as as 444-468 CAC TAA TTC CGC GGC TCT 
TGA GCA C 
Fusion PCR 
53 hPDE5LL333AA as as 985-1043 AAA TCT AGA GAT TGT TGT 
TCT TCA AAA ATT AAA CTA 
GCA AGG TCA GCC GCC ACC 
TGA TTT CT 
Xba I 
54 PDE5 XbaI (as) as 1020-1037 AAA TCT AGA GAT TGT TGT 
TCT TCA AAA 
XbaI From 
Sandra 
55 hPDE5 SphI s 407-423 AAA GCA TGC TAA CCC CTC 
CAA GGT TT 
SphI 
From Ana 
2.5.2.4 rPDE2 GAF domain 
Table 2.7: Cloning primers of rat PDE2 
# Name o Position Sequence (5’ 3’) Comment 
56 PDE2N-ter Bam s s 1-18 AAA GGA TCC ATG GTC 
CTG GTG TTG CAC 
BamHI 
57 PDE2N-term.stu as s 547-564 AAA AGG CCT GCG CTG 
CTG CAG GGC CTG 
StuI 
58 PDE2 GAF. Stu s s 571-600 AAA AGG CCT GAA GCT 
GTT CAG AAC ACC TCA 
GCA GAT CCC 
StuI 
59 PDE2GAF Xba s s 646-663 (r)  
682-702 (h) 
AAA TCT AGA AAG ATC 
CTG CAA CTG TGT 
XbaI 
60 PDE2GAF Bam s s 619-636 AAA GGA TCC GAG AAG 
GGA TAC ACC GCC 
BamHI 
61 Mouse XhoI as as 1616-1638 AAA CTC GAG ATT CAC CTT 
TTT GTA TAG GAG AG 
XhoI From 
Tobias 
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2.5.2.5 hPDE2 GAF domain 
Table 2.8: Cloning primers of hPDE2 
# Name o Position Sequence (5’ 3’) Comment 
62 hPDE2N-terBam s s 1-18 AAA GGA TCC ATG GGG 
CAG GCA TGC GGC 
BamHI 
63 hPDE2GAF Sma as as 755-776 AAA CCC GGG TCT CCT GCT 
GCA GGT 
SmaI 
64 hPDE2GAF Sma s s 770-790 AAA CCC GGG CAT CCC 
GCT GCT GCC 
SmaI 
65 hPDE2GAF Bam s s 682-699 AAA GGA TCC CGC AAG 
ATC CTC CAA CTG 
BamHI 
66 hPDE2GAF Hind as as 1669-1686 AAA AAG CTT (TCA) ATA 
CTG AGC CTC ATT CAC 
HinDIII 
67 hPDE2GAFA s s 694-717 AAA CAA TTG TGC GGG 
GAA CTC TAC GAC 
MfeI 
68 hPDE2N-ter L231S 
as 
as 676-699 AAA CAA TTG GCT GAT 
CTT GCG GTC GCG 
MfeI 
69 hPDE2N-ter I230S 
as 
as 676-699 AAA CAA TTG GAG GCT 
CTT GCG GTC GCG 
MfeI 
70 hPDE2GAFA afl as as 1147-1170 AAA CTT AAG TTT CTG TTC 
CTT CTG GAA 
AflII 
71 hPDE2CS/LL396AA 
s 
s 1165-1203 AAA CTT AAG TGT GAG 
TCC CAG GCT GCT GCC 
CAA GTG GCA AAG 
AflII 
72 hPDE2C393S s s 1165-1185 AAA CTT AAG TGT GAG 
TCC CAG GCT CTT CTC 
AflII 
73 hPDE2 LL396AA s s 1165-1203 AAA CTT AAG TGT GAG 
TGC CAG GCT GCT GCC 
CAA GTG GCA AAG 
AflII 
74 hPDE2(-N) 
IL230AA BamHI 
s 682-708 AAA GGA TCC CGC AAG 
GCC GCC CAA CTG TGC 
GGG GAA 
BamHI 
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2.6 Buffers and solutions        
MilliQ water was used; pH values were adjusted at RT, unless indicated otherwise. 
2.6.1 Molecular biology 
 
All solutions and buffers for molecular biology methods were either sterile-filtered (0.22 µm) 
or autoclaved for 20 min at 121oC (1bar) 
2.6.1.1 Solutions for DNA treatment: 
TAE       TE buffer 
40 mM  Tris/Acetate pH 8.0    10 mM  Tris/HCl pH 7.5 
  1 mM  EDTA        1 mM  Na2EDTA 
 
10x Klenow buffer     10x TBE buffer (LI-COR) 
200 mM  Tris/HCl pH 7.5    1.34  M  Tris/HCl pH 8.3 
  60 mM  MgCl2       440 mM  Boric acid 
  10 mM  Dithiothreitol        25 mM  Na2EDTA 
 
4x Loading sample buffer (BX)   dNTP’s 
0.05 %  Bromophenol blue    25 mM of each dNTP   
0.05 %  Xylenecyanol      
   50 %  Glycerol      
 
10x dephosphorylation buffer   10x-CM buffer 
500 mM  Tris/HCl pH 8.5    100 mM  CaCl2 
    1 mM  Na2EDTA     100 mM  MgCl2 
 
2.6.1.2 Solutions for Bacterial culture media 
LB-Agar plates    LB-medium 
35g/l LB Agar 20g/l LB broth   
 
Antibiotic stock solutions   LB-antibiotic-Agar plates 
100 mg/ml Ampicillin in water  100 µg Ampicillin/ml LB Agar  and/or 
 50 mg/ml Kanamycin in water  50  µg  Kanamycin/mL LB Agar 
   5 mg/ml Tetracycline in ethanol 
2.6.1.3 Solutions for blue/white selection  
IPTG       X-GAL 
0.1M IPTG in water    20 mg/ml in DMF 
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2.6.2 Protein chemistry 
 
2.6.2.1 Protein Purification with Ni+2-NTA- Agarose 
 
The pH was adjusted at 4oCand all solutions were kept at 4oC.  
 
Pellet washing buffer    Cell lysis buffer 
50 mM Tris/HCl pH 8.0    50 mM Tris/HCl pH 8.5 
  1 mM EDTA      
       0.02 % α-monothioglycerol 
 
Washing buffer A     Washing buffer B 
  50 mM Tris/HCl pH 8.5      50 mM Tris/HCl pH 8.5 
400 mM NaCl      400 mM NaCl 
    2 mM MgCl2         2 mM MgCl2 
 7.5 mM imidazole, pH 8.5      15 mM imidazole, pH 8.5 
     20% Glycerol          20 % Glycerol 
 
Washing buffer C     Elution buffer 1 
50 mM Tris/HCl pH 8.5      50 mM Tris/HCl pH 8.5 
10 mM NaCl        10 mM NaCl 
  2 mM MgCl2             2 mM MgCl2 
25 mM imidazole, pH 8.5    300 mM imidazole, pH 8.5 
 20% Glycerol          20 % Glycerol 
 
Dialysis buffer 1     DNAse buffer 
50 mM Tris/HCl pH 8.5     10 mM  Tris/HCl pH 7.5 
10 mM NaCl           10%  Glycerol 
  2 mM MgCl2      2 mg/ml DNAse  
   35 % Glycerol 
 
2.6.2.2 SDS-Polyacrylamide gel electrophoresis 
 
Resolving gel buffer     Stacking gel buffer 
1.5 M Tris/HCl pH 8.8    500 mM Tris/HCl pH 6.8 
0.4 % SDS          0.4 % SDS 
 
10x electrophoresis buffer    Coomassie staining solution (see) 
250 mM Tris      0.2 % Brilliant blue G-250 
 1.92 M  Glycine     45% ethanol 
       1 % SDS      10 % Acetic acid 
 
4x sample buffer      Bleaching solution for SDS-PAGE gel 
130 mM Tris/HCl pH 6.8    10 % Acetic acid 
     10 % SDS      30 % Ethanol 
     20 % Glycerol 
     10 % β-mercaptoethanol    APS solution 
   0.06 % Bromophenol blue     10% APS in water 
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2.6.2.3 Western Blot 
 
 
TBS buffer (Tris Buffered Saline)   Ponceau S staining solution 
  20 mM Tris/HCl pH 7.5    0.1 % (w/v) Ponceau S 
150 mM NaCl      5 % Acetic acid 
 
TBS-T      M-TBS-T 
0.1 % Tween 20 in TBS buffer    5 % Milk powder in TBS-T buffer   
 
Towbin- Blot buffer     Primary antibody: 
  25 mM Tris/HCl     RGS-His4-antibody 
192 mM Glycine     0.04-0.2 µg/ml in M-TBS-T 
  20 %    Methanol 
His4- antibodies 
Secondary antibody     0.1 µg/ml M-TBS-T 
Goat anti-mouse polyclonal antibodies  
conjugated with horseradish peroxidase 
diluted 1: 5000 in M-TBS-T 
 
 
2.6.2.4 Cyclase Enzyme test 
 
 
ATP Stock Solution     cAMP or cGMP Stock solution 
5 mM  ATP pH 7.5 (adjusted with Tris)  40 mM  cNMP pH 7.5 (adjusted by Tris) 
 
10x AC Start solution    cNMP (for allosteric activation) 
750 µM ATP with serial dilution from the above stocks  
1500-2500 kBq (α-32P)-ATP/ml solution  have been prepared and used in the  
A concentration of 0.1 and 1 mM have  assay (volume of 10 µl) 
been used in the substrate kinetics    
        
AC Stop buffer     3H-cAMP (internal standard) 
3 mM cAMP/NaOH pH 7.5    20 mM cAMP 
3 mM ATP      10-20 kBq/ml of [2,8-3H-cAMP] (NH4+ ) 
1.5 % SDS      pH was adjusted to 7.5 by Tris solution 
 
 
2x AC-Cocktail 
100 mM Tris/HCl pH 7.5 
20 mM MgCl2 
43%  Glycerol 
Different buffers of the same concentration substituted Tris/HCl in pH dependence studies. 
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2.6.2.5 Dimerization buffers 
 
The proteins for dimerization studies should be free of Tris, therefore, new solutions for 
protein purification were prepared, in addition to the dimerization solution which was used 
for the reaction 
 
Washing buffer D     Washing buffer E 
  50 mM phosphate buffer pH 7.4     50 mM phosphate buffer pH 7.4 
400 mM NaCl      400 mM NaCl 
    2 mM MgCl2         2 mM MgCl2 
 7.5 mM imidazole, pH 8.0      15 mM imidazole, pH 8.0 
     20% Glycerol          20 % Glycerol 
 
Washing buffer F     Elution buffer 2 
50 mM phosphate buffer pH 7.4     50 mM phosphate buffer pH 7.4 
10 mM NaCl        10 mM NaCl 
  2 mM MgCl2             2 mM MgCl2 
25 mM imidazole, pH 8.0    300 mM imidazole, pH 8.0 
 20% Glycerol          20 % Glycerol 
 
Crosslinking buffer 
50 mM Phosphate buffer pH 7.4 
10 mM NaCl 
22%  Glycerol 
 
2.6.2.6 Other solutions 
 
Crystallization buffer         
10 % Glycerol        
10 mM Tris/HCl pH 7.5     
  1 mM MgCl2             
 0.05% thioglycerol          
 
For the crystallization of CyaB1 PAS domain, the above crystallization buffer but with 20% 
glycerol was used 
 
 
FPLC buffer  
  50 mM Tris/HCl pH 7.5 
200 mM NaCl 
   2  mM MgCl2 
    20%   Glycerol 
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3 Methods 
 
3.1 Bioinformatics and Databases      
Since 1977, DNA sequences of thousands of organisms have been decoded and stored in 
Databases [86-88]. A comparison of genes within a species or between different species can 
show similarities between protein functions.  
In this work, different databases have been employed to determine the domain-organization 
and domain boundaries of different enzymes, gene and protein sequences, in addition to 
exploring other proteins that contain similar domains and show the identity and similarity 
with our query. These databases include: 
1. SMART search: (http://smart.embl-heidelberg.de) 
2. BLAST search: (http://www.ncbi.nlm.nih.gov/blast 
3. Pfam search: (www.sanger.ac.uk/software/pfam/search) 
4. Expasy PROSITE: (http://Expasy.org) 
5. Cyanobacteria database: (http://bacteria.kazusa.or.jp/cyano/) 
 
DNA STAR and GeneDoc (programs for handling of DNA and protein sequences) were used. 
RasTop was employed to evaluate the crystal structures of proteins. 
 
3.2 Molecular biology methods        
3.2.1 Polymerase Chain Reaction (PCR) 
The PCR reactions were run in 50 µl with a thermocycler with heatable lids. The samples 
contained 1-5 ng of DNA to be amplified, 200 µM dNTP, 0.5 µM of each primer, 1 U Taq-
DNA-Polymerase or 2 U of pfu-polymerase enzyme in addition to 1 x of corresponding 
reaction buffer (2 mM MgSO4 was already included). The temperature program is shown in 
table 3.1: 
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Table 3.1: The temperature program used for PCR 
 Taq- polymerase 
Phase Temp. time 
Denaturation 95oC 5 min 
Denaturation 95oC 1 min 
Primer annealing Ta 1 min 
 
25-30 
cycles Extension 72oC 1 min/ kb 
Fill up 72oC 5 min 
 4oC pause 
 
The annealing temperature was calculated with the formula: 
Ta (oC)  =  2  × (AT)  +  4  ×  (GC)  
AT and GC represent the number of A + T and G + C respectively in the primer sequence. 
The lower annealing temperature was used in cases where the annealing temperatures of the 
two primers were different. 
When there is no possibility for silent introduction of restriction sites, the fusion cloning was 
used. In a fusion PCR, two separate PCR reactions are performed; the antisense primer of 
PCR1 and the sense primer of PCR2 have a short region of overlapping homology (~ 10 bp) 
at their ends. At the end of the reaction, the product of PCR1 and PCR2 are gel-purified and 
used as template for a third reaction which fuses the two linear DNA fragments in one 
fragment as follows: 
In a 0.5 ml PCR tube, 100 ng of each of the two PCR products was mixed with 5 µl pfu-
polymerase buffer containing MgSO4, 0.2 mM of dNTP mixture and 0.5 µM of the 5’- primer 
of the first PCR and the 3’- primer of the second PCR. Water was added to a final volume of 
49 µl and the PCR mixture was heated to 95oC before 1 µl of pfu-polymerase is added and the 
program was continued. A pre-run of 5 cycles at lower temperature (8oC below the calculated 
Ta) was performed followed by 25 cycles at 6oC higher temperature. 
At the end of the reaction 10 µL of the PCR product is run on the agarose gel, the band of the 
correct size is excised from the gel and purified using NucleoTrap® DNA purification kit. The 
ends of DNA fragments produced by taq polymerase were blunted and phosphorylated, while 
those produced by pfu polymerase were phosphorylated directly without prior Klenow 
digestion. 
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3.2.2 Isolation of DNA by Agarose gel electrophoresis: 
Agarose was dissolved in TAE-buffer by heating in a microwave. The solution was poured 
into a mould in which a well-forming comb was fitted and left to congeal, the agarose 
concentration was chosen according to the expected size (bp) of the DNA fragments: 
  ≥  2000  bp   0.8  -  1 % 
500-2000 bp  1    -  1.8 % 
  ≤  500 bp  2  % 
 
TAE buffer was used for electrophoresis, agarose gels were placed horizontally in an 
electrophoresis apparatus, the DNA samples were mixed with loading sample buffer (BX), 
and electrophoresis was performed at 80-100 V for 45-60 min at room temperature.  
The size markers EcoRI/Hind III-digested λ-DNA (λ Marker) and MspI/SspI digested 
pBluescript II SK (-)-Vector (π Marker) were coelectrophoresed with DNA samples. 
 
Table 3.2: DNA size markers used in agarose gel. 
λ  Marker (bp) π Marker (bp) 
21226 489 
5184 404 
4973 312 
4277 270 
3530 242/241 
2027 215 
1904 190 
1584 157 
1330 147 
983 110 
831 67 
564 57 
125 34 
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For DNA detection, the gel was emerged in an ethidium bromide bath (0.01 mg/ml) for 2 min, 
run for another 10 min, DNA bands were visualized by UV-light and photographed. Long 
exposure of the DNA to UV light can damage the DNA and should be avoided. In some cases, 
the bands were excised and purified for further reactions.  
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3.2.3 Purification of DNA fragments from agarose gel 
3.2.3.1 Use of DNA purification kit 
Upon running a PCR product or restriction digestion by agarose gel electrophoresis, the 
desired band was excised from the agarose gel using a scalpel, and purified by Nucleotrap 
DNA purification kit according to the manufacturer‘s protocol. The purified DNA was eluted 
using 25- 50 µl water and stored at 4oC or -20oC. In the case of DNA with sticky ends, storage 
at -20oC should be avoided due to the damage of the sticky ends caused by freezing. 
3.2.3.2 Use of squeeze-freeze method 
For simple, quick, and safe handling of small amounts of DNA (less than 1 microgram) or 
small fragments of DNA (80-100 bp), the squeeze-freeze method [89] was carried out. After 
electrophoresis, bands of interest are cut out of the gel. A hand-made filtration assembly was 
prepared by cutting the upper part of an eppendorf tube; make a small hole in the lower part 
and covering the hole by small piece of glass wool. The gel slices were put over the glass 
wool, another empty eppendorf tube was put below, the whole set was put into a small box to 
avoid the fall of ice into the opened tube and frozen at -80oC for 30 min, thawed and 
centrifuged through the filtration assembly (14000 rpm, 10 min) whereby the DNA-
containing buffer was squeezed out. To concentrate the DNA solution and exchange the TAE 
buffer by water, further purification by ethanol precipitation was performed (see section 
3.2.11.3).  
3.2.4 Generation of blunt ends: 
After PCR using Taq polymerase or restriction digestion, the DNA fragment was blunted 
using the Klenow fragment of the DNA polymerase I. Maximally 500 ng DNA, 1 µl of 10x 
Klenow buffer and 0.8 µl of Klenow polymerase (1U/µl) in a 10 µl reaction volume were 
mixed. The reaction mixture was incubated for 10 min at 37oC. Then, 1µl of dNTP (20 mM) 
was added and the incubation continued for another 28 min. The Klenow enzyme was 
inactivated by heating the sample at 70oC for 10 min. 
3.2.5  5’-Phosphorylation of PCR products: 
In order to ligate the PCR product into the EcoRV-restricted pBluescript, the DNA should be 
phosphorylated. The 10 µl Klenow-treated DNA solution is cooled for 5 min in ice, mixed 
with 2.5 µl of ATP (1.7 mM), 1 µl of T4 polynucleotide kinase (10U), and 1.5 µl of T4-PNK 
buffer (1X) in 15 µl were incubated at 37oC for 1 hr. At the end of the reaction, the content 
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was mixed with 400 µl of NT2 solution of Nucleotrap® kit and the DNA purification was 
continued accordingly (section 3.2.3.1) 
3.2.6 Dephosphorylation of plasmid vectors: 
To avoid religation of digested-vectors without insert, the 5’-phosphate was removed using 
alkaline phosphatase. 500 ng DNA, 1U/pmol of enzyme and 1X dephosphorylation buffer 
were mixed in 20 µl and incubated at 37oC for 1 hr. The compatibility of alkaline phosphatase 
with all buffer systems allowed the dephosphorylation directly after restriction digestion of 
the plasmid without the need to change or modify the buffer system. 
3.2.7 Photometric determination of the DNA concentration: 
Using a 1 cm quartz cuvette, the content of the double-stranded DNA was measured at 260 
nm. An OD of 1 corresponds to 50µg/ml for double stranded DNA. The ratio OD260/OD280 
was calculated to estimate purity. A ratio of > 1.8 was desirable. 
3.2.8  Ligation of the DNA fragment: 
DNA fragments were ligated to each other using the Rapid Ligation Kit according to the 
instructions of the manufacturer. The molar ratio of vector to insert should be 1:3 which was 
estimated from the bands of agarose gel. 
3.2.9 Transformation of the recombinant DNA  
3.2.9.1 Preparation of the competent cells: 
E.coli competent cells were prepared by CaCl2 method [90]. Small quantity of cells from 
glycerol stock was inoculated into 5 ml LB medium containing 10 µg/ml tetracycline in case 
of XL1 cells and 50 µg/ml of kanamycin in case of BL21 and grown at 37oC and 210 rpm 
overnight. In the morning, the preculture was transferred into 200 ml of fresh LB-medium 
(without antibiotic for XL1 and with kanamycin for BL21) and incubated to an OD of 0.2-0.4. 
Then the cells were cooled in ice for 15 min, centrifuged (2000 x g, 4oC, 10 min). The pellets 
were combined during careful suspension in 50 ml of sterile cold 0.1M CaCl2 solution, cooled 
in ice for another 20 min and centrifuged as before. The pellets were suspended in 10 ml of 
0.1 M of CaCl2 / 20% glycerol solution, cooled in ice for 3-5 hrs, portioned in Eppendorf cups 
as 100 µl portions and stored at -80oC. Competent cells can not be defrosted more than once. 
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3.2.9.2 Transformation of DNA-plasmid into competent cells   
The DNA ligation reaction (21µl from a rapid ligation kit protocol) was added to 100 µl- 
competent cells, mixed gently and incubated in ice for 20-30 min, cells were then heat-pulsed 
at 42oC for 60 sec. and incubated in ice for another 10-20 min. 500 µl of LB-broth (without 
antibiotic) were added and cells were incubated at 37oC for 1 hr at 210 rpm. 100-200 µl of the 
mixture were spread over preheated LB/Amp or LB/Amp/Kan agar plates. Plates were 
incubated in an inverted position (to prevent water condensation) for 12-16 hrs at 37oC. 
To retransform an already purified plasmid, 1 µl of the purified miniprep was added to 
competent cells, incubated in ice for 5-10 min, heat shocked at 42oC for 50 sec, incubated 
again in ice for 2 min, 200 µl LB medium is added, left at room temperature for 10 min and 
100 µl is plated on agar plate (with the suitable antibiotic) or all was added to 5 ml-LB test 
tube and incubated at 37oC for overnight. 
3.2.10 White-blue colony screen 
If the transformation was made with a PCR product ligated in pBluescript then a blue-white 
screen is performed. X-gal is used to indicate whether a bacterium expresses the beta 
galactosidase enzyme which is encoded by the LacZ gene. X-gal is cleaved by β-galactosidase 
yielding galactose and 5-bromo-4-chloro-3-hydroxyindole which is oxidized to 5,5'-dibromo-
4,4'-dichloro-indigo, an insoluble blue dye. Thus, when 40 µl of X-gal (2%) and 40 µl of 
0.1M IPTG, an inducer of β-galactosidase, are spread over an agar plate, colonies which have 
a functional lacZ gene can easily be distinguished by blue colour, while those carrying the 
recombinant DNA in the lacZ gene form white colonies. 
3.2.11 Isolation of DNA  
3.2.11.1 Isolation and purification of DNA from bacterial cultures (minipreps): 
Plasmid DNA was isolated from bacterial cultures using miniprep kits. The standard protocol 
of the wizard Plus Minipreps DNA Purification system (PROMEGA) was carried out using 5 
ml of overnight bacterial culture. The DNA was eluted with 50-60 µl of sterile water. The 
purified plasmid could be stored at 4oC or -20oC.  
3.2.11.2 Phenol/chloroform extraction 
If the BL21 (DE3) [pREP4) E.coli cells were used for cloning, DNAses destabilize the DNA 
and further purification of minipreps by phenol/chloroform is advisable. The purified DNA 
was mixed with half its volume of phenol and the mixture is vortexed for 1 min and 
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centrifuged (1 min, 13600 rpm, RT). The upper aqueous layer was transferred carefully to 
new Eppendorf cup, extracted by chloroform (a volume equal to that of phenol) twice, 
vortexed and centrifuged. The chloroform layer was discarded and the aqueous phase was 
further purified by ethanol precipitation. 
3.2.11.3 Ethanol precipitation 
To concentrate DNA or change buffer, an ethanol precipitation was carried out. The volume 
of DNA solution was measured by pipette and precipitated by addition of 0.375* VDNA and 
2.5*VDNA of cold 95% ethanol, mix well, incubate at 4°C for 30 min and pellet the DNA by 
centrifugation at 14000 x g for 20 min at 4°C. A subsequent wash with half the volume of 
70% ethanol, followed by brief centrifugation (14000 rpm, 10 min, 4oC) was performed to 
remove residual salt and moisture. The ethanol is left to dry, the DNA is dissolved in 60 µl 
water, heated at 42oC and vortexed. 
3.2.12 Enzymatic digestion: 
In 10 µl volume, 400-600 ng of DNA was incubated with 1U of restriction enzyme in the 
respective buffer, 5 µg of BSA was added to stabilize some enzymes. The DNA-enzyme 
mixture was incubated at the recommended temperature for a minimum of 1hr and a 
maximum of overnight. In the case of simultaneous digestion with 2 or more enzymes, the 
most compatible buffer was used. If no compatible buffer is available, the digestion is 
performed for each enzyme alone with its buffer and Nucleotrap® purification between the 
two digestions was carried out. The digest was analysed by electrophoresis to visualize the 
fragments pattern and to test for complete digestion. The bands were excised and purified 
when ligation to another DNA is required. 
3.2.13 DNA sequencing 
3.2.13.1 Chain terminating sequencing: 
DNA fidelity was ascertained by sequencing using the thermo sequenase Fluorescent labelled 
primer cycle sequencing kit (GE Health care) [91]. 8-10 µl (~130 ng/Kb) plasmid-DNA were 
mixed with 2 µl (2-3 µM) fluorescent labelled primers, 3% DMSO and then the volume was 
completed to 18 µl with water. 4 µl of these mixtures were mixed each with 2µl of the 
reaction mixture (see manufacturer’s protocol), covered with a drop of chill out wax and then 
run in a thermocycler according to the following program: 
 
Table 3.3: Temperature program used for Li-Cor sequencing reaction 
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Phase Temperature Time Cycles 
Denaturation 95oC 2 min  
Denaturation 95oC 20 s 
Primer annealing Ta 20 s 
Extension 70oC 20 s 
 
30 
Filling-up 4oC ∞  
 
Annealing temperatures were according to table 2.3 (section 2.5.1).  
After completion, samples were mixed with 6 µl stop buffer and 1 µl samples were loaded on 
6% polyacrylamide gel. Electrophoresis was performed with TBE buffer at 50 W (1500 V, 37 
mA, 50oC) using Li-Cor DNA sequencer Model 4000.  
 
3.2.13.2 Capillary DNA sequencing: 
For the last constructs, the Capillary DNA sequencing was used [92, 93],. The concentration 
of the DNA and OD280/260 were measured. In a small eppendorf tube, 4 µl of the diluted 
sequencing kit are pipetted to the bottom of the tube, 1.2 µl of a suitable nonlabled primer (20 
pmol/µl) are pipetted to the side followed by pipetting 5 µl of purified DNA (100 ng/µl) at the 
lid of the eppendorf tube. The eppendorf tube is closed and centrifuged for a short time and 
PCR reaction is carried out using the program in table 3.4 
 
Table 3.4: Temperature program used for capillary sequencing reaction 
Phase Temperature Time Cycles 
Denaturation 96oC 1 min  
Denaturation 96oC 10 s 
Primer annealing 50oC 5 s 
Extension 60oC 4 min 
 
25 
Filling-up 4oC ∞  
 
 After completion, DNA was precipitated using 40µl of isopropanol, left at RT for 10 min, 
and centrifuged at 13000 rpm for 30 min, and the isopropanol layer was removed and 
discarded. The DNA was washed by 150 µl of 80% ethanol, centrifuged (13000 rpm, 5 min), 
ethanol is discarded and DNA pellets are dried in a speed Vac. Eppendorf tubes are kept at 
4oC until applied to the robot. Before loading to the capillary electrophoresis, DNA pellets are 
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dissolved in 15 µl of HiDi buffer (High-Divalent-cation: 368 mM NaCl, 10 mM KCl, 13.8 
mM CaCl2, 101 mM MgCl2, and 10 mM HEPES pH 7.6), left at RT for 15 min vortexed and 
centrifuged. Samples were automatically loaded by the capillary sequencing robot. 
3.2.14 Glycerol stocks: 
For long term storage of the recombinant DNA, 1 ml of the overnight bacterial culture (with 
cDNA) was centrifuged (2 min, 13600 x g, RT) the pellet was suspended carefully in 750 µl 
of a mixture of LB-broth/glycerol (4:1) and stored at -80oC. 
3.3 Protein Chemistry         
3.3.1 Preculture: 
E.coli strain BL-21 (DE3) [pREP4] (KanR) was used for expression. DNA in expression 
vectors pQE30, pQE82 or pET-pQE30 MCS was transformed into BL21 (DE3) [pREP4] cells 
and a glycerol stock was prepared. The preculture was prepared by inoculating 10 ml of LB-
broth containing 100 µg/ml ampicillin and 25 µg/ml kanamycin with a small amount of the 
glycerol stock using a sterile tip and the preculture was incubated for overnight at 37oC and 
210 rpm. 
3.3.2 Expression: 
The 5-10 ml of the overnight preculture were inoculated and grown in 200 ml LB-broth 
containing 100 µg/ml Ampicillin and 25µg/ml Kanamycin at 30oC, 210 rpm to A600 of 0.5-0.6 
(approx. after 1.5-2.5 hrs).The protein expression was induced by 300 µM IPTG (21- 27oC, 
210 rpm). Constructs which consist of three or more distinct domains were induced by 30-50 
µM IPTG (16-19oC, 210 rpm, overnight). 10 mM MgCl2 was added wherever CyaB1 catalytic 
domain is within the construct. 
Initially, two hours after induction, 1 ml of culture is centrifuged at 13,000 rpm for 2 min, 
washed by 1ml cell wash buffer and centrifuged again. Pellets are resuspended in 100 µl of 
cell lysis buffer, destroyed by sonification (3 times for 5 sec, level 4) in ice and centrifuged 
(14,000 rpm, 15 min, 4oC). 15 µl of the supernatant was mixed with 5 µl of SDS 4x sample 
buffer, heated for 95oC for 5 min and loaded on SDS-PAGE while pellets were suspended in 
50 µl of water, 20 µl were mixed with 20 µl of 4x sample buffer, heated to 95oC for 5 min, 
centrifuged shortly and 5 µl was loaded. The supernatant and pellets of enzyme were run 
concomitantly with empty pQE30 expressed under the same expression conditions. 
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3.3.3 Cell harvesting and washing 
After 4-6 hrs for one or 2 domain constructs and 16-20 hrs in larger constructs, cells were 
harvested (15 min, 5000 x g, 4oC), the supernatant was discarded, the pellet was resuspended 
in 40 ml of cold cell wash buffer, transferred into 50 ml-Falcon tubes, centrifuged (15 min, 
5500 × g, 4oC), flash-frozen in liquid N2 or/and stored at – 80oC. 
3.3.4 Purification of soluble proteins from E.coli: 
Frozen pellets  were thawed on ice (10-15 min), suspended in 20 ml of cell lysis buffer, 
passed twice through the French Press (1000 psi) and the homogenate was centrifuged (30 
min, 18000 x g, 4oC). The supernatant was mixed with 250 mM NaCl and 15 mM imidazole 
end concentrations, 110-350 µl Ni+2-NTA agarose was mixed with 5 ml cell lysis buffer, 300 
µl NaCl (5M), 75 µl imidazole (1M), 25 µl MgCl2 (2M). The mixture was added to the 
supernatant and slowly rocked for 1.5-3 hrs in ice. Samples were then centrifuged (5 min, 
2500 x g, 4oC). The supernatant was discarded, and Ni+2-NTA resin was poured into 10 ml 
syringe with a Wizard mini-column attached, washed by 2 ml of each washing buffer A, B, C 
and the protein was eluted by 400-600 µl elution buffer 1. 
3.3.5 Protein dialysis 
To remove imidazole and change buffer, samples of 600 µl-6 ml were dialyzed (VISKING 
Dialysis Tubing, MWCO 12000-14000) for 14-16 hrs at 4oC against either the dialysis buffer, 
dimerization buffer or the crystallization buffer and the protein was used immediately or kept 
at -20oC in the corresponding buffer. 
3.3.6 Bio-Rad Protein determination: 
The Bio-Rad protein assay according to Bradford was used [94]. 
3.3.7 Sample concentration: 
For crystallization experiments, protein concentration was required. Two types of 
concentrators were used. Samples were concentrated by ultrafiltration using the NANOSEP 
10K (Omega membrane) centrifugal devices MWCO 10000 using an eppendorf centrifuge 
(11,000 x g, 4oC, 5-30 min) or by Vivaspin 10k concentrator using Heraeus Megafuge 1.0 R 
centrifuge (4300 x g, 4oC, 5-15 min) until the desirable protein concentration was achieved. In 
NANOSEP concentrators, the protein was recovered from the filter with pipette. For 
Vivaspin, the protein was obtained by the centrifuging the concentrator in an inverted position 
Methods 
 43
for 1 min to get the protein into the lid. Both devices were kept at 4oC with 0.5 ml of 
crystallization buffer for repeated use. 
3.3.8 SDS-PAGE: 
 SDS-PAGE according to Laemmli is probably the worlds most widely used biochemical 
method. [95]. Two 80×60×6mm ( L×W×T) minigels were casted according to the proteins 
molecular weights to be run as determined in table 3.5. 
 
Table 3.5: The components of resolving and stacking gels, used in preparation of two SDS-PAGE 
minigels. 
Resolving Gel (pH 8.8) 7.5% 10% 12.5% 15% Stacking gel (pH 6.8) 4.5% 
Resolving gel buffer 3 ml 3 ml 3 ml 3 ml Stacking gel buffer 1 ml 
H2O 6 ml 5 ml 4 ml 3 ml H2O 2.4 ml 
Acrylamide/Bisacrylamide 
37.5:1 (30%) 
3 ml 4 ml 5 ml 6 ml Acrylamide/Bisacrylamide 
37.5:1 
0.6 ml 
TEMED 10 µl 10 µl 10 µl 10 µl TEMED 10 µl 
APS 10 % 80 µl 80 µl 80 µl 80 µl APS 10 % 40 µl 
 
Mighty small II vertical electrophoresis apparatus from HOEFER was used. A volume 
equivalent to 2-4 µg of protein samples was mixed with 5 µl of 4x- sample buffer, heated for 
95oC for 5 min and loaded on the gel. 10 µl PeqGold protein size marker (table 3.6) was run 
simultaneously: 20mA, 200V, 1 hr, stained with coomassie blue for 30 min with gentle 
agitation, decolourised for 20-25 min and washed with water until bands are clearly detected.  
 
Tabl 3.6: PeqGold marker for protein size determination contains 1 µg of each protein. 
PeqGold Marker Mw (kDa) 
Lysozyme 14.4 
β-Lactoglobulin 18.4 
RE Bsp981 25 
Lactate dehydrogenase 35 
Ovalbumin 45 
Bovine serum albumin 66 
β -galactosidase 116 
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3.3.9 Western Blot 
The semi-Dry electrophoretic transfer of sample proteins to membranes for immunoblotting 
occurs after protein separation by SDS-PAGE [96]. Care must be taken when working with 
PVDF (polyvinylidene fluoride) membranes, forceps is used and membranes are handled by 
their edges so as not to damage the surface. The blot membrane (6×8cm) was successively 
soaked in methanol (to improve its wettability) for 10 min, wetted in water for another 10 min 
and then transferred to towbin buffer together with the gel and six pieces of Whatman 3MM 
papers (7.5×9.5cm) for a third 10 min interval. The following sandwich set-up was built up 
for the electric transfer: 
- Three soaked Whatman 3 MM papers were layed on the anode plate. 
-the blot membrane was layed over them, the gel was spread evenly over the membrane using 
glass rod to remove air bubbles and finally three soaked Whatman papers were layed again on 
the side of the cathode plate. Excess buffer was wiped off using a tissue paper before the lid is 
being fixed. 
Protein transfer was carried out for 2.5-3 hr at 20V and 2.5 mA/cm2. The gel was stained in 
Coomassie Brilliant blue to check transfer efficiency. 
The membrane was stained in Ponceau S for about 5 min, then it was decolourized with 
deionized water until the protein bands were clear enough for the marker bands to be marked 
with a pencil (note: Ponceau S is preferred over coomassie because it has better water 
solubility and so can be easily washed from the membrane). To prevent the non-specific 
binding of the antibodies, the membrane was blocked with M-TBS-T buffer for at least 1 hr at 
RT or overnight at 4oC and excess milk was washed with TBS-T buffer (2 x 10 sec, 2 x 5 
min). It was then incubated with the primary antibody (mouse monoclonal RGS-His4 
antibody 1:2000, or Tetra His antibody 1:1000 diluted in M-TBS) for 1 hr. After washing by 
TBS-T (1x 15 min, 2 x 5 min), the membrane was shaken with the secondary antibody (goat 
anti-mouse IgG-Fc horseradish peroxidase conjugated antibodies 1:5000 diluted in M-TBS) 
for 1hr and then washed as above with TBS-T. 
The chemilumescent reaction with the ECL Plus Western Blotting Detection Kit (GE Health 
Care) was carried out according to the manufacturer’s instructions. After their exposure to the 
detection reaction, the bands were detected by exposing the membrane to hyperfilm ECL 
(exposure time from 3 sec to 5 min).  The films were developed using a Konica medical film 
processor. 
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3.3.10 Adenylyl cyclase enzyme Assay: 
[α-32P]-ATP was used as a substrate and cyclic [32P] AMP was isolated using a two-column 
technique (Dowex 50 and neutral alumina) to separate the cAMP product from ATP substrate 
[97]. [2,8-3H] cAMP was used as internal standard to monitor yield.  
A standard test 100 µl contained. In 1.5 ml eppendorf tube 40 µl of protein sample including 
substances like BSA, cGMP and cAMP was mixed with 50µl of AC test cocktail, 10 µl of (α-
32P)-ATP (750 µM, 150-250 kBq) was added to start the reaction and the tubes were 
incubated in  shaking heating block (37oC, 1000 rpm) unless indicated otherwise. The final 
concentrations were: 50 mM Tris/HCl buffer pH 7.5, 22% glycerol, 10 mM MgCl2, 0.25 
µg/µl, 75 µM ATP (15-25 kBq). The reaction was stopped by addition of 150 µl of stop 
buffer. 10 µl of [2, 8-3H]-cAMP were added as internal standard followed by 750 µl of water 
and the mixture was poured on a dowex column (9 ×1 cm glass column with 1.2 g Dowex 
50), after washing with 3 ml water, the samples were eluted with 5 ml water onto Al2O3 
columns (10 × 0.5 cm plastic column with 1 g active neutral Al2O3 90). Samples were eluted 
with 4.5 ml 0.1 M Tris/HCl pH 7.5, mixed with 4 ml of Ultima Gold XR Scintillator solution 
and counted.  
Dowex columns were regenerated with 1×5 ml 2M HCl, 1×10 ml water and 1×5 ml water, 
while Al2O3 columns with 2×5 ml 0.1 M Tris/HCl pH 7.5. 
 Specific activity (A) (pmol/mg/min) was calculated with the following formula 
[ ][ ] [ ] [ ] [ ][ ]total blanksamplesamplesample total Pcpm
PcpmPcpm
PHcpm
Hcpm
gproteintime
lMSubstrateA 32
3232
323
3
%3)(
1000
(min)
100)( −×−××
×= μ
μμ  
 
3% of the phosphorous counts were subtracted from the tritium value for each sample because 
of the spell over of 32P into the tritium channel. Activities lower than double background (in 
cpm) were considered zero. 
In CyaB1 and CyaB2 GAF-containing constructs, cAMP is a product of AC assay and may 
cause allosteric activation, so such constructs were assayed for 4 min and with a concentration 
of protein that gives an activity of 300-400 cpm. Constructs which are not activated by cAMP 
were assayed for 10 min. 
The average and the standard error of 4-6 samples were calculated and the activity or specific 
activity was plotted against the variable parameter. 
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3.3.11 Crystallization 
The x-ray crystallography is used for structure elucidation.  
3.3.11.1 Hanging drop vapour diffusion method: 
In the hanging drop vapour diffusion method (fig 3.1) the protein/precipitant solution is 
equilibrated in a closed container with a larger reservoir, where the precipitant concentration 
is in the appropriate range to produce crystals.  
 
Figure 3.1: Principle of the hanging drop vapour diffusion method where the hanging drop was 
prepared on a siliconized slide cover by mixing the protein sample and the precipitant (1:1), the slide 
cover is inverted then over a well ( reservoir) containing 500µl of the precipitant. 
 
500 µl of precipitant solution is filled into each well of a VDX crystallization plate containing 
24 wells (Hampton research). 1.0 µl of precipitant is mixed with 1.0 µl of protein solution (3-
21 mg/ml) on a siliconized coverslip (Hampton Research). The coverslip containing the drop 
hanging up-side down was sealed with grease over the well. For initial crystallization 
conditions, crystallization screens Wizard I and II (Emerald Biostructures), Crystal Screen I, 
II, and lite (Hampton Research) were used. The plates were kept at 12oC or 16oC and 
examined under a polarization microscope every day for the first week and then once a week. 
Conditions containing crystals were optimized by individually devised screens around the 
initial condition by altering buffer, precipitant, and additive concentrations and identities, as 
well as altering the temperature of crystallization (20°C, 12°C and 4°C) and protein 
concentration. 
3.3.11.2 Sitting-drop vapour diffusion method 
For the crystallization of ∆N-hPDE2GAF, the sitting drop vapour diffusion experiments were 
carried out at the department of Biochemistry, University of Tübingen using a Tecan Freedom 
Evo 150 crystallization robot. In this method, a 96-well microplate was used; each well 
contains a raised plastic platform with a depression standing on several legs for carrying out 
the sitting drop inside the well [98] (see fig.3.2). 
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Reservoir solution
Sealing tape
Protein solution
 
Fig.3.2: Principle of sitting drop vapour diffusion method. 
The concentrated protein solution was filtered at 4oC, 10000 rpm using Corning Spin-X 
Centrifugation filters (0.2 µm) to remove any particles or cell debris before being used in the 
robot. Each plate is arranged in an 8 x 12 array. Each array location has a reservoir well and 
two sample wells-each of different size. The maximum fill volume of each reservoir well is 
140 µl, with 4 µl and 10 µl for the two sample wells. 
75 µl of precipitant solution is filled into each well of an Intelli-microplate containing 96 
wells (Art Robbins Instruments). The robot was programmed to mix 300 nl of precipitant with 
300 nl of protein solution (12 mg/ml) on the sample well located on the raised platform of 
each well. Two drops were pipetted in the platform of each well, the protein in the presence 
and in the absence of 2 mM cGMP, providing an economic method to crystallize proteins. 
The plates were sealed by a sealing tape, stored at 4 and 20oC and screened for crystals every 
week. Four kits from Hampton were used, Crystal screen I, II (at 20oC), lite and PEG/Ion kits 
(at 4 and 20oC).   
3.3.12 Size exclusion chromatography (Gel Filtration) 
Buffers have been prepared using milliQ water, filtered through 0.2 µm microfilter, and 
degassed. 200 µl of 1-2 mg/ml protein were applied to a Supradex 200 HR 10/30 column 
previously washed by twice its volume of FPLC-buffer (50 mM Tris/HCl pH 7.5, 200 mM 
NaCl, 2 mM MgCl2, 20% glycerol). The protein was detected by UV detector at 280nm. The 
flow rate was 0.4mL/min (see table 3.7).  
Table 3.7: chromatography conditions and column dimensions: 
Column type Supradex 200 HR 30/10 
Column volume 23.562ml 
Column dimensions 30 cm length × 1 cm diameter 
Elution  30 ml of FPLC buffer 
Start of fractionation 7ml 
Fraction Volume 0.5ml 
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The protein containing fractions (monomer and dimer) were collected and analysed by SDS-
PAGE or western blot. The column was calibrated by different proteins (Combithek, Roche, 
Mannheim) (table 3.8) 
 
Table 3.8: Calibration proteins used in the chromatography and their sizes 
protein Size (kDa) 
Ferritin 450 
Aldolase 158 
Phos b 96 
Bovine serum albumin 68 
Ovalbumin 45 
Cytochrome C 12.5 
 
 
The sizes of calibrated proteins were plotted against their retention volume in a logarithmic 
scale (fig.3.3) and the equation obtained from the straight line was used to calculate the sizes 
of the different proteins. 
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Fig.3.3: Calibration curve of the gel filtration chromatography column. The column used was a 1 x 30-
cm S-200 HR column. Flow was maintained using a peristaltic pump at a constant output of 0.4 
ml/min. The selective permeation range was standardized using known commercial protein standards 
(Combithek, Roche, Mannheim): Ferritin (450 kDa), Aldolase (158 kDa), Bovine serum albumin (68 
kDa), Ovalbumin (45 kDa), and Cytochrome C (12.5 kDa).  
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3.3.13 Dimerization studies: 
Glutaraldehyde is a bifunctional cross-linking reagent capable of reacting with amino acid 
side chains, particularly with the lysine NH2 group, to form Schiff bases [99]. The ability of 
proteins to form dimers was assessed by chemical crosslinking using glutaraldehyde 25% 
(Fluka) as described previously by Ramesh and Nagaraja [100].  
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3.4 Cloning:           
 
 
The key used in the drawing of the cloning procedures was as in fig.3.4 
 
 
 
Fig.3.4: a key indicates the colour used for the representation of each enzyme DNA. Each 1 cm 
represents 200 bp 
 
All PCR products were amplified by Taq DNA-polymerase, treated by Klenow, 
phosphorylated, inserted into EcoRV-digested dephosphorylated pBSKII(-) and sequenced 
and the correct clones were selected for further digestions and ligations. 
The end clones are determined by a box and whether it has N-terminal or C-terminal His-tag 
was also indicated. Most to the constructs were cloned in E.coli XL1 or DH5α and sometimes 
in E.coli BL21 (DE3) [pREP4] and the end clones were transformed into E.coli BL21(DE3) 
[pREP4] for expression. 
The DNAs of the following enzymes were already available in the Laboratory and were used 
as provided or used as templates to clone other constructs. The original DNA of CyaB1 was 
provided as a gift from prof. Ohmori, Tokyo, Japan while that of hPDE2A3 in Paqpaq was 
provided by ALTANA pharmaceuticals, Konstanz, Germany. CyaB1 in pQE30 and 
pBluescript, hPDE5NGAF/CyaB1 chimera in pET-MCS-pQE30 and CyaB2NGAF/CyaB1 in 
pQE30 were obtained from S.Bruder. CyaB1 holoenzyme with different cutting sites and 
modified pBluescript (pBSKII (-)) was obtained from A.Schultz. CyaB2 holoenzyme and 
truncated CyaB1 catalytic domains were obtained from J.Linder. hPDE5 holoenzyme was 
obtained from J.Weber and ΔN-hPDE5GAF was obtained from A.Banjac. 
Some of the construct were cloned by A.Schultz and J.Linder (mentioned wherever 
necessary) 
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The starting clones which were used either as templates or used as they are for comparison 
purposes: 
 
1. CyaB1 holoenzyme in pQE30 (from S.Bruder) 
 
 
 
 
2. CyaB1 holoenzyme with SfuI site in pBSKII (-) (from A. Schultz) 
 
 
 
 
 
3. CyaB2 holoenzyme in pQE30 (from J.Linder) 
 
 
 
 
 
4. CyaB2NGAF/CyaB1 chimera in pBSKII (-) or in pQE30 (from S.Bruder) 
 
 
 
 
 
Methods 
 52 
5. hPDE5 holoenzyme in pcDNA3-Ziocin vector (from J.Weber) 
 
 
6. hPDE2 holoenzyme in Paqpaq vector (from ALTANA pharmaceuticals) 
 
 
7. CyaB1N-rPDE2GAF/CyaB1 in pQE30 (from T.Kanacher) 
 
 
8. ΔN-hPDE5 GAFcr on pQE82 (from A.Banjac). 
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3.4.1 Cloning  of hPDE2 constructs 
3.4.1.1 Cloning of hPDE2NGAF/CyaB1 chimera 
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3.4.1.2 Cloning of ΔN-hPDE2GAF/CyaB1 chimera 
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3.4.1.3 Cloning of hPDE5N-hPDE2GAF/CyaB1 chimera 
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3.4.1.4 Cloning of ΔN-rPDE2GAF/CyaB1 
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3.4.2 Cloning of CyaB2 constructs and mutants 
3.4.2.1 Cloning of (Δaa or + aa)/CyaB1 
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3.4.2.2 Cloning of CyaB2 (ΔR253-A254)/CyaB1 
The cloning of this construct was repreated by A.Schultz due to the presence of non-silent 
mutation in the one prepared above. 
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3.4.2.3 Cloning of CyaB2 (ΔR253-A255) GAFcr for crystallization 
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3.4.2.4 Cloning of CyaB2 (256 + NAA)cr, CyaB2 (M258L/M259L)GAF and CyaB2 
(M258S/M259T)GAF 
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3.4.2.5 Cloning of CyaB2 (M74G/L75G)/CyaB1 and CyaB2 (M74S/L75T)/CyaB1 
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3.4.2.6 Cloning of CyaB2 α2-mutants (CyaB2 (M87S)/CyaB1, CyaB2 (L88S)/CyaB1 
and CyaB2(M87A/L88S)/CyaB1) 
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3.4.2.7 Cloning of CyaB2 connecting helix-mutants (CyaB2 (M258A/M259A)/CyaB1, 
CyaB2 (M258L/M259L)/CyaB1, CyaB2 (M258G/M259G)/CyaB1and CyaB2 
(M258S/M259T)/CyaB1 
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The procedure was continued according to the same way of the shortened and elongated 
mutants in section 3.4.2.1 
3.4.2.8 Cloning of CyaB2 (M74S/L75T/M258S/M259T)/CyaB1 
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3.4.2.9 Cloning of CyaB2 (M258T)/CyaB1 
The original construct was obtained from A.Schultz and was modified to obtain a single 
mutation 
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3.4.2.10 Cloning of CyaB2 (GAFlinker1)/CyaB1 
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3.4.3 Cloning of hPDE2 mutants 
3.4.3.1 Cloning of hPDE2NGAF/CyaB1 α1-helix mutants  
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3.4.3.2 Cloning of hPDE2NGAF/CyaB1 –connecting helix mutants 
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3.4.3.3 Cloning of the quadruple mutant of hPDE2GAF/CyaB1  
ΔN-hPDE2GAF(I230A/L231A/L396A/L397A)/CyaB1 
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3.4.3.4 Cloning of hPDE2NGAFcr 
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3.4.3.5 Cloning of ΔN-hPDE2GAFcr  
 
 
3.4.3.6 Cloning of ΔN-hPDE2GAF (L396A/L397A)cr  
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3.4.3.7 Cloning of hPDE2NGAF (L396A/L397A)cr 
 
 
3.4.3.8 Cloning of ΔN-hPDE2GAF (I230A/L231A/L396A/L397A)cr  
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3.4.4 Cloning of hPDE5 mutants 
3.4.4.1 Cloning of hPDE5NGAF (L152A/L153A)/CyaB1  
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3.4.4.2 Cloning of hPDE5NGAF (L333A/L334A)/CyaB1 and hPDE5NGAF 
(L152A/L153A/L333A/L334A)/CyaB1 
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3.4.4.3 Cloning of hPDE5NGAF and mutants  
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3.4.4.4 Cloning of ΔN-hPDE5GAF (L333A/L334A)  
 
 
3.4.4.5 Cloning of ΔN-hPDE5GAF (L152A/L153A/L333A/L334A)  
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3.4.5 Cloning of CyaB1 constructs 
3.4.5.1 Displacement of CyaB1 PAS by hPDE5 catalytic linker 
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3.4.5.2 Cloning of Constructs IA and IB  
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3.4.5.3 Cloning of CyaB1 (PAS2)/CyaB1  
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3.4.5.4 Cloning of CyaB1 (571+L) 
  
This construct was cloned by A.Schultz 
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3.4.5.5 Cloning of CyaB1 PAS and CyaB1 PAS/catalytic for crystallization purposes 
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3.4.5.6 Cloning of CyaB1 GAFcr for crystallization purposes 
 
 
 
Methods 
 97
3.4.5.7 Cloning of CyaB2 PAS and CyaB2 catalytic domain for crystallization purposes 
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3.4.5.8 Cloning of CyaB2 PAS/catalytic domain for crystallization purposes 
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4 Results 
 
Using the CyaB1 AC as a reporter, the signal transduction through different domains has been 
studied. In this study three approaches have been considered: 
 The effect of different N-termini on the signal transduction and regulation of PDE2 
GAF 
 The effect of the α1- helix preceding GAFa and the connecting helix that connects the 
two GAF motifs  
 The signal transduction through the PAS domain of CyaB1 as this domain is not 
required for the signal transduction in phosphodiesterases. 
   
4.1 The effect of the N-terminal domain on signaling in the 
PDE2 GAF tandem/CyaB1 chimera 
The PDE2 has a long, proline-rich N-terminal domain consisting of about 220 aa’s. This N-
terminus may be expected to be a separate domain and to have a function by itself in the 
regulation of the attached catalytic domain. In this part of work, the effect of two N-termini 
(hPDE2, hPDE5) on the signal transduction of hPDE2/CyaB1 chimera will be studied. In 
addition, when the first chimera of rPDE2/CyaB1 was constructed, the N-terminus of CyaB1 
was included in the construct and again the effect of removal of this N-terminus will be 
studied. 
4.1.1 Biochemical characterization of hPDE2NGAF/CyaB1 chimera 
The domain organization of hPDE2NGAF/CyaB1 is shown in figure 4.1. The N-terminus 
starts at M1–G220, followed by two GAF tandems, GAFa (A221-H368) and GAFb (N402-
N558) connected by a 33 aa-linker (C369-K401). Those are located in front of CyaB1 AC 
(L386-K859). 
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Fig. 4.1: Domain organization of the hPDE2NGAF/CyaB1 chimera, the boundaries of the N-terminus, 
GAF domain of hPDE2 were determined according the crystal structure of mouse PDE2. CyaB1 was 
used as before [80]. The domains related to hPDE2 are colourless while those of CyaB1 are grey. The 
grey circle in the GAFb indicates the allosteric binding site of cGMP. 
4.1.1.1 Expression and purification of hPDE2NGAF /CyaB1 chimera 
The expressed protein has a calculated MW of 116.2 kDa (including the hexahistidine-tag) 
and an isoelectric point of 5.17.  
The hPD2NGAF/CyaB1 chimera was cloned into pQE30, transformed into BL21 (DE3) 
[pREP4] E.coli and expressed for 16-18 hours with 30 µM of IPTG and 10 mM of MgCl2 at 
16oC. Cells were lysed twice by French Press and purified by adsorption to 200 µl Ni+2-NTA 
agarose for 2 hr.  Figure 4.2 shows higher amount of the protein localized in pellet. 200 ml of 
cell culture yielded 120 µg of protein. The enzyme was dialyzed overnight against dialysis 
buffer and the fresh protein was assayed. When required it was stored at -20oC. Storage 
longer than a month decreased both basal activity and fold stimulation. 
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Fig. 4.2: SDS-PAGE (12.5%) and Western blot of hPDE2NGAF/CyaB1 chimera. 
 (1) Cell Pellet, (2) Supernatant after lysis, (3) Supernatant after Ni-NTA binding, (4) Purified protein (2 
µg), (5) Western blot ( 0.3 µg). 
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4.1.1.2 Protein dependence 
The protein dependence ± 100 µM cGMP used 9 nM to 880 nM protein. Figure 4.3 shows 
dimerization achieved at low concentration. 
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Fig 4.3:  Protein dependence curve of hPDE2NGAF/CyaB1 chimera (■ basal activity, ○ + 100µM 
cGMP). Assay conditions: 10 min, 37oC, 75µM Mg+2-ATP, Tris /HCl pH 7.5, n = 6; SEM values are 
shown as error bars. 
4.1.1.3 Dose response study 
cGMP dose response curve was established. Basal activity was 1.32 ± 0.1 nmol/mg.min 
(fig.4.4), stimulation factor was 4.88 ± 0.24 (n = 8), and the EC50 was 9.92 ± 1.04 (n = 8). A 
concentration of 1 mM cAMP had no effect. 
       
cGMP
cAMP
-7 -6 -5 -4 -3
0
1
2
3
4
5
6
7
8
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
A
M
P/
m
g.
m
in
)
Log [cNMP] (M)
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
A
M
P/
m
g.
m
in
)
 
Fig. 4.4: Dose response curve of hPDE2NGAF/CyaB1 chimera. Assay conditions: 4 min, 37oC, 75 µM 
ATP, Tris/HCl pH 7.5, 90 nM protein (n = 8). 
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Log (V/Vmax – V) was plotted against log [cGMP] (fig. 4.5). The Hill coefficient was 0.477 ± 
0.042 (R2 = 0.9754, n = 4); i.e no cooperativity  
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Fig.4.5: Hill plot of hPDE2NGAF/CyaB1 (0.477 ± 0.042, R2 = 0.9754). 
4.1.1.4 Time dependence 
90 nM protein was assayed at different time intervals (1-15 min). The reaction was linear (fig. 
4.6, A), but plotting the specific activity/ time indicates a slight activation over a period of 1- 
2 min, possibly due to cGMP-binding to the GAF domain.  
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Fig. 4.6: Time dependence of hPDE2NGAF/CyaB1 chimera. (■) Basal activity, (○) +100µM cGMP). 
Assay conditions: 75µM Mg+2-ATP, 37oC, Tris/HCl pH 7.5, 90 nM protein (n = 4) (A) Activity against 
time (B) Specific activity against time. 
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4.1.1.5 Temperature dependence 
The reaction velocity increases with temperature until temperature-induced denaturation of 
the enzyme. The optimum temperature of the unactivated chimera was 50oC, while that of the 
cGMP-activated was 55oC (Figure 4.7 A and B).  
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Fig 4.7: Temperature dependence of hPDE2NGAF/CyaB1 chimera. (■) Basal activity, (○) +100µM 
cGMP). Assay conditions: 10 min, 75 µM Mg+2-ATP, Tris/HCl pH 7.5, 90 nM protein, 10-65oC (n = 4) 
(A) For both the activated and unactivated (B) For unactivated to show the maximum temperature and 
(C) Arrhenius plot. 
 
The activation energy (Ea) according to Arrhenius plot was 54 kJ/(mol.K) for the basal 
activity and 68 kJ/(mol.K) for 100 µM cGMP-activated enzyme. This mirrors the results 
obtained for CyaB1 holoenzyme which was calculated by T.Kanacher to be 65 kJ/(mol.K) for 
the activated enzyme but it was lower than the value of the unactivated construct (97 
kJ/(mol.K)). 
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4.1.1.6 pH dependence 
The extremes of the pH can lead to denaturation of the enzyme because the structure of the 
catalytically active protein molecule depends on the ionic character of the amino acid side 
chains. Different buffer systems and different pH’s have been used (see fig.4.8). At pH’s 
lower than isoelectric point of the protein (4.0-5.5), the protein has a negative or zero charge 
and so the activity was almost zero. The optimum pH was found to be between 7.0-8.5 for the 
unactivated enzyme and 8.5 for the cGMP-activated construct. Tris/HCl and MOPS/Tris have 
shown to be the best for the protein AC activity but Tris/HCl was preferred due to its use in 
all other CyaB1 chimeras and hence, reasonable comparisons can be made. pH optimum for 
CyaB1 holoenzyme was 7.5 and so Tris/HCl pH 7.5 was used for the assay of all chimeras.  
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Fig 4.8: pH dependence curve of hPDE2NGAF/CyaB1. Basal activity: empty symbols, 100 µM cGMP-
activated: filled symbols. Assay conditions: 10 min, 75 µM ATP, 10 mM MgCl2, 37oC, 90 nM protein, 
pH 4-10 (n = 4) 
 
4.1.1.7 ATP kinetics 
The substrate kinetics were tested for hPDE2NGAF/CyaB1 chimera with ATP from 2 to 100 
µM ATP. Michaelis-Menten and Lineweaver-Burke plots show that the unactivated state had 
a Km of 16.70 ± 3.88 µM ATP and a Vmax of 1.41 ± 0.23 nmol/mg.min while the activated 
enzyme had a Km of 5.13 ± 1.92 µM ATP and a Vmax 10.52 ± 1.75 (Fig.4.9). Accordingly, the 
use of an ATP concentration of 75 µM was meaningful. Compared to CyaB1 holoenzyme 
values, the Km was 38 for the unactivated and 24 for the cAMP-activated form [79]. The Hill 
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coefficient was 0.733 ± 0.037 (R2 = 0.9851) for the unactivated and 0.693 ± 0.13 (R2 = 0.985) 
for the activated form which shows no cooperativity. 
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Fig. 4.9: Substrate kinetics of hPDE2NGAF/CyaB1 chimera (A) Michaelis-Menten plot (B) 
Lineweaver-Burke plot and (C) Hill plot for both activated and unactivated forms of the enzyme. Assay 
conditions: 4 min, 37oC, 0.1 M Tris/HCl pH 7.5, 130 nM protein and ATP 2-100 µM. 
 
4.1.2 Effect of N-terminus on CyaB1 AC activity 
PDE2A2 and PDE2A3 were found to be membrane-bound while PDE2A1 is cytosolic (ref.). 
To see whether the N-terminal of hPDE2A3 affect AC activity, activation or cGMP affinity, 
the N-terminus was removed and hPDE2 (228-558)/CyaB1 chimera was generated (Fig.4.10). 
The boundaries of the GAF domain of human PDE2 were determined by a BLAST Search of 
the GAF sequence (www.ncbi.nlm.nih.gov/blast). 
Results 
 106
CN AC-catalystPAS
R
22
8
K
 8
59
H
 3
68
N
 4
02
L 
38
6
G
 5
95
hPDE2GAF
CyaB1
N
55
8
GAFbGAFa
R
22
8
K
 8
59
H
 3
68
N
 4
02
L 
38
6
G
 5
95
N
55
8
 
Fig. 4.10: Domain organization of ∆ N1-227-hPDE2GAF/CyaB1 showing the amino acid boundaries. 
Grey circle: allosteric binding site of cGMP.  
 
4.1.2.1 Expression and purification of the protein 
The pQE30-∆ N1-227-hPDE2GAF/CyaB1 DNA was transformed into BL21 (DE3) E.coli cells. 
Bacterial cells were grown to OD600 of 0.5-0.6 at 30oC and induced by 30 µM IPTG and 10 
mM MgCl2 (overnight at 16oC). The protein was bound to 350 µl Ni-NTA agarose for 90 
min. The eluted His-tagged protein has a calculated MW of 91.86 kDa and >95% purity 
(Fig.4.11). 
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Fig.4.11: SDS PAGE (12.5%) of ∆ N1-227-hPDE2GAF/CyaB1 (1) Pellets (2) Supernatant (3) 
Supernatant after Ni-NTA (4) Purified proteins (2 µg) (5) Western Blot (0.1 µg) 
4.1.2.2 Protein dependence 
The protein dependence was assayed for 11 to 1100 nM (fig.4.12). Specific activity was 
constant at the low concentrations and declined at  higher concentrations which could be due 
to oligomerization or accumulation of pyrophosphate. The basal activity (12.2 ± 0.8 
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nmol/mg.min, n = 4) was higher than that of hPDE2NGAF/CyaB1 (1.32 ± 0.08 nmol/mg.min, 
n = 4). 
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Fig. 4.12: Protein dependence of ∆ N1-227-hPDE2GAF/CyaB1. Assay conditions: 4 min, 37oC, 0.1M 
Tris/HCl pH 7.5, 75 µM Mg+2-ATP (n = 4) (A) Activity against protein concentration (B) Specific activity 
against protein concentration. 
 
 
4.1.2.3 Dose response study 
The AC activity of the chimera was assayed at increasing concentrations of cGMP. 
Stimulation factor was 4.2 ± 0.09, cGMP-EC50 of 7.7 ± 0.08 and Hill coefficient of 0.47 ± 
0.02; i.e identical to the WT chimera. 
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Fig. 4.13: Dose response curve of ∆ N1-227-hPDE2GAF/CyaB1. Assay conditions: 10 min, 37oC, 75 µM 
Mg+2-ATP, Tris/HCl pH 7.5, 55 nM protein (n = 4). 
 
4.1.2.4 Time dependence 
The time dependence was linear for both unactivated and activated protein (fig.4.14 A and B).  
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Fig. 4.14: Time dependence of ∆ N1-227-hPDE2GAF/CyaB1. Assay condition: 37oC, 75 µM Mg+2-ATP, 
Tris/HCl pH 7.5, 109 nM protein, 1-15 min (n = 6).  (A) Activity against time (B) Specific activity against 
time 
 
4.1.2.5 Substrate kinetics 
The Km of ∆ N-hPDE2GAF/CyaB1 chimera was 15.65 ± 2.35 (n = 4) as deduced from a 
Lineweaver-Burke plot. The protein activated by 100µM cGMP had a Km of 4.34 ± 0.89 µM 
(fig.4.15). Vmax values were 7.31 ± 0.54 and 41.62 ± 3.55 nmol/mg.min for unactivated and 
cGMP-activated, respectively. The Hill coefficients were 0.85 ± 0.06 (R2 = 0.98) and 0.68 ± 
0.02 (R2 = 0.98) for unactivated and activated forms, respectively; indicated no cooperativity. 
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Fig. 4.15: Substrate kinetics of ∆ N-hPDE2GAF/CyaB1. (■ basal activity, ○ + 100µM cGMP). Assay 
conditions: 4 min, 37oC, 0.1M Tris/HCl pH 7.5, 109 nM, 2-100 µM ATP (n = 4) (A) Michaelis-Menten 
Plot (B) Lineweaver-Burke plot  and (C) Hill Plot. 
 
4.1.2.6 Crystallization of ∆ N1-227-hPDE2GAF/CyaB1  
The crystallization of this construct was attempted. The protein was dialysed against 
crystallization buffer (section 2.6.2.6 with 10% glycerol) and concentrated by ultrafiltration 
using Nanosep filter (11,000 rpm, 4oC) to 8.2 mg/ml. 
Crystal screens I, II and lite (from Hampton) were employed using the hanging drop method. 
Plates were kept at 16oC and examined one week later. Rosette-like crystals appeared with CS 
I # 12 (30% isopropanol, 0.1M Na HEPES pH 7.5 and 0.2M MgCl2) and CS I # 19 (30% 
isopropanol, 0.1M Tris/HCl pH 8.5 and 0.2M ammonium acetate). Crystallization was 
reproducible yet efforts to optimize shape and size failed.  
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4.1.3 Exchange by hPDE5 N-terminus 
The N-terminus of the hPDE5 had a regulatory and inhibitory effect on the enzyme (Bruder, 
2006).  A chimera consisting of hPDE5 N-terminus (M1-S150), hPDE2 GAF (R228-558) and 
CyaB1 (386-859) was cloned in pQE30 (fig. 4.16), transformed into BL21 (DE3)[pREP4] 
E.coli cells and expressed. 
 
CN AC-catalystPAS
R
22
8
K
 8
59
H
 3
68
N
 4
02
L 
38
6
G
 5
95
hPDE2GAF
CyaB1 AC
N
55
8
GAFbGAFaN-ter
M
 1
S 
15
0
hPDE5N-terminus
R
22
8
K
 8
59
H
 3
68
N
 4
02
L 
38
6
G
 5
95
N
55
8
M
 1
S 
15
0
 
Fig.4.16: Domain organization of hPDE5N-ter-PDE2GAF/CyaB1. The exchanged N-terminus was 
determined according to an alignment between hPDE5 and rPDE2. Grey circle: allosteric binding site 
of cGMP. 
 
 
The protein was purified by binding to 200 µl of Ni-NTA agarose for 3 hr and eluted by 600 
µl elution buffer. The protein has a calculated MW of 109.2 kDa, an isoelectric point of 5.25. 
The yield was 150 µg/200 ml culture (fig.4.17). 
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Fig.4.17: SDS-PAGE (7.5%) of hPDE5N-PDE2GAF/CyaB1. (1 and 2) are supernatant and pellet of 
pQE30 as control (3 and 4) are supernatant and pellet of hPDE5N-PDE2GAF/CyaB1, respectively (5) 
Purified protein (2 µg) (6) Western blot (0.3µg protein and 12.5% SDS-PAGE) 
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4.1.3.1 Protein dependence 
The protein dependence was linear for both the activated and unactivated enzymes (Fig.4.18). 
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Fig. 4.18: Protein dependence of hPDE5N- hPDE2GAF/CyaB1. (■) unactivated protein (○) +300µM 
cGMP. Assay conditions: 37oC, 10 min, 75 µM ATP, Tris/HCl pH 7.5 (n = 4).  
4.1.3.2 Dose response study 
A stimulation factor of 6.44 ± 0.32 and a Hill coefficient of 0.56 ± 0.11, calculated from the 
dose response curve of the enzyme (fig.4.19), were consistent with the values obtained for 
hPDE2NGAF/ CyaB1. The basal activity of 0.67 ± 0.078 and a cGMP-EC50 of 3.67 ± 0.52 
were lower for the hPDE5-N-terminally construct than that of the hPDE2 N-terminally 
chimera. 
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Fig 4.19: Dose response curve of hPDE5N-hPDE2GAF/CyaB1. Assay condition: 37oC, 75 µM Mg+2-
ATP, 10 min, Tris/HCl pH 7.5, 92 nM Protein concentration (n = 4). 
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4.1.4 Truncation of rat PDE2GAF.CyaB1 N-terminus 
The first successful chimera which has the CyaB1 AC as a reporter was 
CyaB1N.rPDE2GAF/CyaB1 [80] 
I removed the CyaB1 N-terminus and obtained rPDE2GAF (207-546)/CyaB1 which is most 
similar to hPDE2GAF (228-558)/CyaB1 (fig.4.20) 
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Fig. 4.20: Domain organization of (A) CyaB1N-rPDE2GAF/CyaB1 and (B) rPDE2GAF (207-
546)/CyaB1. The grey circles in GAFb domain indicate the noncatalytic binding site of cGMP. 
 
For CyaB1N.rPDE2/CyaB1, the protein dependence was linear up to 300 nM and then 
decreased. For ∆ N1-206-rPDE2GAF/CyaB1, linearity of the protein dependence was up to 1.1 
µM (see fig.4.21). 
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Fig. 4.21: Protein dependence (A) CyaB1N-ter.rPDE2GAF/CyaB1. (Western blot at right, 0.6 µg) (B) 
∆ N1-206-rPDE2GAF/CyaB1 (western blot, 0.1 µg). (■) Basal activity, (○) +100µM cGMP.  
Assay conditions: 10 min, 37oC, 75 µM Mg+2-ATP, 0.1M Tris/HCl pH 7.5 (n = 4) 
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Dose response curves indicate lower fold stimulation of CyaB1N.rPDE2/CyaB1 (1.90 ± 
0.046) compared to the N-terminally truncated construct (21.16 ± 0.538). The cGMP-EC50 
values were comparable (11.15 ± 1.84 versus 7.34 ± 0.62 respectively, n = 4) and the Hill 
coefficient of 0.419 ± 0.057 (R2 = 0.9803) and 0.829 ± 0.02 (R2 = 0.9870) for both constructs, 
respectively, show no cooperativity (fig. 4.22 and table 4.1) 
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Fig. 4.22: Dose response of rPDE2 chimeras. Assay conditions: 10 min, 37oC, 75µM Mg+2-ATP, 0.1M 
Tris/HCl pH 7.5, 100 nM protein (n = 4). (A) CyaB1N-ter.rPDE2GAF/CyaB1 (B) ∆ N1-206-
rPDE2GAF/CyaB1 
 
Table 4.1: Summary of kinetic parameters of PDE2GAF/CyaB1 chimera compared to different N-
termini inserted in the front of the GAF domain  
 
construct Basal activity cGMP-EC50 
(µM) 
Stimulation 
factor (x) 
Hill 
coefficient 
figure 
hPDE2NGAF/CyaB1 1.32 ± 0.08 9.92 ± 1.04 4.88 ± 0.24 0.477 ± 0.042 
(R2 = 0.9754) 
4.4 
hPDE5N-PDE2GAF/CyaB1 0.67 ± 0.078 3.67 ± 0.52 6.44 ± 0.315 0.56 ± 0.11 
(R2 = 0.9909) 
4.13 
(∆N1-227-hPDE2GAF/CyaB1 12.2 ± 0.8 7.68 ± 0.072 4.16 ± 0.092 0.469 ± 0.020 
(R2 = 0.9760) 
4.20 
CyaB1N-rPDE2GAF/CyaB1 4.1 ± 0.12 11.2 ± 1.84 1.90 ± 0.046 0.419 ± 0.057 
(R2 = 0.9803) 
4.23-A 
(∆N1-206-rPDE2GAF/CyaB1 0.63 ± 0.02 7.34 ± 0.62 21.16 ± 0.538 0.829 ± 0.02 
(R2 = 0.9870) 
4.23-B 
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4.2 Role of the connecting helix of the GAF-tandem  
Three GAF tandems, CyaB2, hPDE2 and hPDE5, have been selected for this study. The crystal 
structure of two of them has been solved, mouse PDE2 and CyaB2 [23, 24]. 
4.2.1 CyaB2 GAF tandem 
4.2.1.1 Biochemical characterization of CyaB2 GAF/CyaB1 AC chimera 
The chimera has been characterized [101]. In this chimera, the CyaB2 GAF (M1- K441) was 
swapped in front of the AC CyaB1 in pQE30 with an N-terminal His-tag (see fig. 4.23). The 
protein has a calculated MW of 104.58 kDa and isoelectric point of 5.44. 
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Figure 4.23: Domain organization of CyaB2NGAF/CyaB1 chimera showing the amino acid boundaries 
of each domain determined by its crystal structure. Circles on the GAF domain indicate binding sites of 
cAMP to both GAF motifs. 
 
The protein was expressed in E.coli BL21(DE3)[pREP4] cells overnight at 19oC, lysed by 
French Press (twice) and purified by binding to 200 µl of Ni+2-NTA Agarose. The eluted 
protein was dialyzed against dialysis buffer overnight at 4oC to remove imidazole. 0.4 mg of 
protein was purified from 600 ml culture, and this was stable in 35% glycerol at -20oC 
(fig.4.24). 
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Fig. 4.24: SDS-PAGE (12.5%) of CyaB2NGAF/CyaB1 (1) pellet (2) Supernatant (3) Supernatant after 
Ni-NTA (4) Purified protein (4 µg) (5) Western blot (0.2 µg) 
 
The protein dependence (fig. 4.25.A) was linear. A slight decrease in activity was observed at 
high concentration. The dose response curve (fig.4.25.B) shows a large activation by cAMP 
(747 ± 82 fold; n = 4). The EC50 for cAMP was 0.53 ± 0.013 µM (n = 4). A Hill coefficient of 
2.84 ± 0.30 (R2 = 0.9231, n = 4) shows positive cooperativity [101]. 
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Fig. 4.25: (A) Protein dependence study of CyaB2NGAF/CyaB1 chimera. Assay condition: 37oC, 75 
µM ATP, 4 min and Tris/HCl pH 7.5. (■) Unactivated protein (○) +1 mM cAMP (B) cAMP-dose 
response of CyaB2GAF/CyaB1 chimera. Assay conditions: 37oC, 75 µM ATP, 4 min and 0.1 M 
Tris/HCl pH 7.5, 20 nM protein (n = 4). 
 
4.2.1.2 Role of connecting helix length 
According to the crystal structure of CyaB2 GAF (figure 4.26) [17], the boundaries of the 
GAF connecting helix were between F231-K263. The connecting helix was aligned with the 
connecting helices of CyaB1 and different PDE-GAF domains. Similarity was poor (fig.4.27). 
A leucine or isoleucine and two hydrophobic residues (either methionines or leucines) were 
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the only conserved residues. An accidental mutation of the first methionine of CyaB2 to 
threonine (M258T) reduced the fold-stimulation by cAMP (unpublished data). Here, I studied 
the effect of insertion or deletion of aa’s or the exchange with the connecting helix from 
CyaB1 on signal transduction. 
GAFa
GAFb
α1-helix
Connecting helix
 
Fig. 4.26: Crystal structure of CyaB2 GAF from [23], showing the GAFa α1 helix (V58-H78) (yellow) 
and connecting helix (F231-K263) (red) in addition to GAFa and b (green) 
 
CyaB1    : FAASIGIILETCQSFYVAARNQRGVTALLRATQ : 229 
CyaB2    : FAPSIRLILESSRSFYIATQKQRAAAAMMKAVK : 263 
hPDE2    : CFHYTSTVLTSTLAFQKEQKLKCECQALLQVAK : 401 
hPDE5    : YLAFCGIVLHNAQLYETSLLENKRNQVLLDLAS : 338 
hPDE6α   : YLNFVSIILRLHHTSYMYNIESRRSQILMWSAN : 248 
hPDE10   : NLAWASVAIHQVQVCRGLAKQTELNDFLLDVSK : 193 
hPDE11A4 : YLPFCGIAISNAQLFAASRKEYERSRALLEVVN : 394 
mPDE2    : CFHYTGTVLTSTLAFQKEQKLKCECQALLQVAK : 377 
Figure 4.27: ClustalW alignment of the GAF connecting helices of PDEs, CyaB1 and CyaB2. 
red: 100% similarity, grey: 80% similarity, blue:  60% similarity residues and Black: <60% similarity.  
 
Due to high affinity toward cAMP and high fold-stimulation, the CyaB2 GAF/CyaB1 chimera 
was selected for this study. Hence, any change in the affinity or fold-stimulation will be easily 
observed. 
4.2.1.2.1 Shortening of the connecting helix 
Each amino acid in an α-helix contributes to 100o of the turn which means that 3.6 amino 
acids are required to form one turn. To shorten the connecting helix between the two GAF 
motifs, deletion of up to one turn of the α-helix was suggested. Four constructs have been 
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cloned, in which 1, 2, 3 or 4 aa’s were deleted. RAAA which precede the two conserved 
hydrophobic amino acids were selected. The three alanines of the RAAA in CyaB2 are not 
conserved (Fig.4.27). 
 The four constructs were cloned in pQE30 with N-terminal His-tag, expressed in BL21 (DE3) 
[pREP4] E. coli (30 µM IPTG, 10 mM MgCl2 at 18oC, overnight). The proteins were purified 
by shaking with 350 µl Ni+2-NTA agarose for 90 min. The 104-kDa purified proteins were 
dialysed overnight against dialysis buffer and assayed. All proteins had good expression and 
little degradation on the western blot (fig.4.28). 
The protein dependence of the four constructs is shown in figure 4.28. Two constructs, (∆ 
R253)/CyaB1 (curve A) and CyaB2 (∆ R253-A255)/CyaB1 (curve C), have the same profile, 
a linear increase which levels off. Both constructs reached similar specific activity for both 
the activated and the unactivated states. In CyaB2 (∆ R253-A254)/CyaB1 (curve B) and 
CyaB2 (∆ R253-A256)/CyaB1 (curve D), the linearity continued but with different slopes. 
The specific activities were lower for these two constructs. 
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Fig. 4.28: Protein dependence of CyaB2 shortened GAF chimeras. Assay conditions: 4 min, 37oC, 75 
µM ATP, 10 mM MgCl2, 0.1M Tris/HCl pH 7.5 (n = 4). (■) Unactivated protein (○) +1 mM cAMP (A) 
CyaB2 (∆ R253)/CyaB1 (B) CyaB2 (∆ R253-A254)/CyaB1 (C) CyaB2 (∆ R253-A255)/CyaB1 (D) 
CyaB2 (∆ R253-A256)/CyaB1, the Western blot is shown to the right of each curve (0.2 µg) 
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Next, cAMP-dose response curves were performed for the four constructs (Figure 4.29).  
CyaB2 (∆253)/CyaB1 has a stimulation factor of 31.1 ± 2.43, an EC50 of 16.3 ± 3.40 and a 
Hill coefficient of 0.7880 ± 0.040 (R2 = 0.9766) (fig.4.29.A). CyaB2 (∆253-254)/CyaB1 has a 
fold-stimulation of 3.35 ± 0.32, an EC50 of 14.9 ± 1.7 and a Hill coefficient of 0.4577 ± 0.054 
(R2 = 0.9793) (Fig.4.29.B). CyaB2 (∆ 253-255)/CyaB1 has a fold-stimulation of 21.4 ± 1.26, 
an EC50 of 17.9 ± 2.00 and a Hill coefficient of 0.5474 ± 0.034 (R2 = 0.9801) (Fig.4.29.C) and 
CyaB2 (∆ 253-256)/CyaB1 has a fold-stimulation of 4.88 ± 0.44, an EC50 of 335 ± 1.00, and a 
Hill coefficient of 0.262 ± 0.013 (R2 = 0.9833) for (Fig.4.29.D). Basal activities and other 
parameters are summarized in table 4.2. 
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Fig. 4.29: Dose response curve of CyaB2 shortened GAF chimeras (A) CyaB2 (∆ R253)/CyaB1 (B) 
CyaB2 (∆ R253-A254)/CyaB1 (C) CyaB2 (∆ R253-A255)/CyaB1 (D) CyaB2 (∆ R253-A256)/CyaB1. 
Assay conditions: 4 min, 37oC, 0.1M Tris/HCl pH 7.5, 75 µM ATP, 20-50 nM protein (n = 4). 
 
4.2.1.2.2 Elongation of the connecting helix 
 
A flexible sequence (NAAIRS) has been established as an appropriate tool [102, 103]. This 
motif fits in any molecular structure of the protein without affecting its folding. Here, the 
connecting helix of CyaB2 GAF is elongated by 3-4 amino acids from the above motif (~1 
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turn) in the middle of the helix. Two constructs (CyaB2 (256+NAA)/CyaB1 and CyaB2 
(256+NAAI)/CyaB1) were generated. They were cloned, expressed and purified as mentioned 
above (section 4.2.1.2.1). CyaB2 (256+NAA)/CyaB1 was expressed and purified as intact 
protein while CyaB2 (256+NAAI)/CyaB1 was degraded during purification. Unlike the 
shortened constructs, both elongated ones had a linear protein dependency (Fig.4.30.A and 
B). The western blots of both constructs, CyaB2 (256+NAA)/CyaB1 showed a single band 
with little degradation while CyaB2 (256+NAAI)/CyaB1 showed only two bands of 
degradation products. Longer exposure of the film had shown a very thin band at the correct 
size of the protein. In AC assay, the amount of the protein was estimated to be 1% of the 
measured concentration and according to that the specific activities of protein dependence and 
dose response assays were calculated. 
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Fig. 4.30: Protein dependence of the elongated constructs. Assay conditions: 4 min, 37oC, 0.1M 
Tris/HCl pH 7.5, 75 µM ATP (n = 4). (A) CyaB2 (256+NAA)/CyaB1 (B) CyaB2 (256+NAAI)/CyaB1. 
Western blots are on the right. 
CyaB2 (256+NAA)/CyaB1 (fig.4.31.A) was stimulated 54.1 ± 6.6 fold with an EC50 of 10.6 ± 
0.28 and a Hill coefficient of 0.8212 ± 0.068 (R2 = 0.9833). CyaB2 (256+NAAI)/CyaB1 
curve (figure 4.31.B) shows a fold-stimulation of 42.43 ± 5.01, an EC50 of 8.11 ± 1.10 and 
Hill coefficient of 0.722 ± 0.051 (R2 = 0.9828) which are similar to the values obtained by 
CyaB2(256+NAA)/CyaB1. 
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Fig. 4.31: Dose response curve of CyaB2 elongated GAF constructs. Assay condition: 4 min, 37oC, 75 
µM Mg+2-ATP, 0.1M Tris/HCl pH 7.5 (n = 4). (A) CyaB2 (256+NAA)/CyaB1, 20 nM protein. (B) CyaB2 
(256+NAAI)/CyaB1, 9 nM protein. 
 
4.2.1.2.3 Exchange of the connecting helix 
 
Next, the whole connecting helix was exchanged with that of CyaB1 (Fig.4.32). The region 
(P233-K263) was replaced by the same number of amino acids (A199-Q229) from CyaB1. 
 
End of the helix exchangedBeginning of the helix exchanged
CyaB1 : NIPFNRNDEESFRDFAASIGIILETCQSFYVAARNQRGVTALLRATQTLGQS-LDLEATLQIVMEQAR : 249
CyaB2 : NQGFTSADEQLFQEFAPSIRLILESSRSFYIATQKQRAAAAMMKAVKSLSQSSLDLEDTLKRVMDEAK : 284
 
 
Fig.4.32: ClustalW alignment of CyaB1 and CyaB2 connecting helix region showing the amino acids 
exchanged between CyaB2 and CyaB1 tandem GAFs. 
 
The chimera was cloned (section 3.4.2.10), expressed at different concentrations of IPTG at 
18oC (fig.4.33) and purified as the CyaB2 wild type chimera. Expression using 30 µM IPTG 
have the least degradation. Lowering the temperature to 16oC increased degradation.  
Results 
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Fig.4.33: SDS-PAGE (12.5%) of optimization of expression conditions of CyaB2 (CyaB1 connecting 
helix)/CyaB1 chimera at different concentration of IPTG and 18oC. 
According to the dose-response curve (Fig.4.34), the stimulation factor of CyaB2GAF 
(CyaB1 connecting helix)/CyaB1 was 181.4 ± 26.1, the cAMP-EC50 was 0.62 ± 0.146 and 
Hill coefficient was 0.912 ± 0.018 (R2 = 0.9581, n = 4) 
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Fig.4.34: Dose response curve of CyaB2GAF (CyaB1 connecting helix)/CyaB1 Assay conditions: 
37oC, 75 µM ATP, 0.1M Tris/HCl pH 7.5, 4 min, 92 nM protein (n = 4) 
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Table 4.2: Summary of the different parameters for constructs of deleted or inserted aa’s compared to 
those of CyaB1 (WT) chimera 
Construct 
(aa inserted or deleted) 
Basal activity 
(nmol/mg.min) 
EC50 (µM) Fold-
stimulation  
(by cAMP) 
Hill 
coefficient 
(R2 is between 
parenthesis) 
figure 
CyaB2NGAF/CyaB1 
(wild type) 
1.85 ± 0.216 0.53 ± 0.013 747± 82 2.84 ± 0.3 
(0.9223) 
4.25.B 
CyaB2 (∆253)/CyaB1 
(-R) 
3.39 ± 0.440 16.3 ± 3.40 31.1 ± 2.43 0.788 ± 0.040 
(0.9766) 
4.29.A 
CyaB2 (∆253-254)/ CyaB1 
(-RA) 
1.04  ± 0.152 14.9 ± 1.7 3.35 ± 0.32 0.458±  0.054 
(0.9793) 
4.29.B 
CyaB2 (∆ 253-255)/ 
CyaB1 
(-RAA) 
3.77 ± 0.185 17.9 ± 2.00 21.4 ± 1.3 0.547 ± 0.034 
(0.9801) 
4.29.C 
CyaB2 (∆ 253-256)/ 
CyaB1 
(-RAAA) 
3.23 ± 0.434 335  ± 1.00 4.9 ± 0.44 0.26 ± 0.013 
(0.9833) 
4.29.D 
CyaB2 (256+NAA)/CyaB1 
(+ NAA) 
4.34 ± 1.143 10.6 ± 0.28  54.1  ± 6.6 0.82 ± 0.07 
(0.9833) 
4.31.A 
CyaB2 
(256+NAAI)/CyaB1 
(+NAAI) 
1.22 ± 0.28 8.11 ± 1.10 42.43 ± 5.01 0.72 ± 0.05 
(0.9828) 
4.31.B 
CyaB2GAF(CyaB1 
connecting helix)/ CyaB1 
0.74 ± 0.133 0.62 ± 0.146 181.4 ± 26.1 0.91 ± 0.02 
(0.9581) 
4.34 
 
4.2.1.3 Crystallization of CyaB2 (∆ R253-A255) and CyaB2 (256+NAA) 
In order to understand the conformational changes caused by shortening or elongation of the 
GAF connecting helix, attempts to crystallize one construct of each group were carried out. 
4.2.1.3.1 CyaB2GAF (∆ R253-A255) 
The coding region for amino acids V58-Q445 of CyaB2 was amplified by PCR using non-
mutated primers and CyaB2 (∆R253-A255)/CyaB1 as template and subcloned into the 
expression vector pQE60. The resultant plasmid pQE-CyaB2 (∆R253-A255) was transferred 
into E. coli strain BL21 (DE3)[pREP4] for overexpression (0.3 mM IPTG, 22oC for 5-7 hr). 
The recombinant CyaB2 (∆ R253-A255) protein was purified by binding to 200 µl of Ni+2-
NTA agarose slurry for 3 hr. The purification yielded 1.8 mg with a purity >95% from 600 ml 
cell culture. The C-terminal His-tagged protein has a calculated molecular weight of 43.92 
kDa. The expression, size and purity of the protein were evaluated by SDS-PAGE and 
western blot (fig. 4.35) 
Results 
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Fig.4.35: SDS-PAGE (12.5%) of CyaB2 (∆ R253-A255)cr (M) PeqGold protein marker (1) Pellet (2) 
Supernatant (3) Supernatant after Ni+2-NTA (4) Purified protein (2 µg) (5) Western blot (0.2 µg) 
The size exclusion chromatography of the protein produced a one peak-profile with a 
calculated MW of 84.6 kDa proves a dimer (42.3 kDa for the monomer) and this is consistant 
with the calculated  MW mentioned above (Fig.4.36). 
6 8 10 12 14 16 18 20 22
0
20
40
60
80
100
120
U
V 
ab
so
rb
an
ce
(m
AU
)
Volume (ml)
84.6 kDa
U
V 
ab
so
rb
an
ce
(m
AU
)
 
Fig. 4.36: Gel filtration of CyaB2 (∆R253-A255)cr using Supradex 200 (50 mM Tris/HCl pH 7.5, 
200mM NaCl, 10% glycerol and 2 mM MgCl2), No fractions were collected. 
 
The protein was dialyzed overnight at 4oC against the crystallization buffer, concentrated by 
ultrafiltration to 21.5 mg/ml, mixed with 2 mM cAMP and screened by crystal screen I, II and 
lite (from Hampton) using the hanging drop vapour diffusion method and the plates were kept 
at 12oC and examined. 
Large separated plates (300 × 200 µm) or rod clusters (300 ×50 µm) appeared one week later 
in Crystal screen II # 23 (1.6 M ammonium sulphate, 0.1M MES pH 6.5 and 10% v/v 1,4-
dioxane). Although the crystals were large, their thickness didn’t exceed 15 µm, and that was 
Results 
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not enough for having an image with good resolution. Further optimization of the size and 
form of the crystals was performed (see table 4.3). 
 
Table 4.3: optimization of the crystals of obtained CyaB2 (∆R253-A255)cr 
Fixed condition Variable Result 
0.1M MES pH 6.5 1.6M 
(NH4)2SO4, 21.5 mg/ml 
protein, 12oC 
1,4-dioxane 
(5,10,15,20,30%) 
10%1,4-dioxane was the only concentration 
which gave crystals (300 × 30) 
10% 1,4-dioxane, 0.1M 
MES pH 6.5, 21.5 mg/ml 
protein, 12oC 
 (NH4)2SO4 (M) 
(0.8,1.6,2.0,2.4, 3.2) 
Only 1.6M (NH4)2SO4 gave crystals 
10% 1,4-dioxane, 0.1M 
MES pH 6.5, 21.5 mg/ml 
protein, 12oC 
1.6M of different salts None of the salts gave crystals so (NH4)2SO4 
was a second precipitant. 
10% 1,4-dioxane, 1.6M 
(NH4)2SO4, 21.5 mg/ml 
protein, 12oC 
Buffer and pH 
Acetate and MES pH< 
6.5 
MES pH 6.5 
Tris/HCl pH 7.5-9.0 
 
No crystals (only precipitate) 
 
Large crystals (300 × 30) 
 Different sizes of crystals with the largest 
with pH 7.5. 
 
Different sizes of plate-shaped crystals have been obtained but with a maximum thickness of 
30 µm. Some of the crystals were measured by Dr. Schal from the department of 
Biochemistry, Tübingen University, but the resolution was 8 Ǻ upon diffraction. No further 
optimization has been done. The shape and size of the crystals obtained by the first trial and 
by optimization are shown in Fig.4.37.  
Results 
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Fig. 4.37: Crystals of CyaB2 (∆R253-A255)cr  (A and B) Initial crystallization trials by crystal screen II 
# 23 (C) The reproducibility of the crystallization by my own solutions (D) Crystals optimized by 10% 
dioxane 0.1M Tris/HCl pH 7.5, 1.6M (NH4)2SO4 (E) Crystals obtained by 10% dioxane, 0.1M Tris/HCl 
pH 8.5, 1.6M (NH4)2SO4. 
 
4.2.1.3.2 CyaB2GAF (256 + NAA)cr 
The cloning, overexpression and purification of CyaB2 (256+NAA)cr used the same 
protocols as for CyaB2 (∆ R253-A255)cr. The resulting protein has a calculated MW of 44.47 
kDa and excellent purity (fig.4.38, A). Crystallization was set as mentioned before, but no 
crystals were obtained after time interval reaches to one year. The gel filtration of 200µl (2 
mg/ml) of the purified protein shows a dimer of 81.2 kDa (40.6 kDa for the monomer) (see 
Fig.4.38, B) 
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Fig. 4.38: (A) SDS-PAGE of CyaB2 GAF (256+NAA)cr (M) PeqGold protein marker (1) Pellet  (2) 
Supernatant (3) Supernatant after Ni-NTA (4) Purified protein (2 µg) (5) Western blot (0.2 µg) (B) Gel 
filtration of 40 µg of CyaB2 (256+NAA) showing single peak for a dimer. No fractions were collected.  
 
4.2.1.4 Mutation of GAFa α – helices 
4.2.1.4.1 α1 – helix 
according to results obtained from shortening and elongation of the CyaB2 GAF connecting 
helix and the dramatic decrease in the fold stimulation and affinity to cAMP, I have observed 
another 2 similar hydrophobic aa’s (methionine, leucine or isoleucine) in the α1–helix in the 
alignment prepared by Martinez et al [24]. All α1–helices of CyaB and PDE GAFa domains 
were aligned (fig.4.39) and the alignment showed the poor homology in the presumed α1–
helix.  
Results 
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hPDE2  : ---PPEGTAEDQKGGAAYTDRDRKILQLC--GELYDLDASSLQLKVLQYLQQETRASRCCLLLVSEDN :  271
hPDE5  : ---KEQMPLTPPRFDHDEGDQCSRLLELV-KDISSHLDVTALCHKIFLHIHGLISADRYSLFLVCEDS :  194
hPDE6a : ----KEAAVDFSNYHSPSSMEESEIIFDLLRDFQENLQTEKCIFNVMKKLCFLLQADRMSLFMYRTRN :  103
hPDE10 : ----KEVSRYQDTNMQGVVYELNSYIEQR---LDTGGDNQLLLYELSSIIKIATKADGFALYFLGECN :  121
hPDE11 : ---QYPPTAIDYKCHLKKHNERQFFLELV-KDISNDLDLTSLSYKILIFVCLMVDADRCSLFLVEGAA :  247
CyaB1  : SVNEFVCLLDFITAEFQQFLRAIELINNE----ALENMLEKVLEAITLKIGQILQAEHTAIFLVDYDK :  96 
CyaB2  : ----FKQVVTEVEQKLQIVHQTLSMLDSH----GFENILQEMLQSITLKTGELLGADRTTIFLLDEEK :  113
 
α2- helixα1- helix
 
Fig.4.39: Alignment of cyanobacterial AC’s and human PDE’s α1-helices preceding the GAFa domain 
determined according to the crystal structure of mouse PDE2 and CyaB2 
In CyaB2, these residues are methionine and leucine (ML). M74 and L75 were either mutated 
to Glycines or to M74S and L75T which are hydrophilic in nature. The protein dependence 
curves (fig.4.40) were not linear over the tested range. 
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Fig. 4.40: Protein dependence (A) CyaB2 (M74G/L75G)/CyaB1 (B) CyaB2 (M74S/L75T)/CyaB1. 
Assay conditions: 4 min, 37oC, 0.1M Tris/HCl pH 7.5, 75 µM ATP, 10 mM MgCl2 (n = 4)  
 
 
The cAMP-dose response of CyaB2 (M74G/L75G)/CyaB1 (fig.4.41) shows a 261 fold 
stimulation (± 14.4), and cAMP-EC50 of 7.95 ± 0.17 µM. CyaB2 (M74S/L75T)/CyaB1 
mutant has 133 fold stimulation (± 13.9) and cAMP-EC50 of 4.16 ± 0.3 µM. The Hill 
coefficients of both mutants were showing no or little cooperativity (1.19 ± 0.02 (R2=0.9877), 
1.29 ± 0.07 (R2=0.9758), respectively). 
 
Results 
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Fig. 4.41: Dose response of (A) CyaB2 (M74G/L75G)/CyaB1 (B) CyaB2 (M74S/L75T)/CyaB1. Assay 
conditions: 4 min, 37oC, 0.1M Tris/HCl pH 7.5, 75 µM ATP, 10 mM MgCl2, 25 nM protein (n = 4)  
 
 
 
4.2.1.4.2 α2- helix 
Similar to the ML residues in α1–helix, another ML residues were observed in the α2– helix 
of CyaB2. Single mutation of each one of them to serine followed by double mutation for 
both of them to alanine/serine produced three different constructs. 
The protein dependence curves of the three mutants (Fig.4.42) showed an increase in the 
specific activity by increasing the protein concentration which levels off at a concentration of 
100 nM. 
Results 
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Fig. 4.42: Protein dependence of α2-helix mutants. Assay condition: 4 min, 37oC, 75 µM ATP, 10 mM 
MgCl2, 0.1M Tris/HCl pH 7.5 (A) CyaB2 (M87S)/CyaB1 (B) CyaB2 (L88S)/CyaB1 (C) CyaB2 
(ML87AS)/CyaB1 
 
 
CyaB2 (M87S)/CyaB1 had a 128 fold-stimulation of (± 7.6), an EC50 of 1.15 ± 0.03 and a Hill 
coefficient of 3.07 ± 0.2 according to the curve in fig.4.43.A, so the EC50 and the Hill 
coefficient were comparable to the WT but the mutant had a lower fold stimulation. The 
second mutant, CyaB2 (L88S)/CyaB1, had 343 fold-stimulation (± 14.0) and higher EC50 of 
12.0 ± 1.69 µM cAMP. The Hill coefficient was showing cooperativity with a value of 1.43 ± 
0.07 (R2 = 0.9737, n = 4) (curve B). The double mutant, CyaB2 (M87A/L88S)/CyaB1 was 
sharing the characteristics of both mutants, the low fold stimulation of 145 ± 4.5 fold and the 
low EC50 of 1.16 ± 0.27 µM cAMP, which is similar to the first mutant and a Hill coefficient 
of 1.57 ± 0.21 (R2 = 0.945) of the second mutant. 
Results 
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Fig. 4.43: Dose response curves of α2-helix mutants. Assay conditions: 4 min, 37oC, 75 µM ATP, 10 
mM MgCl2, 0.1M Tris/HCl pH 7.5, 40-50 nM protein (n = 4) (A) CyaB2 (M87S)/CyaB1 (B) CyaB2 
(L88S)/CyaB1 (C) CyaB2 (M87A/L88S)/CyaB1 
Table 4.4: summary of enzyme parameters of CyaB2 α-helix mutants. 
construct Basal activity 
(nmol/mg.min) 
EC50 (µM) Fold-
stimulation  
(by cAMP) 
Hill 
coefficient 
figure 
CyaB2NGAF/CyaB1 1.85 ± 0.216 0.53± 0.013 746.8 ± 82.4 2.84 ±0.3 
(0.9223) 
4.25.B 
CyaB2(ML74GG)/CyaB1 2.86 ± 0.195 7.95± 0.17 260.9± 14.4 1.19 ± 0.02 
(0.9877) 
4.41.A 
CyaB2(ML74ST)/CyaB1 1.64 ± 0.187 4.16± 0.3 133.5 ± 13.9 1.29 ±  0.07 
(0.9758) 
4.41.B 
CyaB2(M87S)/CyaB1 1.64 ± 0.131 1.15±0.03 127.8 ± 7.6 3.07 ± 0.2 
(0.9825) 
4.43.A 
CyaB2(L88S)/CyaB1 1.23 ± 0.058 12.0±1.69 342.5 ± 14.0 1.43 ± 0.07 
(0.9737) 
4.43.B 
CyaB2(ML87AS)/CyaB1 0.77 ± 0.049 1.16±0.27 144.8 ± 4.5 1.57 ± 0.21 
(0.9448) 
4.43.C 
Results 
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4.2.1.5 Mutation of connecting helix of CyaB2 GAF 
According to the alignment in fig.4.27, the two conserved hydrophobic amino acids were 
leucines in almost all the PDE GAF connecting helices. Five mutants in which one or both 
methionines were mutated were prepared. The first mutant contained the accidental mutation 
of M258T and this was recloned as in section (3.4.2.9) to get rid other mutations, the next four 
mutants had both methionines mutated, once to glycines, to alanines, to leucines and fourth to 
serine/threonine. These were cloned, expressed and run on the SDS-PAGE to check purity 
(Fig.4.44). All constructs were well-expressed with good yield. The protein dependence 
assays of four of them are shown in figure 4.45. All activated proteins had low activity at low 
protein concentration which increased with protein concentration. Although leucine does not 
differ in size from methionine, CyaB2 (M258L/M259L)/CyaB1 protein was dead with zero 
activity and activation, possibly due to misfolding. 
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Fig.4.44: The expression of the five mutants in addition to the WT (4 µg each) (1) CyaB2NGAF/CyaB1 
(2) CyaB2 (M258T)/CyaB1 (3) CyaB2 (M258A/M259A)/CyaB1 (4) CyaB2 (M258S/M259T)/CyaB1 (5) 
CyaB2 (M258L/M259L)/CyaB1 (6) CyaB2 (M258G/M259G)/CyaB1. 
 
Results 
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Fig. 4.45: Protein dependence of CyaB2GAF connecting helix muants. Assay conditions: 4 min, 37oC, 
75 µM ATP, 10 mM MgCl2, 0.1M Tris/HCl pH 7.5 (n = 4) (A) CyaB2 (M258T)/CyaB1 (B) CyaB2 
(M258G/M259G)/CyaB1 (C) CyaB2 (M258A/M259A)/CyaB1    (D) CyaB2 (M258S/M259T)/CyaB1. 
 
In the cAMP-dose response curves, the fold-stimulation of CyaB2 (M258T)/CyaB1 was 223.5 
± 14.2, the EC50 was 2.42 ± 0.09 µM cAMP and a Hill coefficient of 1.56 ± 0.023. CyaB2 
(M258G/M259G)/CyaB1 had a fold-stimulation of 60.0 ± 10.24, an EC50 of 19.2 ± 1.24 µM 
cAMP and Hill coefficient of 0.926 ± 0.04. For the third construct, CyaB2 
(M258A/M259A)/CyaB1, the fold-stimulation was 199.2 ± 8.5, an EC50 of 27.7 ± 2.4 µM and 
a Hill coefficient of 1.55 ± 0.2. The last mutant, CyaB2 (M258S/M259T)/CyaB1, had a fold-
stimulation of 102.5 ± 5.7, an EC50 of 7.85 ± 0.58 and a Hill coefficient of 1.54 ± 0.06 
(Fig.4.46.A-D). 
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Fig.4.46: Dose response curve of the CyaB2 connecting helix mutants. Assay conditions: 4 min, 37oC, 
75 µM ATP, 10 mM MgCl2,0.1M Tris/HCl pH 7.5, 40-50 nM protein (n = 4) 
 
From the two mutants of the α1–helix, CyaB1 (M74S/L75T)/CyaB1 had lower fold 
stimulation and from that of the connecting helix, CyaB2 (M258S/M259T)/CyaB1 and CyaB2 
(M258G/M259G)/CyaB1 had the least fold-stimulation. The mutants to hydrophilic amino 
acids of both helices were combined in a chimeric quadruple mutation, expressed and assayed 
for protein dependence and dose response. The protein dependence curve was showing an 
interesting result as the activity was increasing in a parabolic manner and the specific activity 
in a linear manner. The effect could be due to disturbance in the dimerization of the GAF 
domain which led to a decrease in the specific activity of the enzyme at low concentration of 
the protein and as the concentration increases, the dimerization increases and the response to 
the cAMP increases as well (fig.4.47). 
Results 
 134
           
[Protein] (nM)
BA
0 50 100 150 200 250 300
0
20
40
60
80
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
0 50 100 150 200 250 300
0
40
80
120
160
200
A
ct
iv
ity
(p
m
ol
cA
M
P/
m
in
)
[protein] (nM)
0 50 100 150 200 250 300
0
3
6
9
12
15
18
A
ct
iv
ity
(c
AM
P
/m
in
)
[protein] (nM)
0 50 100 150 200 250 300
0
1
2
3
4
5
6
7
(n
m
ol
 c
AM
P/
m
g.
m
in
)
[Protein] (nM)
116
66
45
35
D
10 24 48 72 96 191 287
0
3
6
9
12
15
Fo
ld
-S
tim
ul
at
io
n
[ protein ] (nM)
C
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
A
ct
iv
ity
(p
m
ol
cA
M
P/
m
in
)
A
ct
iv
ity
(c
AM
P
/m
in
)
A
ct
iv
ity
(c
AM
P
/m
in
)
(n
m
ol
 c
AM
P/
m
g.
m
in
)
(n
m
ol
 c
AM
P/
m
g.
m
in
)
Fo
ld
-S
tim
ul
at
io
n
Fo
ld
-S
tim
ul
at
io
n
 
Fig. 4.47: Protein dependence of CyaB2 (M74S/L75T/M258S/M259T)/CyaB1. Assay conditions: 4 
min, 37oC, 75 µM ATP, 10 mM MgCl2, 0.1M Tris/HCl pH 7.5 (n = 4) (A) Activity against protein 
concentration (B) Specific activity against protein concentration. (C) Plot shows the effect of protein 
concentration on the fold-stimulation (D) Western blot of 0.3 µg protein. 
 
 
The dose response curve of CyaB2 (M74S/L75T/M258S/M259T)/CyaB1 (Fig.4.48) showed a 
fold stimulation of 6.4 ± 0.56, an EC50 of 9.1 ± 0.04 µM cAMP and a Hill coefficient of 0.47 
± 0.06, i.e loss of cooperativity. 
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Fig. 4.48: Dose response curve of CyaB2 (M74S/L75T/M258S/M259T)/CyaB1. Assay conditions: 4 
min, 37oC, 75 µM ATP, 10 mM MgCl2, 0.1M Tris/HCl pH 7.5, 30 nM protein (n = 4).   
 
 
 
Table 4.5: different parameters of CyaB2 GAF connecting helix mutants compared to the wild type 
Mutation Basal activity 
(nmol/mg.min) 
EC50 (µM) Activation 
factor (x) 
(by cAMP) 
Hill 
coefficient 
figure 
WT 1.85 ± 0.216 0.53 ± 0.013 746.8 ± 82.4 2.84 ± 0.3 
(0.9223) 
4.26.B 
M258T 1.01 ± 0.189 2.42 ± 0.09 223.5 ± 14.2 1.56± 0.023 
(0.9883) 
4.48.A 
M258G/M259G 1.59 ± 0.25 19.2 ± 1.24 60.0 ± 10.24  0.926 ±0.04 
(0.9774) 
4.48.B 
M258A/M259A 1.89 ± 0.123 27.7 ± 2.4 199.2 ± 8.5 1.554 ± 0.2 
(0.9764) 
4.48.C 
M258L/M259L Inactive enzyme  
M258S/M259T 1.70 ± 0.455 7.85 ± 0.58 102.5 ± 5.7 1.54 ± 0.06 
(0.9782) 
4.48.D 
M74S/M75T/M258S/M259T 3.01 ± 0.358 9.08 ± 0.036 6.4 ± 0.56 0.47 ± 0.06 
(0.9907) 
4.50 
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4.2.1.6 Dimerization study and gel filtration. 
From the above constructs, two GAF domains were selected to be cloned in pQE60 and 
studied for the dimerization to see if this decrease in the fold stimulation and affinity toward 
cAMP is due to dimerization proposed to occur through these two amino acids or it was a 
folding problem. CyaB2 (M258S/M259T) and CyaB2 (M258L/M259L) were selected and 
checked for dimerization, using both glutaraldehyde and gel filtration. The two constructs 
were cloned using the same primers as used in the preparation of the crystallized CyaB2GAF 
(V58-Q445), transformed into BL21 (DE3)[pREP4] E.coli cells, overexpressed at 22oC, 300 
µM IPTG for 6 hrs. Both proteins were expressed in good yield (600 µg/200 ml culture) and 
evaluated by SDS-PAGE for size and purity (fig.4.49). Good purity was observed for CyaB2 
(M258S/M259T) and the size was matching the calculated MW (44.7 kDa). For CyaB2 
(M258L/M259L), the purity was excellent but the size was much higher so the sequencing of 
the DNA was repeated to exclude frame shifting by mutations and it was found to be correct 
which suggested the increase in protein volume due to misfolding and this explains the earlier 
results obtained for the chimera of this mutant which produced inactive enzyme. 
116
25
35
45
66
BA
 
Fig.4.49: SDS-PAGE (12.5%) showing the correct size of CyaB2 GAF (M258S/M259T) (A) and the 
wrong size for CyaB2 GAF (M258L/M259L) (B) 
The gel filtration was performed for both constructs and they were showing a dimer in both 
mutants with a broad peak of larger size than calculated for CyaB2GAF (M258L/M259L) (see 
fig.4.50) 
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Fig.4.50: Gel filtration of CyaB2GAF connecting helix mutants (A) CyaB2GAF (M258S/M259T) and 
(B) CyaB2GAF (M258L/M259L). No fractions were collected. 
 
4.2.1.7 Crystallization of CyaB2 PAS (444-568), Catalytic (569-860) and PAS/Catalytic 
(444-860) domains. 
The different domains of CyaB2 enzyme were cloned. CyaB2 PAS (E444-R568), 
PAS/Catalytic (E444-K860), Catalytic (L569-K860) were cloned in pQE30, transformed into 
E.coli BL21 (DE3) [pREP4) cells and expressed (27oC, 300 µM IPTG, 6 hr). The washed-cell 
pellets were suspended in lysis buffer, lysed by passing twice through French press and 
purified by shaking with 200 µl Ni-NTA agarose for 3 hr. 
In fig.4.51, CyaB2 PAS/catalytic was degraded and no band of 48.43 kDa appears on the gel 
which make the crystallization experiments not possible. For CyaB2 catalytic, one band 
appears at the correct size (34.89 kDa) but with a lot of impurities, in addition to the low 
concentration of protein so optimization of expression was required but it was not done due 
large number of domains prepared at the same time from both CyaB1 and CyaB2 enzymes for 
crystallization purposes. The CyaB2 PAS domain was expressed in a very high purity (see 
fig.4.51) but the estimated MW of the protein (19 kDa) was higher than the calculated one 
(15.09 kDa). Nevertheless, the protein was expressed again on large scale, purified, dialysed 
against crystallization buffer (10% glycerol) and concentrated (NANOSEP®) to 21.5 mg/ml. 
Crystal screens I, II, and lite were used. Yet, no crystals were obtained. 
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Fig.4.51: (A) SDS-PAGE (15%) of CyaB2 PAS and CyaB2 catalytic compared to pQE30 (1) Purified 
CyaB2 PAS (2 µg) (2) purified CyaB2 catalytic (2 µg) (3 and 4) Supernatant and pellets of CyaB2 PAS 
respectively (5 and 6) Supernatant and pellets of CyaB2 catalytic respectively (7 and 8) Supernatant 
and pellets of pQE30, respectively. 
(B) SDS-PAGE (15%) of CyaB2 PAS/Catalytic compared to pQE30 (1) Purified protein (2µg) (2 and 3) 
Supernatant and pellets of CyaB2 PAS/Catalytic (4 and 5) Supernatant and pellets of pQE30 as 
control. 
 
4.2.2 hPDE2 GAF domain 
4.2.2.1 Mutation of GAFa α1– helix  
In the crystal structure of the mouse PDE2A GAF tandem, the dimer observed was consistent 
with earlier data of PDE2A holoenzyme that suggested that the N-terminal region is 
responsible for dimerization [104]. GAFa rather than GAFb was involved in the dimerization 
as observed from the crystal structure shown in fig.4.52. 
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Fig.4.52: The crystal structure of mouse PDE2 GAF domain showing the dimerization involving the 
GAFa motif 
 
In PDE2A, several hydrophobic residues in GAFa are involved in the dimer interface between 
the two monomers, including L223 of helix α1 which inserts into a hydrophobic pocket 
formed by I222’, L223’, C226’, all from helix α1’, and Y365’ from the kink between α5’ and 
the connecting helix. D219’ on α1’ seals the pocket from the solvent [24]. These amino acids 
mentioned in the dimerization of mPDE2 GAFa (I222, L223, C226, Y365 and D219) 
correspond to residues I230, L231, C234, Y372, and D227 in human PDE2 GAFa. 
The two corresponding amino acids in the α1-helix were mutated to explore the effect of 
dimerization on the affinity to cGMP and on stimulation. Either I230S or L231S were 
prepared. The constructs were cloned in pQE30 and were expressed in E.coli 
BL21(DE3)[pREP4] for overnight at 16oC and induced by 30 µM IPTG and 10 mM MgCl2. 
The washed, frozen pellets were resuspended in lysis buffer, lysed by French Press and the 
proteins were purified by binding to Ni+2-NTA agarose for 3 hr with a yield of 240 µg/200 ml 
culture. The purified proteins had a calculated MW of 116.2 kDa. 
The protein dependence was assayed (Fig.4.53.A and B). hPDE2 (I230S)/CyaB1 was linear 
while for hPDE2 (L231S)/CyaB1, higher activity was observed at lower protein 
concentrations.  The proteins were run on SDS-PAGE (12.5%) followed by Western blot.  
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Fig. 4.53: Protein dependence of α1-helix hPDE2 mutants. (■) Unactivated protein (○) +300µM cGMP. 
Assay conditions: 4 min, 37oC, 75 µM ATP, 10 mM MgCl2, 0.1M Tris/HCl pH 7.5 (A) hPDE2NGAF 
(I230S)/CyaB1, to the right western blot (0.5µg) (B) hPDE2NGAF (L231S)/CyaB1. Western blots 
(0.1µg) at right. 
  
In figure 4.54, hPDE2NGAF (I230S)/CyaB1 and hPDE2NGAF (L231S)/CyaB1 were 
showing a stimulation factor of 16.9 ± 0.8 and 23.9 ± 0.9 respectively, which is higher than 
that of wild type (5.2 ± 0.4 ) (Section 4.1.1), the EC50 for cGMP was 6.5 ± 0.53 and 5.9 ± 0.4, 
respectively, i.e. not different from the wild type. Although Hill coefficient was higher for 
both of them (1.18 ± 0.118 R2 = 0.9670 for I230S and 0.844 ± 0.072, R2 = 0.9844 for L231S), 
only I230S was showing some cooperativity. 
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Fig. 4.54: Dose response curve of α1-helix hPDE2 mutants. Assay conditions: 37oC, 75 µM ATP, 10 
mM MgCl2, Tris/HCl pH 7.5, 10 min, 86 nM protein (n = 4) (A) hPDE2 NGAF (I230S)/CyaB1. (B) 
hPDE2 NGAF (L231S)/CyaB1. 
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4.2.2.2 Mutation of the connecting helix of hPDE2NGAF/CyaB1 
According to the alignment of the hPDE2GAF and CyaB2 GAF connecting helix (Fig. 4.55), 
the helix connecting the two GAF domains has a poor homology (15 % identity and 27 % 
similarity). 
hPDE2 : EHVIQHCFHYTSTVLTSTLAFQKEQKLKCECQALLQVAKNLFTHLDDVSVLLQEIIT 419
CyaB2 : EQLFQEFAPSIRLILESSRSFYIATQKQRAAAAMMKAVKSLSQSSLDLEDTLKRVMD 281
Start of connecting helix end of connecting helix  
Figure 4.55: ClustalW alignment of CyaB2 and hPDE2 GAF connecting helices as determined from 
their crystal structures. Arrows determine the beginning and end. [24]. 
 
To study the effect of cysteine and the two leucine residues on signal transduction, three 
mutants were generated. The first mutant was a triple mutation (C393S/L396A/L397A). The 
construct was cloned in pQE30 with an N-terminal His-tag, expressed in BL-21(DE3) 
[pREP4]. Protein expression was induced by 50 µM IPTG, 10 mM MgCl2 at (16oC, 210 rpm, 
overnight), and the protein was purified using 200 µl Ni-NTA agarose (0oC, 3 hrs). The 
purified protein was dialysed overnight at 4oC against dialysis buffer and assayed 
immediately. 
The protein dependence was linear (0.0088-0.88 µM) with lower fold stimulation than the 
wild type (fig.4.56) 
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Fig. 4.56: Protein dependence of hPDE2 (C393S/L396A/L397A)/CyaB1. (■) unactivated protein (○) 
+300µM cGMP. Assay conditions: 10 min, 37oC, 75 µM ATP, 10 mM MgCl2, 0.1M Tris/HCl pH 7.5 (n = 
4). Western blot (0.5 µg) at right. 
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The cGMP-EC50 was calculated to be 0.354 ± 0.077 µM (n = 6) which is 28-fold lower than 
that of the WT chimera (9.92 ± 1.04 µM). The stimulation factor was also lower (3.37 ± 0.2, n 
= 6) and the Hill coefficient of 0.57 ± 0.08 (R2 = 0.9901, n = 6) indicated no cooperativity 
(see Fig.4.57). 
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Fig.4.57: Dose response curve of hPDE2NGAF (C393S/L396A/L397A)/CyaB1 chimera. Assay 
conditions: 4 min, 37oC, 75 µM Mg+2-ATP, 0.1M Tris/HCl pH 7.5, 90 nM protein (n = 6) 
 
Because it was difficult to know whether cysteine or the two leucines were responsible for 
this data, mutation was separated by cloning of two constructs, i.e. C393S and L396A/L397A. 
The mutants were expressed and purified as the triple mutated construct.  
The protein dependence (fig.4.58.A and B) was linear for hPDE2NGAF (C393S)/CyaB1 but 
for hPDE2NGAF (L396A/L397A)/ CyaB1, the specific activity was increasing up to 90 nM 
and then it leveled off. 
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Fig.4.58: Protein dependence of (A) hPDE2NGAF (C393S)/CyaB1 and (B) hPDE2NGAF 
(L396A/L397A)/CyaB1. (■) Unactivated protein (○) +100µM cGMP. Assay conditions: 75µM ATP, 10 
mM MgCl2, 37oC, 0.1M Tris/HCl pH 7.5, 10 min (n = 4). 
 
cGMP stimulated 4.8 fold (± 0.17) (Fig.4.59) and the EC50 and Hill coefficient of were 4.80, 
5.1 ± 0.06 µM and 0.54 ± 0.03 (R2 = 0.987, n = 4), respectively, i.e. not significantly different 
Results 
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from those of hPDE2NGAF/ CyaB1. The construct, hPDE2NGAF (L396A/L397A)/CyaB1, 
had a fold-stimulation of 3.8 ± 0.07, an EC50 of 0.44 ± 0.0335 and a Hill coefficient of 0.9 ± 
0.17 (R2 = 0.9518) consistent with the triple mutated construct so the decrease in EC50 was 
due to the leucines residues and not the disulfide bridging of the cysteine. 
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Fig. 4.59: Dose response curves of (A) hPDE2 (C393S)/CyaB1 (B) hPDE2 (L396A/L397A)/CyaB1. 
Assay conditions: 75µM Mg+2-ATP, 37oC, 0.1M Tris/HCl pH 7.5, 10 min (n = 4) 
 
4.2.2.3  Quadruple mutation of both helices 
Accordingly, a truncated ∆ 1-227 construct with quadraple mutation in both GAFa α1 helix 
and the connecting helix was prepared. The  ∆ N hPDE2GAF 
(I230A/L231A/L396A/L397A)/CyaB1 was cloned in pQE30, expressed in BL21 (DE3) 
[pREP4] as for other mutants, the purified protein has a MW of 91.8 kDa. The protein 
dependence curve was linear (Fig.4.60). 
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Fig. 4.60: (A) protein dependence of ∆N-hPDE2GAF (I230A/L231A/L396A/L397A)/CyaB1. (■) 
Unactivated protein (○) +100µM cGMP. Assay conditions: 37oC, 10 min, 75 µM Mg+2-ATP, 0.1M 
Tris/HCl pH 7.5 (n = 4). (B) SDS-PAGE (12.5%) with 4 µg protein (C) Western blot (0.2 µg). 
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The construct was not activated by cGMP. In addition, basal activity was higher than all 
PDE2 constructs and mutants (Fig.4.61). 
-8 -7 -6 -5 -4 -3 -2
0
5
10
15
20
25
30
35
40
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
Log[cNMP] (M)
cAMP
cGMP
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
 
Fig. 4.61: Dose response curve of ∆ N- hPDE2 (I230A/L 231A/L396A/L397A)/CyaB1. Assay 
conditions: 37oC, 10 min, 75 µM Mg+2-ATP, 0.1M Tris/HCl  pH 7.5, 109 nM protein (n = 4) 
The time dependence was examined ± 100µM cGMP. It was linear and cGMP did not 
stimulate (Fig.4.62.A and B). The parameters of hPDE2 chimeras and mutants are 
summarized in table 4.6 
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Fig.4.62: Time dependence of ∆ N- hPDE2 (I230A/L231A/L396A/L397A)/CyaB1. (■) unactivated 
protein (○) +100µM cGMP. Assay conditions: 37oC, 0.1M Tris/HCl pH 7.5, 75 µM Mg+2-ATP, 1-15 min, 
109 nM protein (n = 4) (A) activity against time (B) specific activity against time. 
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Table 4.6: Summary for the parameters of hPDE2 chimeras and mutants. 
construct Basal activity 
(nmol/mg.min) 
EC50 (µM) 
(n =4) 
Activation 
factor (x) 
(by cAMP) 
Hill coefficient 
hPDE2NGAF/CyaB1 1.32 ± 0.08 9.92 ± 1.04 5.2 ± 0.37 0.477 ± 0.042 
(R2 = 0.9754) 
∆ N -hPDE2 GAF/CyaB1 12.2 ± 0.8 7.7 ± 0.072 4.2 ± 0.092 0.469 ± 0.020 
(R2 = 0.9760) 
hPDE2 (I230S)/CyaB1 0.9 ± 0.14 6.49 ± 0.53 16.9 ± 0.9 
(n = 4) 
1.18 ± 0.118 
(R2 = 0.9670) 
hPDE2 (L231S)/CyaB1 1.3 ± 0.04 5.94 ± 0.37 23.9 ± 0.9 
(n = 4) 
0.844 ± 0.072 
(R2 = 0.9844) 
hPDE2 (C393S)/CyaB1 0.89 ± 0.05 5.1 ± 0.063 4.8 ± 0.17  
(n = 4) 
0.539 ± 0.032 
(R2 = 0.9871) 
hPDE2 (LL396AA)/CyaB1 2.5 ± 0.03 0.44 ± 0.034 3.79 ± 0.068 
(n = 4) 
0.897 ± 0.172 
(R2 = 0.9518) 
hPDE2 (C393S/LL396AA)/CyaB1 0.74 ± 0.06 0.35 ± 0.08 3.366 ± 0.18 
(n = 4) 
0.571 ± 0.075 
(R2 = 0.9901) 
∆ N-hPDE2 (I230A/L231A/ 
L396A/L397A) /  CyaB1 
28.3 ± 0.93 ND* 1.11 ± 0.055 
(n = 4) 
ND* 
* ND means not determined. 
4.2.2.4 Crystallization of hPDE2GAF ± N-terminus 
4.2.2.4.1 hPDE2NGAFcr 
hPDE2NGAF (M1-562) was cloned in pQE30 and transformed into BL21 (DE3) [pREP4] for 
expression.  200-ml batches of LB-medium were inoculated by 5 ml of an overnight culture 
and induced (0.3 mM IPTG, 22oC for 6 hr). The protein was purified by 200 µl Ni+2-NTA 
agarose for three hours. The 62.9-kDa, His6-tagged protein was analysed by SDS-PAGE and 
Western blot (fig.4.63). 200 ml culture produced 0.16 mg protein. The protein was 
concentrated by ultrafiltration (NANOSEP filters) yet much was lost on the filter and only a 
concentration of 3-7.5 mg/ml was obtained. 
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Fig 4.63: SDS-PAGE (12.5%) of hPDE2NGAFcr (1) Pellets (5µl) (2) Supernatant (10µl) (3) 
Supernatant after Ni-NTA (10µl) (4) Purified protein (2 µg) (5) Western blot (100 ng) 
No crystals were obtained. 
4.2.2.4.2 ∆ N-hPDE2 GAF 
The ∆ N-hPDE2 GAF was cloned in pQE30 with an N-terminal His-tag, expressed and 
purified as mentioned for hPDE2NGAF protein (Fig.4.64). The protein of a calculated MW of 
38.5 kDa, was pure (yield 0.4 mg/200 ml culture), a concentration of 12 mg/ml was obtained 
by ultrafiltration (Vivaspin, Sartorius) as described (section 3.3.11.2). Crystallization trials 
were performed ± 2 mM cGMP using the sitting drop method. Crystal screens I, II, lite, 
PEG/Ion 2 were used for the initial screening of the crystals. No crystals were obtained for a 
time as long as one year. 
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Fig. 4.64: SDS-PAGE (12.5%) of ∆ N1-227-hPDE2 GAF. (1) Pellet (2) Supernatant (3) Supernatant after 
Ni+2-NTA (4) Purified protein (4 µg) (5) Western blot (0.1 µg) 
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4.2.2.5 Glutaraldehyde dimerization and gel filtration of hPDE2GAF and mutants. 
GAF domain or their mutants were purified as usual, washed by 2 ml of wash buffer D, E, and 
F and eluted using elution buffer 2 and dialyzed against crosslinking buffer (50 mM 
phosphate pH 7.4, 10 mM NaCl, 22% glycerol). In 16 µl, GAF or mutant proteins (0.1, 0.3 or 
1 µg) were incubated with freshly diluted glutaraldehyde (0.06 and 0.12%) at RT for 60 min. 
The reactions were stopped by the addition of SDS loading dye, boiled at 95oC for 5 min, and 
subjected to 10-15% SDS-PAGE followed by Western blotting. 
The gel chromatography of the hPDE2NGAF (the crystallized construct) is indicating a dimer 
as a major peak with a calculated MW of 175.8 kDa, a small peak of a monomer and another 
for an oligomer were also observed, similar results were obtained by dimerization 
experiments with glutaraldehyde which has demonstrated a dimer (fig.4.65.A and B).  
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Fig. 4.65: Dimerization study of hPDE2NGAFcr performed by (A) Gel filtration showing a size of 175.8 
kDa which was a dimer. Fraction collection started 7 ml and fractions mentioned above corresponds to 
F3: 8.5 ml retention volume, F11: 12.5 ml and F17: 15.5 ml. (B) Glutaraldehyde crosslinking shows 
dimer formation.  
 
The removal of the N-terminus showed one peak for a dimer with a shoulder corresponding to 
monomer, the first peak and the major peak gave a band for a monomer on the western blot 
(Fig.4.68.A). The glutaraldehyde study of ∆N-hPDE2 GAFcr shows a band for the unreacted 
and proves the presence of dimer for the protein crosslinked (Fig.4.66.B). 
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Fig.4.66: Dimerization study of ∆N-hPDE2 GAFcr. (A) Gel filtration showing a size of 89.4 kDa which 
was estimated to be a dimer Fractions collection starts at 7 ml and fractions mentioned above 
corresponds to F3: 8.5 ml retention volume, F14: 14 ml (B) Glutaraldehyde dimerization study 
performed at different protein concentrations 0.1, 0.3 and 1 µg/16 µl reaction ± 10 mM glutarladehyde. 
 
Then the GAF domain of the mutant hPDE2NGAF (L396A/L397A)cr was cloned in pQE30 
and run on the gel chromatography. A peak appears at the beginning due to oligomerization 
when tested by Western blotting, monomers were observed (data not shown). The second 
peak at retention volume of 11 ml was due to membrane fraction of the hPDE2 NGAF. The 
third peak indicates a dimer and the fourth a monomer. The crosslinking experiment shows 
two faint bands at the sizes of monomer and dimer (Fig.4.67.A and B). 
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Fig.4.67: Dimerization study of hPDE2NGAF (L396A/L397A)cr (A) Gel filtration shows a large peak of 
oligomer at the beginning of plot and one peak for a monomer (B) Glutaraldehyde crosslinking 
experiment showing a two faint bands of monomer and dimer at 1µg amount of protein.  
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The removal of the N-terminus and mutating the leucines in the connecting helix showed a 
different profile (fig.4.68.A). Only three peaks appeared an oligomer, a dimer and a monomer. 
With the mutation, the monomer peak is distinct compared to that of the ∆N-hPDE2GAF in 
figure 4.66.A. The glutaraldehyde crosslinking study shows the three peaks as bands at 1µg 
protein so double mutation in the connecting helix and N-terminus truncation, did not abolish 
dimerization. 
The quadruple mutation in both α1-helix and connecting helix with the truncation of the N-
terminus produced a major peak of a monomer and small dimer peak (Fig.4.69.A). The 
glutaraldehyde crosslinking shows a monomer, dimer and oligomer at 1 µg protein, which 
indicating that the dimerization was disturbed but not abolished (Fig.4.69.B). 
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Fig.4.68: Dimerization of ∆N-hPDE2 (L396A/L397A) (A) Gel filtration showed a large peak of oligomer 
at the beginning and a higher peak for a dimer and smaller one for a monomer, fractions were 
collected starting at 7 ml, and the numbers corresponds to the following volumes, F3: 8.5, F14: 14 ml, 
F17: 15.5 ml and F19: 16.5 ml. (B) Glutaraldehyde crosslinking experiment showing three bands of 
monomer, dimer and oligomer which is more evident at higher protein concentrations (1µg) 
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Fig.4.69: Dimerization study of ∆N-hPDE2 (I230A/L231A/L396A/L397A) (A) Gel filtration showed a 
large peak of oligomer at the beginning and a peak for a monomer. Fraction at 7 ml, F3 corresponds to 
8.5 ml, F12: 13 ml, F17: 15.5 ml and F26: 20 ml (B) Glutaraldehyde crosslinking experiment showing a 
streak of monomer, dimer and oligomer at 1 µg protein. 
 
4.2.3 hPDE5 GAF tandem 
Similar to the CyaB2 and hPDE2 GAF mutations, the corresponding residues present in the 
α1 helix and connecting helix of hPDE5 were mutated. 3 different mutated chimeras were 
generated and compared to  hPDE5NGAF/CyaB1 chimera obtained from S.Bruder. Figure 
4.70 shows the domain organization of this protein. 
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Fig. 4.70: Domain organization of hPDE5NGAF/CyaB1 chimera with aa bounderies of the GAF 
domain determined according to an alignment with CyaB2 and hPDE2 GAF domains. The blue circle 
in GAFa domain indicates the allosteric binding site of cGMP. 
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Three hPDE5 mutants were prepared: one with mutations of the two corresponding leucines 
in the α1 helix to alanines, the second has a double mutation of the two respective leucines in 
the connecting helix to AA and the third is a quadruple. 
The three proteins, including the wild type PDE5 chimera, were cloned in pET-pQE30 MCS, 
expressed in E.coli BL21 (DE3) [pREP4] at 16oC overnight using 50 µM IPTG and 10 mM 
MgCl2 for induction. Proteins were purified by binding to 110 µl Ni+2-NTA agarose for 90 
min. The four proteins had an N-terminal hexaHis-tag with a calculated MW of 113 kDa and 
pI of 5.62. The mutants were compared to the wild type through the protein dependence and 
dose response assays. 
The purified protein dependence of hPDE5NGAF/CyaB1 was linear (Fig.4.71.A). The cGMP 
dose response curve showed a basal activity of 21.25 ± 1.55 nmol/mg.min, EC50 of 22.3 ± 1.8 
µM, a fold-stimulation of 14.5 ± 0.56 and a Hill coefficient of 0.769 ± 0.04 (R2 = 0.9762) i.e. 
not cooperative. 
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Fig.4.71: Evaluation of hPDE5NGAF/CyaB1 chimera. Assay conditions: 10 min, 75 µM Mg+2-ATP, 
37oC, 0.1M Tris/HCl pH 7.5 (n = 4) (A) Protein dependence ((■) Unactivated protein (○) +100µM 
cGMP), western blot of 0.1µg protein is to the right (B) Dose response curve with the same assay 
conditions and 9 nM protein. 
 
4.2.3.1 hPDE5/CyaB1 mutants 
For the hPDE5 mutants, protein dependence was established. Usually, the protein is in the 
monomeric form and dimerizes at increasing protein concentrations. For the first mutant of 
hPDE5, hPDE5 (L152A/L153A)/CyaB1, the curves were linear. In the mutant of the 
connecting helix and the quadruple mutant, hPDE5 (L333A/L334A)/CyaB1 and hPDE5 
(L152A/L153A/L333A/L334A)/CyaB1, the curves decreased by increasing protein 
concentration (Fig.4.72.A-C). 
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Fig. 4.72: Protein dependence of hPDE5 mutants (■) Unactivated protein (○) +100µM cGMP (A) 
hPDE5NGAF (L152A/L153A)/CyaB1 (B) hPDE5NGAF (L333A/L334A)/CyaB1 (C) hPDE5NGAF 
(L152A/L153A/L333A/L334A)/CyaB1, Western blot is shown to the right of each curve (0.3 µg). Assay 
conditions: 10 min, 75 µM Mg+2-ATP, 37oC, 0.1M Tris/HCl pH 7.5 (n = 4) 
The dose response curves showed a decreased fold–stimulation and cGMP-EC50 for the two 
constructs with double mutations. In hPDE5 (L152A/L153A)/CyaB1, the fold-stimulation 
was 3.4 ± 0.1, the EC50 was 1.7 ± 0.2 µM cGMP and the Hill coefficient was 0.51 ± 0.04 (R2 
= 0.977, n = 4). hPDE5 (L333A/L334A)/CyaB1 has also lower fold stimulation and EC50 of 
1.64 ± 0.072 and 0.327 ± 0.07, respectively. The Hill coefficient of 0.585 ± 0.14 (R2 = 0.9402, 
n = 4) showed no cooperativity. A quadruple mutations of both helices caused loss of 
regulation. Regarding basal activity of the mutants, the double mutations in the connecting 
helix had the highest basal activity (94.8 ± 7.5 nmol/mg.min), the mutations in the α1-helix 
had the lowest basal activity (41.8 ± 2.3 nmol/mg.min) while the quadruple mutant had a 
basal activity between the two (72.19 ± 3.42 nmol/mg.min) (see Fig.4.73 and table 4.7). 
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Fig.4.73: Dose response curves of (A) hPDE5NGAF(L152A/L153A).CyaB1 (B) 
hPDE5NGAF(L333A/L334A)/CyaB1 (C) hPDE5NGAF(L152A/L153A/L333A/L334A)/CyaB1. Assay 
conditions: 10 min, 75 µM Mg+2-ATP, 37oC, 0.1M Tris/HCl pH 7.5, 9-18 nM protein (n = 4). 
Table 4.7: Kinetic parameters characterizing hPDE5NGAF/CyaB1 chimera and its mutants 
construct Basal activity 
(nmol/mg.min) 
EC50 (µM) Fold-stimulation 
(by cAMP) (x) 
Hill coefficient 
(Correlation factor) 
hPDE5NGAF/CyaB1 21.3 ± 1.6 22.3 ± 1.8 14.50 ±  0.56 0.769 ± 0.04 
(R2 = 0.9762) 
hPDE5 (L152A/L153A)/CyaB1 41.8 ± 2.3 1.7 ± 0.19 3.4 ± 0.1 0.512 ± 0.04 
 (R2 = 0.9770) 
hPDE5(L333A/L334A)/CyaB1 94.8 ± 7.5 0.33 ± 0.07 1.6 ± 0.072 0.585 ± 0.14 
 (R2 = 0.9402) 
hPDE5(L152A/L153A/L333A/ 
L334A)/CyaB1 
72.2 ± 3.4 ND* 1.01 ± 0.02 ND* 
* ND means Not Determined  
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4.2.3.2 Dimerization by Glutaraldehyde and gel filtration of hPDE5 and mutants: 
To reasonably interpret the results from above, the GAF domain of the hPDE5 and mutants ± 
N-terminus were cloned. The dimerization was investigated for different GAF domains of 
hPDE5 in the presence and absence of the N-terminus. In the gel filtration curve (4.74.A), a 
large peak in the size of dimer is skewed to the left due to the presence of oligomers. A small 
peak for a monomer (41.3 kDa) was also observed. Figure 4.74.B shows the formation of a 
dimer upon crosslinking with glutaraldehyde at the three protein concentrations. 
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Fig.4.74: Dimerization of hPDE5NGAF performed by (A) Gel filtration showing a size of 163.5 kDa 
which was estimated to be a dimer. Fractions collection starts at 7 ml and fractions mentioned above 
corresponds to the following volumes, F3: 8.5 ml retention volume, F11: 12.5 ml and F17: 15.5 ml (B) 
Glutaraldehyde dimerization shows dimer formation. 
 
The gel filtration of hPDE5 (L152A/L153A) showed similar curves to the hPDE5NGAF in 
which the dimerization was not disrupted by double mutations in the α1-helix (Fig.4.75). The 
glutaraldehyde crosslinking experiment showed formation of dimers at all protein 
concentrations (Data not shown). 
Results 
 155
0 5 10 15 20 25
0
5
10
15
20
25
30
U
V 
ab
so
rb
an
ce
(m
A
U
)
Volume (ml)
171.4 kDa
42.2 kDa
U
V 
ab
so
rb
an
ce
(m
A
U
)
 
Fig.4.75: Dimerization of hPDE5NGAF (L152A/L153A) performed by gel filtration showing a size of 
171.4 kDa which was estimated to be a dimer and another of a monomer 
 
hPDE5 (L333A/L334A) which contains the mutation in the connecting helix also exhibited a 
similar profile with the four peaks with the dimer as the major peak. This means that double 
mutations of the connecting helix alone do not affect the dimerization of the hPDE5 GAF 
domain (Fig.4.76.A). The glutaraldehyde crosslinking experiment didn’t show any difference 
(Fig.4.76.B). 
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Fig.4.76: Dimerization of hPDE5NGAF (L333A/L334A) performed by (A) Gel filtration showing a size 
of 177.8 kDa which was estimated to be a dimer and another of a monomer (B) Glutaraldehyde 
dimerization shows dimer formation. 
 
The quadruple mutant had a different profile (Fig4.77.A). The three peaks became distinct for 
an oligomer, dimer and monomer. The Western blot of the fractions of the last three peaks 
showed a band for the first two but no band for the third. 
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Fig.4.77: Dimerization study of hPDE5NGAF (L152A/L153A/L333A/L334A) (A) Gel filtration showing 
three different peaks: oligomer, dimer and monomer. Fraction collected started at 7 ml F8: 11 ml, F12: 
13 ml and F17: 15.5 ml (B) Glutaraldehyde crosslinking showing a band for a dimer at high protein 
concentration with a smaller band for a monomer. 
 
The truncation of the N-terminus of hPDE5 had a MW of 44.4 kDa (with His-tag). In ∆N1-135-
hPDE5GAF, the truncation of the N-terminus increased the ratio of monomer to dimer as seen 
in the gel chromatogram (fig.4.78.A), but the dimer was still the major peak. A third peak to 
the left of the dimer was a distinct peak for an oligomer which is not distinct in the presence 
of the N-terminus and this could be due to the larger size of the proteins with N-terminus so 
the two peaks are not well-separated. Application of the fractions to SDS-PAGE showed 
bands of monomer size for all peaks. In the glutaraldehyde crosslinking, only dimer is seen at 
low concentration, while at higher protein concentration (1 µg) both monomer and dimer were 
observed (Fig.4.78.B). 
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Fig.4.78: Dimerization of ∆N1-135-hPDE5GAF performed by (A) Gel filtration showing a size of 122.5 
kDa which was estimated to be a dimer (B) Glutaraldehyde dimerization shows dimer formation as a 
major band.  
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The truncation of the N-terminus in the presence of the connecting helix mutation increased 
the ratio of monomer to dimer which means that it disturbed dimerization but didn’t abolish it 
(Fig.4.79.A). The glutaraldehyde crosslinking showed bands of the unreacted protein but faint 
ones for the crosslinked (Fig.4.79.B). 
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Fig.4.79: Dimerization of ∆N1-135-hPDE5GAF (L333A/L334A) performed by (A) Gel filtration showing a 
size of 418 kDa for oligomer, 132 kDa for a dimer and 41.8 for a monomer and three peaks proved to 
be ∆N1-135-hPDE5GAF (L333A/L334A) protein by exposing the fractions to western blot F8: 11 ml, 
F12: 13 ml, F17: 15.5 ml (B) Glutaraldehyde dimerization shows clear bands for the unreacted protein 
and faint bands for a monomer and a dimer for the crosslinked ones. 
 
The truncation of the N-terminus accompanied by quadruple mutation has obviously disturbed 
dimerization. For ∆N1-135-hPDE5GAF (L152A/L153A/L333A/L334), the gel filtration 
(Fig.4.80.A) showed three peaks again but with the monomer as a major peak. Applying the 
fractions of each peak to SDS-PAGE followed by Western blot showed a band of a monomer 
size (Fig.4.80.A). Glutaraldehyde crosslinking showed a band for a monomer and a streak of 
dimer-oligomer only at high protein concentration (Fig.4.80.B). 
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Fig.4.80: Dimerization of ∆N1-135-hPDE5GAF (L152A/L153A/L333A/L334) performed by (A) Gel 
filtration showing a size of 441 kDa for oligomer, 136 kDa for a dimer and 43.6 for a monomer and 
three peaks proved to be protein by exposing the fractions to western blot, F8: 11 ml, F12: 13 ml, F17: 
15.5 ml (B) Glutaraldehyde dimerization shows no bands at low amount of protein and mainly a 
monomer with a streak for the dimer and oligomer. 
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4.3 Signal transduction through the PAS domain of CyaB1 
Comparing the domain organizations of cyanobacterial adenylyl cyclases, CyaB1 and CyaB2, 
with PDEs 2, 5, 6, 10 and 11, figure 4.81 shows that the cyclases possess a PAS domain of 
100-180 aa in front of the catalytic domain. Removal of the PAS domain of CyaB1 and 
linkage the GAF domain directly in front of the catalytic domain was found to abolish 
signaling (J.Linder, personal communication). 
 
Cyanobacterial AC
PDEs 2,5,6,10,11 Catalytic domainNH2 GAF b COOHGAF a
Catalytic domainNH2 GAF b COOHGAF a PAS  
 
Fig.4.81: Domain organization of Cyanobacteria adenylyl cyclases (CyaB1 and CyaB2) and GAF 
domain containing mammalian PDEs. Image modified according to ref [16]. 
 
According to a BLAST search, the amino acids from 389 to 468 were annotated as a PAS 
domain while the amino acids 469 to 562 may represent a linker of unknown function. The 
catalytic domain is from 563 to 795. Three approaches were used to examine signal 
transduction through the PAS domain of CyaB1. First, the PAS domain was replaced by the 
linker from hPDE5 which joins the GAF tandem to the catalytic region. Two different lengths 
were used. Second, the CyaB1 PAS domain was replaced by the PAS domain of CyaB2 
enzyme which is longer than the PAS of CyaB1 and lacks the linker region. Third, a flexible 
linker was inserted between PAS and catalytic domains. The CyaB1 (WT) holoenzyme served 
as positive control. The kinetic values were in agreement with the published data [80]. 
It was attempted to crystallize the different domains of CyaB1.  
4.3.1 Exchange of CyaB1 PAS domain by the PDE5 linker. 
To study the mechanism by which GAF domain tandem signals to the catalytic domain, the 
PAS domain was replaced by the hPDE5 linker. Two different lengths of the hPDE5 were 
used (fig. 4.82.A); (A) hPDE5 linker consists of 25 aa’s (E513-T537) and (B) consists of 36 
aa’s, starting exactly the same as (A) and ends at V548. Four different N-terminally truncated 
catalytic domains were used (fig.4.82.B).  
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Fig.4.82: (A) Alignment of the PDE5 linker region with that of hPDEs 2, 6, 10 and 11. Rectangles and 
arrows show the beginning and the end of the PDE5 linker regions used in the study. (B) Domain 
organization of the N-terminally truncated catalytic domains used showing the beginning of each 
construct. 
 
4.3.1.1  Control (truncated catalytic domains):  
To explain the difference in the basal activities obtained by different constructs, the four 
truncated catalytic domains (fig.4.81.B) were transformed into BL21 (DE3) [pREP4] E.coli 
cells, expressed and assayed. The expression was induced by 300 µM of IPTG, 10 mM MgCl2 
(27oC, 300 min). Cells were harvested, washed, centrifuged and frozen at -80oC. The pellets 
were suspended in cell lysis buffer, lysed by passing twice through French press and purified 
by shaking with 350 µl of Ni+2-NTA for 90 min. The eluted proteins were dialysed against 
dialysis buffer overnight at 4oC and used immediately or stored at -20oC. The yield and MW 
of the four constructs are in table 4.11 in section 4.3.4.3. The SDS-PAGE (Fig.4.83) showed 
the high purity of the four catalytic domains. 
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Fig.4.83: SDS-PAGE (15%) of N-terminally truncated catalytic domains (2 µg) 
Constructs I and II to achieve a steady activity at lower protein concentrations with while the 
constructs III and IV were do no achieve maximal activity at 3 µM protein. Furthermore, the 
highest activities were several fold higher for the shorter constructs than the longer ones 
which could be due to dimerization of the catalytic domain. Dimerization can be observed by 
a band of construct IV (Fig.4.84) 
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Figure 4.84: Protein dependence of N-terminally-truncated CyaB1 AC’s. Assay conditions: 37oC, min, 
75 µM Mg+2-ATP, 0.1M Tris/HCl pH 7.5, 10 min (n = 4). Western blots are shown to the right. 
 
The protein dependence was established for the constructs. The basal activity of the truncated 
catalytic domains mirror the basal activities obtained by their corresponding constructs in 
categories A and B (see below)  
All constructs have similar domain organization but differ in sequence of the linker 
(Fig.4.85). GAF domain was from A.Schultz and the four catalytic domain constructs were 
from J.Linder. 
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Fig.4.85: Domain organizations of constructs of category A and B of CyaB1 (PDE5linker). 
 
A total of 8 constructs (2 linkers × 4 N-truncated AC’s) were generated (3.4.5.1), transformed 
into BL21(DE3)[pREP4] E.coli cells, expressed (30 µM IPTG, 18oC, 10 mM MgCl2, 
Results 
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overnight) and purified (200 µl Ni+2-NTA agarose, 3 hr). The proteins were well-expressed 
with good yield and purity (fig.4.86). 
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Fig.4.86: SDS-PAGE (12.5%) of 4µg of the eight constructs (both category A and B) 
 
 
N-terminally truncated catalytic domains were used as controls. Category A contains CyaB1 
GAF 1-387, hPDE5 513-537 and the four catalytic domains. Category B has the CyaB1 GAF 1-387, 
hPDE5 513-548 and the four catalytic domains. 
 
4.3.1.2 Category A 
The protein dependence was established ± cAMP for the four constructs (Fig.4.87). None of 
them was activated by cAMP. The specific activity was high for the two shorter construct (15 
and 18 nmol/mg.min for IA and IIA respectively) and low for the longer constructs (5 and 4 
nmol/mg.min for IIIA and IVA respectively). Western blots for all constructs showed no 
degradation products. 
 
 
Results 
 165
 
0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
2
4
6
8
10
12
14
16
18
20
[Protein] (µM)
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
116
66
45
35
25
IIA
0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
4
8
12
16
20
24
[Protein] (µM)
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
45
116
66
35
25
IA
0.2µg0.4 µg
E
387
GAF ERAMAKQMVTLEVLSYHASAAEEET RS
537
G
513
AC
595
EDALMVE
387
GAF ERAMAKQMVTLEVLSYHASAAEEET RS
537
589
513
G AC
595
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
 
0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
2
4
6
8
[Protein] (µM)
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
116
66
45
35
25
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
0
1
2
3
4
5
[Protein] (µM)
116
66
45
35
25
0.1 µg0.1 µg
IVAIIIA
E
387
GAF ERAMAKQMVTLEVLSYHASAAEEET RS
537
572
513
G AC
595
MYRLTPHVAEQVMALGEDALMV E
387
GAF ERAMAKQMVTLEVLSYHASAAEEET RS
537
560
513
G AC
595
EDISQEKRLKTTMYRLTPHVAEQVMALGEDALMV
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
AM
P/
m
g.
m
in
)
 
Fig.4.87: Protein dependence of constructs of Category A. (■) Basal activity, (○) + 1mM cAMP Assay 
conditions: 75 µM Mg+2-ATP, 37oC, 4 min and 0.1M Tris/HCl pH 7.5 
 
4.3.1.3 Category B 
The protein dependence was mostly linear for these constructs (Fig.4.88). The shorter three 
constructs were not affected by cAMP and they have similar basal activities. The fourth 
construct IVB was the only construct activated by cAMP. Basal activity of the unactivated 
construct was lower.   
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Fig.4.88: Protein dependence of category B. (■) Basal activity, (○) + 1 mM cAMP. 
Assay conditions: 4 min, 37oC, 75 µM Mg+2-ATP, 0.1M Tris/HCl pH 7.5  
 
A cAMP-dose response curve for construct IVB was established. The EC50 of 1.58 ± 0.15 µM 
was similar to the wild type (0.40 ± 0.023 µM). The Hill coefficient of 0.5818 ± 0.064 (R2 = 
0.9865, n = 4) showed no cooperativity. However, the fold stimulation was only 3.34 ± 0.070 
(n = 4); i.e. about one tenth that of CyaB1 (fig.4.89). 
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Figure 4.89: The cAMP-dose response of construct (IVB). Assay conditions: 4 min, 37oC, 75 µM 
Mg+2-ATP and 0.1M Tris/HCl pH 7.5, 81 nM protein (n = 4).  
 
According to T.Kanacher [79], a metal was required for CyaB1 catalytic domain. D606 and 
D650 were responsible for metal binding in CyaB1. I have observed presence of similar 
residues in the PAS domain (see figure 4.90) 
CyaB1.Cat : GE-RKEVTVLFSDIRGYTTLTENLGAAEVVSLLNQYFETMVEAVFNYEGTLDKFIGDA :  651
CyaB1.PAS : KQYQKDILQSLSDA----VISTDM-AGRIVTINDAALELLGC-----------PLGDA :  429
  
Fig.4.90: Alignment by ClustalW showing the 21% identity and 48% similarities between the beginning 
of the PAS domain and the beginning of the AC catalytic domain. The triangles determine the 
aspartate residues responsible for the metal binding in the AC catalytic domains. 
 
 
4.3.2 Exchange of CyaB1 PAS domain by CyaB2 PAS domain. 
The PAS domain of CyaB1 was aligned with that of CyaB2 and segment from K388-K569 
from CyaB1 holoenzyme was exchanged by PAS of CyaB2 (E444-K570) (Fig.4.91.A).  
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Fig.4.91: Construction of CyaB1(PAS2) construct (A) Alignment shows similarities and identities and 
the amino acid boundaries of the PAS domain, (B) Domain organization of CyaB1 (PAS2) construct. 
Blue circle indicates the cAMP binding to the GAFb domain.  
 
The construct (4.92.b) was cloned in pQE30 and expressed as usual Two hours after 
induction, 1 ml was pipetted, treated as mentioned in section 3.3.2 and the supernatant and 
pellets were compared with that of empty pQE30. The protein was well-expressed as soluble 
protein (Fig.4.92), and purified by Ni+2-NTA agarose. Relatively clean bands were obtained 
on the SDS-PAGE and Western blot. The protein has a calculated MW of 91.49 kDa and an 
isoelectric point of 5.52. 
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Fig.4.92: SDS-PAGE (10%) and Western blot of CyaB1 (PAS2) (1 and 3) supernatant and pellet of 
CyaB1 (PAS2), respectively, (2 and 4) Supernatant and pellet of pQE30, respectively, (5) 1.8 µg of 
purified CyaB1(PAS2) and (6) Western blot (0.5 µg). 
 
The protein dependence was linear ± 1 mM cAMP (Fig.4.93). The construct was stimulated 
by cAMP, but less than CyaB1. 
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Fig.4.93: Protein dependence of CyaB1 (PAS2). (■) Basal activity, (○) + 1mM cAMP. 
 Assay conditions: 4 min, 75 µM Mg+2-ATP, 37oC, 0.1M Tris/HCl pH 7.5, (n = 4). 
 
Dose response curve (Fig.4.94) yielded an activation factor of 8.8 ± 0.5 for cAMP, an EC50 of 
3.2 ± 0.23 µM and a Hill coefficient of 0.588 ± 0.023 (R2 = 0.9765, n = 4) which shows no 
cooperativity. 
 
Results 
 170
cAMP
cGMP
-7 -6 -5 -4 -3
0
0.2
0.4
0.6
0.8
1.0
1.2
Log [cNMP]  (M)
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
A
M
P/
m
g.
m
in
)
Sp
ec
ifi
c
ac
tiv
ity
(n
m
ol
 c
A
M
P/
m
g.
m
in
)
 
Fig.4.94: Dose response curve of CyaB1 (PAS2). 
Assay conditions: 4 min, 37oC, 75 µM Mg+2-ATP, 0.1 M Tris/HCl pH 7.5, 325 nM (n = 4). 
 
4.3.3 Insertion of tetradekapeptide linker between PAS and 
catalytic domains of CyaB1. 
A flexible tetradekapeptide linker used by Y.Guo produced an active heterodimer from 
Rv1625 [105]. Here, the same peptide linker was inserted between the PAS and catalytic 
domains of CyaB1. Accordingly, the GAF, PAS of CyaB1 were separated from the catalytic 
domain via the insertion of a DNA sequence that codes for the peptide linker 
“TRAAGGPPAAGGLE” (abbreviated as L) using conventional molecular biology 
techniques. The peptide linker was inserted between T571 and M572. 
The construct was cloned in pQE30, transformed into BL21 (DE3) [pREP4] E.coli cells, 
expressed and purified (section 4.3.1). The purified dialysed N-His tagged- protein had a 
calculated MW of 99.2 kDa and an isoelectric point of 5.65 (Fig.4.95). 
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Fig.4.95: SDS-PAGE (10%) and Western blot of CyaB1 (571+L) (1 and 3) Supernatant and pellet of 
CyaB1 (571+L), respectively, (2 and 4) Supernatant and pellet for pQE30, respectively, (5) 1.9 µg of 
purified CyaB1 (571 + L) (6) Western blot of 0.5 µg (12.5%SDS-PAGE). 
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The protein has low basal activity (0.457 ± 0.057, n = 14) and was not stimulated by 1 mM 
cAMP (fig.4.96). 
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Fig.4.96: Protein dependence of CyaB1 (571 + L) ± 1 mM cAMP. (■) Basal activity, (○) + 1mM cAMP. 
 Assay conditions: 10 min, 75 µM Mg+2-ATP, 0.1 M Tris/HCl pH 7.5, 37oC. 
 
To exclude any effect of the insertion of the linker on the folding of the catalytic domain, 
Substrate kinetics were established ± 1 mM cAMP (Fig.4.97). The Km value was 18.56 ± 1.42 
µM ATP, a Vmax of 0.65 ± 0.008 nmol/mg.min and a Hill coefficient of 1.05 ± 0.02 (R2 = 
0.9887, n = 2) for both activated and unactivated forms. The Vmax for the CyaB1 (571 + L) 
was much lower (less than 1%) than for CyaB1 whereas Km and Hill coefficient were 
comparable. 
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Fig.4.97: Substrate kinetics of CyaB1 (571 + L). (■) basal activity, (○) + 1mM cAMP. Assay conditions: 
37oC, 4 min, 75 µM Mg-ATP and 0.1M Tris/HCl pH 7.5, 300 nM protein (n = 2) (A) Michaelis-Menten 
curve, (B) Lineweaver- Burke, and (C) Hill Plot 
 
4.3.4 Crystallization trials of the CyaB1 domains 
4.3.4.1 Crystallization of CyaB1 GAF domain 
The crystal structure of CyaB2 GAF tandem had shown an antiparallel dimer in contrast to the 
parallel structure of mPDE2 GAF-tandem. In spite of that, the two tandems were functional 
upon exchanging the GAF domain of CyaB1 [80, 101]. The crystallization of CyaB1 GAF 
domain could shed light on the dimerization of this unique enzyme. CyaB1GAF boundaries 
were determined by J.Linder according to the crystallized mouse PDE2 GAF and CyaB2 
GAF, cloned in pQE60 by A.Schultz and DNA-plasmid was transformed into E.coli BL21 
(DE3) [pREP4] cells for expression (see fig.4.98). 
 
Results 
 173
α-helix
CyaB1 : QLINKQ--------------------QGSFTASDEEFMRAFNIQAGVALENARLFENVLLEKQYQKDILQSLSDAVISTDM : 407
CyaB2 : QLVNKKKTGEFPPYNPETWPIAPECFQASFDRNDEEFMEAFNIQAGVALQNAQLFATVKQQEQMQRDILRSLSNGVISTDK : 463
mPDE2 : ELVNKIN-------------------GPWFSKFDEDLATAFSIYCGISIAHSLLYKKVN-EAQYRSHLANEMMMYHMKVSD : 555
 
α-helix
end of my constructB
α2-helix
CyaB1 : DLSVNEFVCLLDFITAEFQQFLRAIELINNEALENMLEKVLEAITLKIGQILQ----AEHTAIFLVDYDKCQLWSKVPQD : 106
CyaB2 : ---QDTFKQVVTEVEQKLQIVHQTLSMLDSHGFENILQEMLQSITLKTGELLG----ADRTTIFLLDEEKQELWSIVAAG : 123
mPDE2 : EAVQNTSVDASEDQKDEKGYTDHDRKILQLCGE--LFDLDATSLQLKVLQYLQQETQATHCCLLLVSEDNLQLSCKVIGD : 256
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Beginning of my construct
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D42
 
Fig.4.98: Construction of the CyaB1 GAF by alignment the GAF domain of CyaB1 with that of CyaB2 
and mPDE2 
(A) Alignment shows the beginning of the three constructs with the first amino acid indicated by a 
rectangle (note that the only conserved residues in the α1-helix are the two hydrophobic residues 
followed by a carboxylic amino acid)  
(B) The end of the alignment of the three GAF domains and the last amino acids are determined by a 
rectangle, code of the alignment: red: highly conserved, blue: more the 60% similarity, Black: 
unconserved.  The secondary structure appears below the alignment is according to the crystal 
structures of both GAF-tandems. 
 
Several 200-ml batches were inoculated by 5 ml of an overnight culture. The cultures (30oC 
until OD600 ~ 0.5-0.6) were induced with 0.3 µM IPTG (22oC for 6 hrs). Cells were harvested 
and the washed pellets were frozen at -80oC.  The pellets were resuspended and passed twice 
through a French Press (1000 Psi). The lysate was centrifuged at 18000 × g, 4oC for 40 min. 
The protein was purified by 200 µl Ni-NTA agarose for three hours and dialyzed against 
crystallization buffer (with 10% Glycerol). The 40.0-kDa, C-terminally hexahistidine-tagged 
protein was analyzed by SDS-PAGE (see fig.4.99). Each 200 ml culture produced 0.3 mg 
protein.  
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Fig.4.99: SDS-PAGE (15% polyacrylamide) of CyaB1GAF crystallized. (M) PeqGold marker (1) Pellet 
(2) Supernatant after centrifugation (3) Supernatant after Ni+2-NTA binding (4) Purified protein (4µg). 
 
The protein was concentrated by ultrafiltration (NANOSEP 10K centrifugal devices) to 11-12 
mg/ml and 2 mM cAMP was added. The mixture was centrifuged and screened by crystal 
screen I, II and lite (from Hampton) and Wizard I and II (from genetic deCode Biostructures) 
using the hanging drop diffusion method (section 3.3.11.1) at 16oC. The plates were inspected 
every day for the first week and then weekly.  
Clusters of needles have appeared with crystal screen II # 39 (3.4M 1,6-hexanediol, 0.1M 
Tris/HCl pH 8.5 and 0.2M MgCl2) after 4 days and increased in number with time but not in 
size (see fig.4.100). Crystallization was reproducible. 
   
 
 
Fig.4.100: Clusters of needle-shape crystals of CyaB1GAF obtained by the hanging drop method 
using crystal screen II #39 (3.4M 1,6-hexanediol, 0.1M Tris/HCl pH 8.5 and 0.2M MgCl2) as 
precipitant.  
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To make sure that these needles are protein, the crystallization was performed without protein 
± 2 mM cAMP. No needles appeared. 
Further optimization of the crystal size and shape have been tried by varying the 
concentration of 1,6-hexandiol, pH and the type and concentration of salt. The conditions 
produced crystals as listed in table 4.8. 
 
Table 4.8: crystals-containing conditions obtained by optimization of the size and shape of CyaB1 
GAF crystals 
 
 
The optimization of these crystals did not succeed. 
4.3.4.2 Crystallization of CyaB1 PAS domain 
 
According to the SMART search (Schultz, 1998), the PAS domain of CyaB1 boundaries starts 
at CyaB1 PAS (K388-T571) was cloned in pQE30 and expressed in BL21 (DE3) [pREP4] 
E.coli cells. Cells were induced at an OD600 of 0.5-0.6 by 300 µM IPTG at 27oC. After 6 h, 
cells were harvested, freeze shocked in liquid nitrogen. Pellets were lysed by passing twice 
through French Press and protein was purified by 200 µl of Ni+2-NTA agarose for three hours. 
The eluted protein was dialysed overnight at 4oC against crystallization buffer (20 % 
Glycerol, 10 mM Tris/HCl pH 7.5, 10 mM MgCl2 and 0.05% thioglycerol). The yield was 
600 µg/200 ml. The purity of CyaB1 PAS protein was monitored by SDS-PAGE and Western 
blot (fig.4.101). The protein has a calculated MW of 22.05 kDa. 
1,6-Hexanediol Tris/HCl pH MgCl2 [Protein] 
+2mM cAMP 
Crystallization conditions Storag
e 
Temp. 
2.6/3.0/3.4/3.8/ 
4.2 
0.1M 8.5 0.2 M 11 mg/ml Needle bundles of 10-
35µm the largest appears 
at 3.8M 
3.4 M 0.1M 8.5 0.1, 0.2, 
0.4, 0.67M  
11 mg/ml Needles of 5-40µm. the 
crystals decrease in 
number and increase in 
size with more MgCl2, 
largest at 0.67M 
0.1M 7.5 0.2 11 mg /ml Many needle shape 
crystals as bundles (15 
µm) 
0.1M 8.0 0.2 11 mg/ml Few needles 20-25 µm 
 
 
3.4 M 
0.1M 9.0 0.2 11 mg/ml Few crystal bundles 20-
30µm 
 
 
 
 
 
12oC 
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Fig. 4.101: SDS-PAGE (15%) and western blot of CyaB1 PAS crystallized. (M) PeqGold marker (1) 
Pellets (2) Supernatant (3) Supernatant after Ni-NTA (4) 12 µg of purified protein showing high purity 
(5) Western blot (15% SDS-PAGE and 0.1 µg protein), the protein has N-terminal His-tag and was 
detected by anti RGS-His4 as primary antibodies. 
 
Samples were concentrated by ultrafiltration over a 10 kDa cut-off filter (Nanosep) to 11.5 
mg/ml and used for crystallization or stored at 4oC. The protein was screened by Crystal 
screen I, II and lite (from Hampton) by the hanging drop method. 1µl of protein sample was 
mixed with 1 µl of each screening buffer (drop mixture 1:1). In the reagent reservoir 0.4 ml of 
the precipitant solution were mixed with 100 µl glycerol 87% to obtain a concentration of 
glycerol 7% higher than the glycerol present in the drop mixture because the crystallization 
buffer contains 20% glycerol. The 24-well plates were incubated at 12oC and examined under 
a polarization microscope every day for the first week and then once a week.  
A huge number of very small cubic crystals (10 ×10 µm) have appeared after 5 days of 
storage at 12oC by the unbuffered crystal screen II # 7 which consists of 10% PEG1000 and 
10% of PEG 8000. Repetition at lower protein concentration (8mg/ml) produced fewer and 
bigger cube-like crystals (35×35 µm) (see fig 4.102.A). Further optimization varied the 
concentration of precipitant components, protein concentration, pH’s, and incubation of the 
plate at lower temperatures to produce nuclei followed by higher temperature to grow the 
crystal. 
First, different concentrations of PEG1500 and PEG8000 were tried but none of the 
conditions produced crystals. In addition, 10% of PEG1000 and 10% of PEG8000 with 0.2M 
of different salts: MgCl2, sodium formate, sodium acetate, ammonium sulphate, sodium 
citrate, lithium chloride, lithium nitrate, potassium nitrate, potassium acetate, potassium 
iodide, sodium thiocyanate, sodium chloride, ammonium acetate in addition to 2% 
isopropanol with protein concentration of 6 mg/ml and incubation temperature of 12oC but 
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none of these conditions produced crystals. Varying the concentration of PEG1000 and 
PEG8000 proved that 10% of each reagent is the optimum to give crystals. 0.1M Tris/HCl 
with different pH’s were tried concomitantly with incubation conditions of the plate at lower 
temperature (12oC) for 2 days followed by higher temperature (18oC) (see table 4.9 and fig. 
4.102.B and C). 
 
50µm
50µm
A B
C 50µm
 
Fig. 4.102: Crystals obtained from CyaB1 PAS. (A) Crystals with crystal screen II # 7 which consists 
of 10% PEG 1000 and 10% PEG 8000 incubated at 12oC with protein concentration of 8 mg/ml (B) the 
crystals obtained with 10 % PEG1000, 10% PEG8000 and 0.1M Tris/HCl pH 8.5 (C) crystals obtained 
with 10% PEG1000, 10% PEG8000 and 0.1M Tris/HCl pH 9.0  (B and C) contain protein 
concentration of 6 mg/ml and incubation conditions of 12oC for 2 days followed by 18oC for another 5 
days. 
 
 
 
 
 
Results 
 178
 
Table 4.9: The results of crystallization optimization of CyaB1 PAS protein 
 
Analysis and Data collection  
The crystals were sent to the Biochemistry Center (BZH) in Heidelberg University to 
elucidate the crystal structure. Several X-ray diffraction data sets were recorded from 
individual crystals at the ESRF in Grenoble, and images with a resolution of 2.1-2.3 Ǻ were 
obtained with three different crystals (data are shown in table 4.10). 
 
Table 4.10: Statistics for datasets P2-5, P1-5 and P1-2 collected from the x-ray of three different 
crystals (from analysis report obtained from I.Tews) 
 P2-5 P1-5 P1-2 
Space group 1 (P1) 1 (P1) 4 (P21) 
Unit cell dimensions 
(a b c [Å] α β γ [°]) 
35.846  45.777 118.809  
90.189 89.951  89.588 
35.960  45.781 118.874  
89.933 89.980  89.465 
45.858  117.825 35.783  
90.000 90.571  90.000 
Beamline Id-23 Id-23 Id-14-2 
Wavelength 0.976 0.976 0.931 
Frames recorded 400 151 400 
Molecules / AU 4 4 2 
Matthews coefficient 2.2 2.21 2.18 
Solvent content 44.0 44.3 43.6 
Resolution [Å] 2.3 2.1 2.18 
Rsym [%] 5.1 4.4 8.1 
I / σ 13.1 14.5 13.4 
PEG 1000 (%) PEG 8000 
(%) 
Additives [Protein] Crystallization conditions Storage 
Temp. 
7.5, 10, 12.5, 
15, 17.5, 20 
10 - 6.5 
mg/ml 
Large number of small 
cubic crystals appeared 
four days after storage 
only with concentrations 
between 7.5-12.5% 
10 7.5, 10, 12.5, 
15, 17.5, 20 
- 6.5 
mg/ml 
Large number of very 
small cubes appeared with 
the same storage 
conditions as above with 
7.5-17.5% 
 
 
 
 
12oC 
10 10 Tris/HCl 
pH 7.5 
6 mg/ml No crystals 
10 10 Tris/HCl 
pH 8.0 
6 mg/ml No crystals 
10 10 Tris/HCl 
pH 8.5 
6 mg/ml Tetragonal crystals (60 × 
50 µm) figure 4.102.B 
10 10 Tris/HCl 
pH 9.0 
6 mg/ml Tetragonal crystals (90 × 
80 µm) figure 4.102.C 
 
12oC for 
2 days 
then 18oC 
for 5 days 
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Completeness [%] 96.2 31.2 99.9 
Average redundancy 1.7 1.3 4.1 
Unique reflections 32275 13795 19795 
Average B factor 49.1 46.4 36.0 
Highest resolution 
bin [Å] 
2.3-2.35 2.1-2.15 2.18-2.21 
Rsym (highest bin) 
[%] 
16.4 23.4 25.4 
 
 Phase determination, model building and refinement 
In Heidelberg University, Molecular replacement was performed with several search models 
derived from the heme binding PAS domain of the bacterial histidine kinase FixL, as these 
bear the highest sequence similarity to the cyaB1 PAS domain, according to the structure-
based alignment and a sequence alignment computed with ClustalX 1.8366, and also with 
models derived from flavin binding or photoactive yellow protein PAS domains. Five models 
were calculated for each alignment and scores based on the energy of the conformation were 
calculated with PROSA2003. The models in Figure 4.103 represent the more likely models 
according to this scoring with model B as the best. The impact of the sequence alignment used 
for the modelling is clearly visible, as the first model has a large insert between helices E and 
F, which appears unstructured. In the second model a large and also unstructured insert can be 
found between helices C and D, and in the third model a large insert can be found between 
helices C and D, along with several smaller inserts in the loop regions between the beta 
sheets. 
BA C
 
Fig.4.103: Homology models of the cyaB1 PAS domain derived from alignments based on (A) Pfam 
00989.11 (B) Smart00091.101, and (C) based on the alignment obtained with the Modeller v8.2 
align2d command. The secondary structure was in the order: Aβ-Bβ-Cα-Dα-Eα-Fα-Gβ-Hβ-Iβ. 
 
4.3.4.3 Crystallization of Catalytic and PAS/catalytic domains of CyaB1 
The CyaB1 PAS/catalytic domain was cloned in pQE30 (section 3.4.5.5) and the DNA’s of 
four N-terminally truncated catalytic domains were obtained from J.Linder. The five 
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constructs were transformed into BL21 (DE3)[pREP4], overexpressed and purified as 
mentioned above for the CyaB1 PAS domain. The size and purity was evaluated by SDS-
PAGE and Western blot (fig.4.82 and 4.83), the AC activity was also assayed (Table 4.11). 
 
Table 4.11: Characteristics of the four truncated catalytic domains and the PAS/catalytic of CyaB1 
enzyme 
 I II III IV PAS/Catalytic 
Description G595-K859 E589-K859 M572-K859 E560-
K859 
388-K859 
Calculated size 
(kDa) 
31.5 32.1 34.1 35.5 54.9 
Steady state activity 
(nmol/mg.min) 
46.2 ± 0.78 48.7 ± 1.1 4.9 ± 0.16 8.3 ± 0.3 5.26 ± 0.26 
Yield (µg) 710 360 700 620 590 
Concentration used 
in the crystallization 
(mg/ml) 
- 8.36 - 7.72 8.46 
 
The CyaB1 PAS/catalytic and two of the truncated catalytic domains (II and IV) were chosen 
for crystallization. 
The constructs II and IV of the catalytic domain had a purity > 95%. They were expressed in 
lager scale, concentrated by ultrafiltration (Nanosep filter) at 11,000 ×g and 4oC and 
crystallized using crystal screen I, crystal screen II and crystal screen lite (from Hampton). 
The plates were left at 16oC and screened as mentioned in section 3.3.11.1 
No crystals were obtained for a time as long as 2 years. Gel filtration for both constructs 
shows presence of a monomer as a major form and in case of construct IV a small shoulder 
for a dimer appears in the curve (fig.4.104) 
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Fig.4.104: Gel filtration of the crystallized constructs: Construct II (A) and IV (B) of the CyaB1 catalytic 
domain 200 µl of 2 mg/ml were loaded to the column and the sample was run without fractionation.  
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For CyaB1 PAS/catalytic, the purity of the protein was not sufficient for crystallization so I 
tried to improve it by: 
1. Taking larger volume of bacterial culture (600 ml instead of 400 ml) and these were 
combined after harvesting, during the washing of pellets. 
2. Incubation of the lysed cells with DNAase solution (2 mg/ml) for 30 min during 
purification prior to the centrifugation of pellets. 
3. Use of less quantity of Ni-NTA (150 or 200 µl) 
According to the above steps, the purity has improved but the use of 150 µl Ni-NTA reduced 
the yield of protein without improving its purity so the 200 µl Ni-NTA was used in the 
purification of the protein on larger scale (see fig.4.105)   
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Fig.4.105: Optimization of overexpression of CyaB1 PAS/Catalytic (1) Before optimization 200 µl Ni-
NTA and 400 ml culture media (2) 600 ml culture media, DNAse after lysis of the cells and 150 µl Ni-
NTA (3) 600 ml culture media, DNAase after lysis of the cells and 200 µl Ni-NTA. 
 
The protein was overexpressed in larger quantities, concentrated and crystallized as 
mentioned for the catalytic domain constructs and again no crystals were obtained with this 
construct. 
The gel filtration and glutaraldehyde dimerization experiments of CyaB1 PAS/catalytic 
showed formation of a dimer of 107 kDa and the smaller peak for 24.5 kDa which appears 
also in the run is suggested to be an impurity or degradation product of the protein (fig.4.106). 
The formation of the dimer in the PAS/catalytic and a monomer in case of catalytic domain 
proves that the PAS domain is responsible for the dimerization of the enzyme. 
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Fig.4.106: Dimerization of CyaB1PAS/catalytic (A) the gel filtration showing single peak of a dimer 
with another smaller peak in the size of impurity (see SDS-PAGE in fig.4.105) and (B) Dimerization by 
Glutaraldehyde showing presence of a dimer. 
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5 Discussion 
Although great progress has been made in characterizing the different groups of 
phosphodiesterases, we are still unable to grasp the idea of how regulation and intramolecular 
signaling occurs within these enzymes. In the last few years, the crystal structure of the 
mPDE2 GAF tandem revealed a parallel dimer with cGMP bound to the GAFb domain of 
each monomer, on the other hand the CyaB2 GAF tandem which was elucidated three years 
later showed an antiparallel dimer with cAMP binding to each of the four subdomains. The 
success of producing the chimeras of rPDE2/CyaB1 and CyaB2/CyaB1 which were regulated 
by different cyclic nucleotides addressed the question: what is the mechanism by which the 
signal is transduced through the PAS domain to the catalytic domain?  
5.1 Biochemical characterization of hPDE2NGAF/CyaB1 
chimera 
5.1.1 hPDE2NGAF/CyaB1 chimera had a 5-fold stimulation 
upon binding of cGMP 
 
In CyaB1, cAMP binding to the GAF domain is responsible for regulation of the catalytic 
domain. Previously, CyaB1 PAS/catalytic (L386-K859) was used as a reporter to study GAF 
domains of CyaB2 and mammalian PDEs 2, 5, 10 and 11 [19, 80, 101, 106].  
In PDE2, there is only one gene coding for this family, which is the PDE2A. PDE2 has two 
binding sites one is a high affinity, non-catalytic binding site, specific for cGMP and the other 
is low affinity catalytic binding site which can hydrolyze both cAMP and cGMP. Because 
PDE2 was found in cells that express little or no PKG, PDE2 is considered to be one of the 
main receptors for cGMP in cGMP-mediated signal-transduction mechanisms, and represents 
a classic site of cross-talk between cAMP and cGMP signaling pathways [5].  
Although the crystal structure of the GAF domain (Y215-Y555 rat PDE2 numbering) of 
mPDE2 and the catalytic domain of hPDE2 (578-919) were elucidated [24, 53], little 
information is available about the structure of the holoenzyme. 
The regulatory domain of hPDE2 was characterized through the generation of 
hPDE2NGAF/CyaB1 AC chimera. The chimera was regulated by cGMP with 5-fold 
stimulation. A recombinant bPDE2A assayed in a mammalian cell extract showed 
approximately 3.5-fold stimulation by cGMP [107]. Purified bPDE2 proteins showed 5–6-
fold stimulation in one report [108] and >50-fold stimulation in another [109]. The rPDE2A1 
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had 1.4-2.3-fold-stimulation while rPDE2A2 had 2.5-3 fold-stimulation depending on the 
method of purification from liver cells [110]. Almost 3-fold stimulation for the unpurified 
recombinant hPDE2 was produced by the addition of 10 mM cGMP [111]. The differences in 
these values may reflect differences in methodology and enzyme status. Alterations in assay 
temperature, assay pH, cGMP concentration and proteolysis of the enzyme affect the 
activation state of the enzyme. In addition, the presence of fatty acids or short chain alcohols 
has been reported to inhibit the activation of cAMP hydrolysis by cGMP [111].  
The cGMP-EC50 of 9.9 ± 1 µM of hPDE2NGAF/CyaB1 chimera was comparable to the other 
hPDE/CyaB1 chimeras. In hPDE5/CyaB1 chimera, the cGMP-EC50 was 9.6 ± 1.8 µM [106], 
72.5 ± 10.1 µM for hPDE11A4/CyaB1 while the cAMP-EC50 of PDE10A1/CyaB1 was 18.1 ± 
1 µM [19]. The value of the EC50 of human PDE2 has been calculated in one report to be 0.3 
µM which is much less than the value obtained here. The Hill coefficients that represent the 
cooperativity of cNMP binding to the GAF domain were ≤ 1 for all PDE/CyaB1 chimeras and 
CyaB1 holoenzyme but cooperative for CyaB2/CyaB1 chimera which may be explained by 
the allosteric binding of the cyclic nucleotide to one GAF motif of each monomer of PDEs 
and CyaB1 GAF but to both motifs of the CyaB2 GAF domain. The Hill coefficient for the 
unactivated hydrolysis of cAMP was ranging from 1.5-2.0 in different variants of mammalian 
PDE2 but it was 1 for the activated hydrolysis of cAMP and for cGMP [104, 110]. 
The time dependence of hPDE2/CyaB1 chimera showed a steady state achieved at as short 
interval as two minutes and this was used as a control to compare other PDE2 mutants. The 
optimum temperatures for the activated and the unactivated differ by 5oC which suggests 
differences in the conformation of the catalytic domain between the activated and the 
unactivated states. The ATP kinetics showed different Km values for the unactivated and the 
activated form of the enzyme as activation reduced the Km value of ATP. This agrees with a 
report evaluating the kinetic of cAMP hydrolysis in PDE2 holoenzyme in the presence and 
absence of cGMP where they found that cGMP reduced the Km value of cAMP rather than 
Vmax [110].  
The optimum pH for hPDE2NGAF/CyaB1 chimera was 8.5. Plotting the fold stimulation 
obtained by the pH-dependence study against pH showed presence of two peaks one at pH 6.5 
(8.5 fold) and the other at pH 8.5 (6.1 fold). This indicates the presence of two optimum pH’s 
one for the non-catalytic binding of cGMP (pH 6.5) and the other for the AC catalytic activity 
(pH 8.5). 
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5.2 Role of the N-terminal domain on the activity and 
regulation of PDE2/CyaB1 chimera 
5.2.1 Effect of the hPDE2 N-terminus 
 
From the three splice variants, the PDE2A1, PDE2A2 and PDE2A3 (PDE2A2 has only been 
found in rats) [107, 111-113], PDE2A1 is cytosolic whereas -A2 and -A3 are membrane 
bound. It has been suggested that different localization of PDE2A2 and -A3 is due to a unique 
N-terminal sequence, which is absent in PDE2A1 (Fig.5.1). These differences in 
hydrophobicity may be the base for the partitioning of the PDE2A activity between 
membrane-associated and soluble fractions of the cell [114]. Despite the PDE2A splice 
variants being different; there is no known difference in their kinetic behaviour [115]. 
 
PDE2A1                          MRRQPAASR DLFAQEPVPP GSGDGA
PDE2A2          MVL VLHHILIAVV QFLRRGQQVF LKPDE-P-PP QPCADS
PDE2A3   MGQACGHSIL CRSQQYPAAR PAEPRGQQVF LKPDEPPPPP QPCADS
25
37
46
 
Fig.5.1: Comparison of the amino-terminal sequence of PDE2A1, PDE2A2, and PDE2A3.  
Sequences are from bovine (PDE2A1), rat (PDE2A2), and human (PDE2A3). Hydrophobic regions are 
highlighted in grey. Alignment re-drawn from ref [115]. 
 
Human PDE2A3, discovered in the brain, has a unique hydrophobic proline-rich N-terminus. 
The truncation of the whole N-terminus of hPDE2 (Δ1-227 aa) had little or no effect on the 
cGMP-EC50, fold stimulation and Hill coefficient, in addition to that the substrate kinetics 
showed similar Km value but higher Vmax for the both activated and unactivated chimeras. An 
increase in the basal activity of about 9 times was observed in the N-terminally truncated 
construct. This increase in the activity of the enzyme can be due to its direct effect on the 
catalytic domain or by reducing the soluble fraction of the enzyme. This could be checked by 
solubilization of hPDE2NGAF/CyaB1 chimera by 1% lubrol and the evaluation of its effect 
on the activity of the enzyme.  
It is note worthy that the N-termini of PDE5 and PDE11 were important for regulation and 
their truncation increased basal activity and the affinity toward cGMP accompanied by 
reduction of the fold-stimulation [106, 116]. 
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5.2.2 Effect of hPDE5 N-terminus on the regulation and activity 
of hPDE2/CyaB1 AC chimera 
 
Similar to PDE2, a significant dissimilarity in the protein sequence of the N-terminus of rat, 
bovine and human PDE5 was observed. Alterations in the N-terminal sequence among the 
three species may lead to differences in the subcellular localization. An N-terminal Gln-rich 
sequence was found in human homolog [117]. 
The effect of different lengths of the N-terminus of PDE5 was studied earlier and truncation 
of more than 101 aa’s of the N-terminus increased the affinity of the GAF domain toward 
cGMP, increased the basal activity and decreased the fold-stimulation in hPDE5/CyaB1 
chimera [106]. Swapping the N-terminus of hPDE5 in front of PDE2/CyaB1 AC chimera had 
also an inhibitory effect on the AC activity compared to the N-terminally truncated construct. 
Although the hPDE5 N-terminus is hydrophilic in nature and had a significant regulatory 
effect on the hPDE5/CyaB1 chimera [106], this effect was not obvious in conjunction with 
PDE2 and only a small decrease in the EC50 with a small increase in the fold-stimulation was 
observed. This means that regardless the hydrophilicity of the N-terminus, it has an inhibitory 
effect on the enzyme without affecting the affinity toward cGMP or the folding of the GAF 
domain. This suggests a difference in the folding of hPDE5 GAF and hPDE2 GAF where no 
interaction between the N terminus of PDE5 and GAF domain of hPDE2 was observed at the 
time it regulates the activity of its GAF domain.  
5.2.3 The CyaB1 N-terminus reduced the fold stimulation by 
cGMP of rat PDE2 GAF 
 
The different expressions of CyaB1N-rPDE2/CyaB1 protein had different values of fold 
stimulation which range from 2-5 fold while the different expressions of ∆N-rPDE2/CyaB1 
had a fold-stimulation of 15-33 fold. In the results obtained by T.Kanacher, the fold-
stimulation was 10-fold by CyaB1N-rPDE2/CyaB1 with basal activity of 2.5 
nmol/mg.min[80].  
In all assays, the fold stimulation of the N-terminally truncated chimera was higher than the 
construct with the CyaB1 N-terminus. The CyaB1 N-terminus may inhibit signal transduction 
from the GAF domain to the catalytic domain without having an effect on the affinity of the 
GAF domain toward cGMP. The same effect of CyaB1 N-terminus was observed in 
CyaB1.N-ter.hPDE11/CyaB1 [116].  
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5.3 Role of the connecting helix in the signal transduction 
5.3.1 Shortening and elongation of the connecting helix of 
CyaB2GAF disturb dimerization and signaling 
 
What is the nature of the signal transmitted by a helix? An obvious answer is dimerization of 
protein monomers. Another possibility is that the helix might be a structural relay. Both of 
these appear to play a role in signaling between CyaB2 GAF motifs. According to the crystal 
structure of CyaB2 GAF, the α1-helix and the connecting helix are responsible for 
dimerization [23]. Shortening or elongation of the connecting helix by 1-3 aa reduced the 
stimulation and the cAMP-affinity, demonstrating that dimerization is essential for full 
potency. Deletion of more than three amino acids led to a dramatic reduction of both fold 
stimulation and cAMP-affinity, while the insertion of aa’s affected the stability, indicating the 
importance of the helix length in signalling and protein stabilization. The enormous reduction 
in the stimulation can be due to several reasons: no dimerization, a change in the rotational 
orientation of the helix will affect the amino acids embedded in the helix and those exposed, 
in addition to the proper orientation of the two GAF motifs. It has been proposed that such 
shifts could occur gradually, without disruption of the helix, by a change in supercoiling about 
the dimer axis; these gradual shifts would require an intermediate region of relatively weak 
interhelical packing [118]. Such an interface shift might be expected to cause significant 
reorientation of CyaB2 GAF motifs at the other end of the helix, capable of suppressing 
activity. Another reason for the effect of such mutations is the signal transduction within the 
GAF domain of CyaB2 itself. In the crystal structure of CyaB2 GAF, cAMP was found to 
bind to both GAFa and GAFb which may explain the cooperativity in CyaB2/CyaB1 chimera. 
The α1, α2, and the connecting helix in the crystal structure look like the HAMP domain in 
their arrangement. The increase in the EC50 of cAMP by both deletion and insertion mutants 
can be due to the disruption of the signaling between the GAFa and GAFb.  
Although the four helices of the two chains are present in the same environment, the 
interaction was inter- rather than intrasubunit which performed the dimerization between the 
two monomers and what stabilized the CyaB2 GAF tandem. In more details, the intrasubunit 
interaction between the α1-helix and the connecting helix in CyaB1 GAF was observed to be 
poor with only one site of hydrophobic interaction (L75 with F245). Intersubunit interaction 
was achieved through the α1-helices, the two connecting helices and α1-helix-connecting 
helix interactions (Fig.5.2). 
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DC
 
Fig.5.2: Different diagrams from CyaB2 GAF crystal structure showing the intra and inter subunit 
interactions between the α1-helices and the connecting helices.  
 
 
The interesting observation in these models was that although all helices were dimerizing with 
each other by hydrophobic bonds, two hydrogen bonds (<3 Ǻ) at the crossing of the two 
connecting helices formed by Gln252 were supporting the whole structure and I will guess 
that mutation of this amino acid residue may dramatically affect signaling between the two 
GAF tandems and hence to the catalytic domain (Fig.5.3) 
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Q252
Q252
 
Fig.5.3: The hydrogen bonding between N-O of Gln252 observed at the crossing of the connecting 
helices of the two GAF subunits. 
 
5.3.2 The effect of CyaB1 connecting helix on the signaling of 
CyaB2 GAF 
The exchange of the CyaB2 GAF connecting helix by that of CyaB1 had decreased the fold 
stimulation to about one fourth without having a great effect on the cAMP-EC50. Although 31 
aa were exchanged, none of them was found to have a stabilization affect on the GAF motifs, 
in addition, there was no rotation in the GAF tandem around the dimerization axis which 
didn’t affect the interaction between the two GAF tandems and hence, the affinity toward 
cAMP was not changed. The exchange of this helix has shown to cause loss of cooperativity 
and this means that the decrease in the fold stimulation could be due to the loss in the cross-
talking between the two GAF motifs a and b which is governed by the linker between the two 
GAFs. 
5.3.3 The role of the two hydrophobic residues (ML) in α1 and 
α2 helices of CyaB2 GAF 
My observation of the presence of the two hydrophobic amino acids in the α1-helix of the 
GAF domain was beneficial in the determination of the beginning of this domain in other 
PDEs, e.g. the re-cloning of the GAF domain of hPDE10 which included this α1-helix has 
produced large crystals. 
The different mutations performed in the different aa’s had included mutation to the small 
non-chiral aa, glycine, the small side chain aa, alanine, the small hydrophilic aa, serine, the 
branched hydrophilic aa, threonine, and the larger branched hydrophobic aa, leucine (Fig.5.4) 
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Glycine
Leucine Methionine
Serine
Threonine
Alanine
 
 
Fig.5.4: Stick model of the amino acids used in the different mutants. Black: carbon, red: oxygen, blue: 
nitrogen, yellow: sulfur and white: hydrogen. 
 
M74 and L75 have different hydrophobic interactions with different residues. L75 forms van 
der Waal forces with F245 and F80 within the same subunit and M259 of the other subunit. 
The mutation of these two amino acids to the small flexible glycines didn’t have a great effect 
on the fold stimulation but obviously decreased the affinity and the Hill coefficient of the 
mutant. The mutation to hydrophilic amino acids (S, T) reduced the fold stimulation more 
than the GG mutant did with less effect on the cAMP-EC50 of the enzyme. Both mutants were 
found to reduce the cooperativity of cAMP binding. 
Other mutations in the α2-helix were done on the M87 and L88 residues.  These two residues 
were found to have interactions with I238, L239 within the same subunit and S266 of the 
other subunit. The mutation of the first residue to the hydrophilic serine reduced the fold-
stimulation dramatically but the EC50 was not affected with a Hill coefficient not changed. 
This can be explained by the involvement of this aa residue in dimerization and signaling but 
not in the stabilization of the GAFa domain. For the second mutant (L88S), the protein 
dependence curve was non-linear with a dose response curve that doesn’t reach a plateau. L88 
has interaction with L239, I119 and V120, the last two residues are part of a β-sheet within 
the GAFa and this explains the dose response curve wherever L88 is mutated (Fig.5.5).  
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BA
 
Fig.5.5: The crystal structure of CyaB2 GAF domain shows the hydrophobic interactions by which 
M87 (A) and L88 (B) stabilize the GAF structure. 
 
 
The double mutation of both residues had produced a mutant with lower fold stimulation of 
both single mutants and shares the no effect on the EC50 of M87 mutant and the reduction in 
the Hill coefficient and the same profile of dose response curve of L88 mutant. 
5.3.4 The role of two methionines in the connecting helix on 
dimerization and signaling 
 
An unplanned mutation of the M258T in the presence of other mutations in the GAF domain 
had showed an obvious decrease in the fold stimulation of the enzyme which shed light on the 
importance of the linker region in general and specifically these two amino acids in the signal 
transduction. I generated a single mutant (M258T). The fold stimulation and the affinity 
toward cAMP were reduced only to one third. The interaction of these aa residues were 
checked in CyaB2 GAF crystal structure. M258 had intrasubunit interactions with I425 and 
intersubunit interaction with L237 while M259 interacts with L75 and L84 of the other 
subunit. I have observed that these 2 aa with their different interactions are holding the two 
GAFa domain together until the distance between D375 of GAFb of one monomer with E187 
of GAFa from the other monomer is 3.7Ǻ.  The four mutants prepared later included double 
mutants of methionines. The mutations of MM to GG or AA were found to decrease the 
cAMP-affinity more than other mutants without having a great effect on the fold stimulation. 
The least fold stimulation was observed for GG and ST mutants. This decrease in both, fold 
stimulation and cAMP-affinity in the GG mutant is due to the fact that glycine is the smallest 
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aa with no chiral carbon. The ST residues are hydrophilic in nature and smaller in size which 
may not only disturb the dimerization but also affect the surrounding aa by its hydrophilicity.  
The most interesting result was obtained with the quadruple mutant (α1-helix (ML) and 
connecting helix (MM) to ST; CyaB2 (M74S/M75T/M258S/M259T)/CyaB1). Calculating the 
fold stimulation with different protein concentrations showed an increase which meant that 
dimerization within the GAF enhances binding of cAMP to the GAF domain or signaling to 
the catalytic domain. The cAMP-EC50 was higher than that of the double mutants. Although 
these double mutants were still showing some cooperativity, the Hill coefficient of the 
quadruple mutant showed no cooperativity. 
Another interesting result was the mutation of the two methionines to leucines. All PDE 
GAFs and CyaB1 GAF contain two leucines in their connecting helix while methionines were 
unique for the CyaB2 GAF connecting helix. Methionine and leucine are considered 
equivalent as they have almost similar size and hydrophobicity but the truth was something 
else. The mutation of the methionines to leucines misfolded the protein and produced an 
absolutely inactive enzyme. The isolated GAF domain of leucine mutant also proved the 
misfolding on the SDS-PAGE and gel chromatography. Although the connecting helix of 
CyaB1 displaced contained two leucines, it was still having its own intersubunit interface of 
CyaB1. This result can be explained by the rigidity of the side chain of leucine represented by 
the branched carbons which may have a steric effect on the dimerization interface between the 
connecting helices of the two monomers compared to the more flexible sulfur containing 
methionine (see Fig.5.4). A question mark is put on the reliability of the thousands of 
alignments we are making every day and rely on it in the comparison of proteins in which M 
is considered similar to L and I, Q is similar to E, D is similar to N at the time all these aa 
residues compared are different in size or physical properties. 
5.3.5 Mutation of two hydrophobic aa residues in the α1-helix 
and another in the connecting helix disturbed the 
dimerization of hPDE2 and hPDE5 GAF domain. 
 
PDEs are dimeric. However, the dimerization is not required for catalytic activity, because the 
monomeric short catalytic domain of PDE5 is active. The structural and functional roles of 
PDE dimerization are poorly understood [119]. The first molecular informations about PDE 
dimerization have been provided by the structure of the mPDE2A tandem GAF [24]. This 
crystal structure demonstrates that GAFa domain is responsible for dimerization of PDE2A, in 
addition to some aa’s in the connecting helix between the two GAF’s. In the hPDE2 α1-helix 
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mutants, the mutation of either I230 or L231 residue, involved in the dimerization of the 
GAFa, increased the fold stimulation by cGMP by 17 and 24-fold, respectively, without an 
effect on basal activity or EC50 of cGMP. The Hill coefficient for L231S mutant was not 
affected but it increased to above 1 for I230S mutant. As the PDE2 GAFa doesn’t bind 
cGMP, the 3-5 times increase in the fold stimulation by cGMP would suggest that a real effect 
on the GAFb folding and signal transduction to the catalytic domain had occurred as the 
affinity toward cGMP was not affected.  
In the connecting helix mutants a slight decrease in the fold stimulation, an 28-fold increase in 
the affinity toward cGMP and no effect on the Hill coefficient were observed with hPDE2 
(L396A/L397A)/CyaB1 mutant, another mutant (C393S), which was found in the crystal 
structure to be involved in the dimerization by forming a disulfide bond, didn’t have any 
effect on the kinetic parameters of cGMP-binding to the GAF domain which agrees with the 
results obtained by Martinez et al [24]. The truncation of the N-terminus accompanied by 
quadruple mutation of the two hydrophobic amino acids in both α1-helix and the connecting 
helix had led to having persistent high basal activity and loss of regulation by cGMP. The 
interesting result of this mutant was although cGMP doesn’t stimulate, it has a stabilizing 
effect on the GAF domain. In order to correlate the parameters obtained from the AC assay 
with the dimerization, a crosslinking experiment was performed for the WT and the mutated 
chimeras. As the PAS domain proved to enhance the dimerization of the catalytic domain of 
CyaB1, the isolated tandem GAF domains ± N-terminus and mutants were cloned. The gel 
filtration and glutaraldehyde crosslinking experiments showed that hPDE2 GAF ± N-terminus 
are dimers which mean that the N-terminus has no effect on the dimerization of the enzyme.  
The dimerization appears to be very important for the stabilization of the GAF folding and for 
providing certain conformation that can bind cGMP.  
In PDE5/CyaB1 mutants the double mutation of the two leucine residues in the either α1-helix 
or the connecting helix increased the affinity of the GAF domain toward cGMP significantly 
and reduced the fold stimulation. The quadruple mutant had lost the regulation by cGMP 
completely. In these mutants, the basal activity of the enzyme was significantly affected, at 
the time hPDE5 (L152A/L153A)/CyaB1 had the double basal activity of WT, hPDE5 
(L333A/L334A)/CyaB1 had 7-fold increase in the basal activity and mutant combine all four 
mutations had produced a construct of 3.5-fold basal activity. To discover if these results are 
due to disturbance of the GAF domain dimerization, the different GAF mutants ± N-terminus 
were cloned and evaluated for dimerization by glutaraldehyde crosslinking and gel filtration. 
∆135-hPDE5 has shown to enhance monomerization by increasing the ratio of monomer to 
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dimer. The double mutation in either α1-helix or connecting helix had little or no effect on the 
dimerization of the GAF domain while the combination of both mutations in a quadruple 
mutant in the presence of the N-terminus had disturbed the dimerization significantly by 
producing a profile in which the monomer is the major peak. Combination of the ∆N-terminus 
with the quadruple mutant had produced similar profile in which the monomer is the major 
peak. This suggests the presence of three dimerization interfaces: one in the region from 101-
135 aa of the N-terminus, a second in the α1-helix and the third in the connecting helix. It was 
obvious that disruption of the dimer interface shifts the conformation of the enzyme toward 
the activated state which requires usually the binding of cGMP to the GAF domain. Such a 
result supports the presence of different conformations for PDE5 and proves that the 
unactivated conformation had higher energy and is the unpreferred conformation in 
comparison to the activated form. 
In the unactivated state, the dimerization decreases the flexibility of the GAF domain of both 
PDEs and form more rigid structure. In the presence of the cGMP, the binding to the GAFa in 
PDE5 and GAFb in PDE2 changes the conformation of the GAF it bound leading to rotation 
of the connecting helix between the two GAFs, weakening the dimerization at the other GAF 
motif and gave more flexibility of the whole regulatory domain. As the different domains: N-
terminal domain, GAFa, GAFb, PAS, and catalytic domain were all attached with each other 
by α-helices, the change in the conformation of one domain will transfer the signal as a 
‘domino’ to the other domains and then to the catalytic domain in which the action of the 
signal transmitted is observed. The length of the helix and the angle, around which this helix 
rotates, determine the amount of signal transferred from one domain to another. In addition 
any substances that may bind directly to any domain will lead to conformational changes in 
that domain and change in the amount of signal transmitted. 
5.4 Signal transduction through CyaB1 PAS domain  
5.4.1 Is it determined by the binding of a divalent cation to the 
PAS domain? 
CyaB1 has been characterized by Ohmori et al [83]. Later, CyaB1 enzyme was evaluated as a 
holoenzyme and a truncated catalytic domain [79]. 
The kinetic properties of the shortest catalytic domain, construct I, CyaB1595-859, were 
assayed at 45oC and pH 8.5 in the presence of Mn+2 or Mg+2 as a divalent metal ion. In the 
presence of Mn+2, the enzyme had higher affinity toward ATP (Km values of 11 vs. 334 µM) 
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and lower Vmax (309 vs. 655 nmol/mg.min) when compared to kinetics in presence of Mg+2 
[80].  
Unlike the truncated catalytic domain, CyaB1 holoenzyme prefers Mg+2 over Mn+2 as a metal 
cofactor. Using Mn+2, as divalent cation, a biphasic curve was obtained by cAMP-dose 
response assays but a monophasic in the presence of Mg+2. This was explained to be due to 
the presence of two different cAMP-binding sites (high and low-affinity) in the presence of 
Mn+2 but only one high affinity binding site in the presence of Mg+2 [80]. 
The presence of two aspartate residue in the PAS domain similar to those responsible for the 
metal binding in the catalytic domain, opened the question whether this high and low metal 
binding sites are really required for the binding of cAMP to the GAF domain or it was the 
binding of this metal to the PAS domain which decides the amount of signal transferred from 
the GAF domain to the catalytic domain. To answer this question, the substrate kinetics in the 
presence of Mg+2 and Mn+2 should be carried out for the following constructs: construct IV 
(beginning of the dimerization without PAS or GAF), CyaB1 PAS/catalytic (dimer with PAS 
domain and no GAF), Construct IVB (GAF domain with no PAS which is able to transmit the 
signal) and CyaB1 WT (GAF, PAS and catalytic are all there). 
5.4.2 CyaB1 catalytic domain utilizes only one ATP catalytic core 
depends on the truncation 
 
The truncated CyaB1 catalytic domains are monomers as observed by gel filtration curves. 
The protein dependence of the two shorter catalytic domains (constructs I and II) had higher 
activity and achieved the steady activity at lower protein concentrations while the two longer 
ones (constructs III and IV) had lower activity and didn’t achieve steady state up to 3 µM 
protein. In addition, the Western blots of the four constructs showed bands in the size of 
monomer for all constructs and another band for a dimer only with the longest one (construct 
IV). The secondary structure of the four constructs as predicted by the Protean program 
(Fig.5.6) indicated that the two short catalytic domains are missing part of the long α-helix, a 
β-sheet and a short α-helix, the third construct lacks the α-helix and the fourth has all. 
I   :595 -----------------------------------GERKEVTVL 
II  :589 -----------------------------EDALMVGERKEVTVL 
III :572 ------------MYRYLTPHVAEQVMALGEDALMVGERKEVTVL 
IV  :560 EDISQEKRLKTTMYRYLTPHVAEQVMALGEDALMVGERKEVTVL 
  
Fig.5.6: An alignment of the truncated catalytic domains shows the beginning of each construct and 
above their secondary structure according to Protean program. 
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I suggest that the catalytic domain of CyaB1 is a monomer in solution. During the assay, ATP 
is inducing homodimerization. In the shorter constructs (I and II), both ATP binding sites 
were utilized to yield the high activity, while the presence of the β-sheet in the third construct 
and a β-sheet and α-helix in construct IV hindered the proper dimerization of the enzyme 
leading to only partial dimerization and utilization of one ATP catalytic site. This explains the 
lower steady activity and failure in achieving steady state. The CyaB1 PAS/catalytic gave a 
result similar to the longer catalytic domain, which suggests the same catalytic domain 
conformation with the one ATP-catalytic core. A scissor like mechanism was suggested for 
this enzyme in which figure 5.7.A represents the more active short truncations of the enzyme 
while B represents the longer less active constructs. 
Short constructs
Long constructs
A
B
 
Fig.5.7: A schematic diagram suggests and explains the decrease in basal activity of CyaB1 catalytic 
domain by elongation of the linker preceding the catalytic domain. (A) Diagram represents the catalytic 
domain in the activated state or short constructs, Modified from [79]. (B) The proposed one catalytic 
pocket theory in the presence of longer catalytic linker.  
 
To see whether the CyaB1 catalytic linker represent any of the domains, its sequence was 
checked by Blast search to find it aligned well with hPDE2 with 22% identity and 44% 
similarity (CyaB1 516-560 and hPDE2 126-165) which suggest for this linker to have an 
inhibitory effect on the activity of the enzyme as observed in hPDE2 N-terminus. 
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5.4.3 The linker of hPDE5 can transduce the signal between GAF 
and catalytic domains of CyaB1 with less efficiency 
From the eight constructs cloned with different lengths of hPDE5 linker and CyaB1 catalytic 
domain, only the construct with the longest hPDE5 linker and the longest CyaB1 catalytic 
linker (construct IVB) was regulated by cAMP. The other seven constructs had different 
activities depending on the truncated catalytic domain attached but they were not regulated at 
all. Construct IVB had similar cAMP-EC50 but only one tenth of the fold-stimulation of 
CyaB1. Different theories were suggested for signaling from the GAF domain to the catalytic 
domain in PDE5. Rybalkin et al. suggested presence of 3 different conformations, 
unactivated, activated by cGMP and one with higher activity which is not regulated by cGMP 
after long storage of the enzyme and it was suggested a physical interaction between the GAF 
and the catalytic domain [120]. Dr. Omori suggested the presence of three conformations, two 
for the activated and one for the unactivated [9] (see Fig.5.8). 
According to this, in construct IVB, hPDE5 linker placed CyaB1 GAF and catalytic domain 
in certain angle to allow physical interaction between the two domains as suggested by the 
above theories which require the CyaB1 catalytic domain to be a monomer to allow this 
physical interaction. I would propose (first) that the PDE5 two helices are holding the GAF 
and catalytic domain in certain angle and once cGMP binds the GAF domain, conformational 
changes in the GAF cause rotation of the first helix which causes a rotation in the second 
helix leading to conformational changes in the catalytic domain to utilize both ATP catalytic 
sites and be activated. The second possibility is that the two α-helices of hPDE5 are parallel to 
each other and not perpendicular which means that the enzyme as a dimer forms a 4-helix 
bundle that may function as a signaling domain. In order to strengthen this possibility, the 
linker of construct IVB was aligned with 2 different PAS domains, CyaB1 PAS which had 
19% identity and 33% similarity and PYP which had 29% identity and 44% similarity. This 
doesn’t mean that hPDE5 linker represents a PAS domain but it looks like and may function 
as a signal transducing domain. 
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Fig.5.8: Mechanism of signaling from the GAF domain to the catalytic domain in hPDE5 upon binding 
of cGMP and phosphorylation of the regulatory domain. PDE5 is directly activated upon cGMP binding 
to its GAF A domain. Without cGMP bound, PDE5 is in a nonactivated state. PDE5 is converted into 
an activated state after binding of cGMP to the GAF A domain. Only activated PDE5 is phosphorylated 
by PKG. (A) As suggested by Rybalkin et al. [10, 120] (B) As suggested by Omori et al [9]. (C) 
Working model of PDE5. The regulatory domain in the amino terminal portion of PDE5 contains the 
phosphorylation site (Ser-92), the two allosteric cGMP-binding sites a and b, and at least a portion of 
the dimerization domain. The catalytic domain in the carboxyl-terminal portion of the protein contains 
the two Zn2+-binding motifs A and B and a cGMP-binding substrate site. Amino acids that are 
potentially involved in the catalytic mechanism are indicated in green and those involved in binding 
cGMP in an allosteric or catalytic site are indicated in yellow suggested by Corbin et al [121]. 
 
The secondary structure of IVB linker was predicted by Protean and found to form two α-
helices each of 17 aa in length, which may suggest a HAMP-like domain which is also a 
transmitter domain present in many organisms, and consists of four α-helices that dimerize 
and interact with each other to transduce the signal in mechanical and interactive modes 
[122]. The alignment of hPDE5 linker with different HAMP domains showed little 
similarities with most of them but some similarity with the HAMP domain of methyl 
accepting chemotaxis protein from Rhodospirillum centenum with 29% identity and 40% 
similarity was observed. 
Accordingly, I would suggest that the CyaB1 catalytic linker arrests the catalytic domain in a 
conformation to be activated while the hPDE5 linker has worked as signal transducing 
domain in this construct. The decrease in the signal transduction to one tenth could be due to 
the difference in the length and transduction properties of IVB linker compared to the PAS 
domain. 
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5.4.4 Exchange of the PAS domain by that of CyaB2 is still able 
to transduce the signal but with less efficiency 
 
The exchange of the CyaB1 PAS with that of CyaB2 didn’t have a significant effect on the 
affinity of the CyaB1 GAF toward cAMP which means that the folding of the GAF domain 
was not affected. The fold-stimulation and the basal activity were affected, the decrease in the 
fold stimulation may be due to the disruption of the signal transduction through the PAS 
domain of CyaB2 as the two PAS domains can’t have the same efficiency in signal 
transduction or they may bind different ligands that help in the transduction of the signal. The 
effect of CyaB2 PAS domain on the folding or dimerization of the catalytic domain of CyaB1 
should also be evaluated by carrying out the substrate kinetics of the chimera. I would expect 
that the CyaB2 PAS domain affects in one way or another the folding of the enzyme or that 
the region replaced doesn’t only include the PAS domain of CyaB1 but another 130 aa 
between the PAS and the catalytic domain which are missed in the sequence of CyaB2 and I 
expect it to have a role in the folding and the function of the catalytic domain due to the fact 
that construct I of CyaB1 catalytic has a different activity from construct IV which has 35 aa 
from this linker.   
5.4.5 The insertion of a flexible linker between the catalytic 
linker and the catalytic domain of CyaB1 completely 
destroyed signaling to the catalytic domain 
The insertion of the flexible linker didn’t only reduce the catalytic activity but also stopped 
signal transduction from the GAF domain to the catalytic domain. In order to see whether this 
linker affected the folding of the CyaB1 catalytic domain, the ATP-Kinetics were carried out 
to find no significant effect on the Km value or the Hill coefficient but a decrease in the Vmax 
compared to CyaB1 holoenzyme which means that the catalytic domain is correctly folded. 
The loss of regulation can be due to the interruption of a very important secondary structured 
element in the catalytic linker as this flexible linker was inserted between T571 and M572. 
The construct which was regulated in the constructs prepared with hPDE5 linker, construct 
IVB, had a linker which starts at E560. Accordingly, although the flexible linker inserted can 
free the movement of the GAF domain over the catalytic domain and allow the physical 
interaction and hence should be regulated, the failure of this construct to transmit the signal 
can’t disprove the theory of the physical interaction between the GAF domain and the 
catalytic domain due to the reason mentioned above. 
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5.4.6 Crystallization of CyaB1 PAS domain 
The discussion for this part of work was written according to the report provided by F.Voigts-
Hoffmann from Heidelberg University. 
The importance of the PAS domain family is shown by its presence in most forms of life 
(plants, animals, and bacteria). There are as many as 140 and 87 different PAS and GAF 
domains identified in Anabaena alone, and many hundreds have been identified in genomes 
sequenced to date [123]. 
Protein sequence analysis [27, 33] and molecular modelling [32] suggested a common fold for 
putative PAS domains from a wide variety of prokaryote and eukaryote sensor proteins. PAS 
domains from PYP [42], FixL [43] and the human HERG potassium channel [124] have a 
distinctive αβ fold with a five stranded antiparallel β-barrel core. It is expected that the more 
than 300 known PAS domains will have a similar three-dimensional structure. At this time, 
relatively little is known about the mechanisms of signal transduction by PAS domains other 
than PYP, HERG and FixL. The common structure of PAS domains suggests that there might 
be different strategies for signalling and different cofactors associated with the fold may 
introduce significant variation in the signaling pathways [125]. According to that solving 
another crystal structure, like CyaB1 PAS, will be important for exploring a new unique 
signalling pathway. 
The crystals CyaB1 PAS produced an image of 2.1 Ǻ. It has been suggested that 40-50% 
sequence identity and a reasonable complete model are required for successful molecular 
replacement but recent studies have demonstrated that successful model can be built on the 
basis of 25-30% sequence identity using data from 1.8-2.1 Ǻ resolution [126]. Although some 
weak sequence homologies have been reported between CyaB1 PAS and other proteins, the 
construction of reliable model suitable for molecular replacement experiments as the 
resolution of 2.1 Ǻ was considered low. The efforts to solve the structure by molecular 
replacement method using different PAS domain structures as search model have so far 
proven unsuccessful. The SeMet method was used but no crystals were obtained with the first 
trial, the purification and the crystallization conditions needed to be modified to get crystals. 
Accordingly, the expected model of the three dimensional structure indicates a similar core 
structure as the ‘PAS fold’, nevertheless, a significant deviations were observed which may be 
required for the interaction with the regulatory GAF domain of the enzyme.  
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5.4.7 Discovering of metal ligand for the CayB1 PAS 
Although the crystal structure of CyaB1 PAS was not solved, the expectation of the PAS 
domain to have a metal binding site was mentioned before. Finding the type of metal bound to 
the PAS will be a strong point in this work but needed some experiments. The exact method 
was mentioned in section 5.4.1. Any difference on the Km and Vmax values of these constructs 
and the effect of this difference on signaling, if any, can be evaluated. 
5.4.8 Importance of this work 
PDEs were considered for decades a good drug targets for the treatment of many diseases. 
Drugs known to date are targeted to the catalytic domain of these enzymes. The high 
similarities in the catalytic domain cause side effects by inhibition of other PDEs. There are 
more than 50 splice variants of PDEs. GAF domains are present in 5 of the 11 families (2, 5, 
6, 10 and 11) while a PAS domain is present in one family (PDE8). This makes the GAF 
domains attractive as drug target. In all the drugs designed so far, a ligand-based rational 
design was performed. Here, the structure-function relationship of the GAF domains (PDE2, 
PDE5 and CyaB2) and PAS domain of CyaB1 provided here were attempts to shift the drug 
design from ligand based rational design to protein based rational design and to use different 
biochemical techniques, x-ray and gel chromatography to provide a new insight into 
signalling by these sensory domains.  
5.4.9 Open questions and outlook 
As the hydrophobic N-terminus of hPDE2 was found to have an inhibitory effect on PDE2 
activity, and the fatty acid and short chains polyalcohols activate the enzyme at low 
concentrations followed by inhibition at higher concentration, I would guess that this happens 
by micellization of the hydrophobic N-terminus by these amphoteric compounds at low 
concentration and binding to hydrophobic regions in the enzyme at higher concentration that 
may affect enzyme activity. The effect of these compounds on activity and activation of the 
hPDE2NGAF/CyaB1 can be evaluated in the presence and absence of the N-terminus. 
Regarding the different mutants of hPDE2/CyaB1 chimeras, I think that the preparation of a 
chimera of hPDE2/CyaB1 and the isolated GAF in the presence of the N-terminus and the 
quadruple mutation in both the α1-helix and the connecting helix hydrophobic residues will 
complete the story of the dimerization effect on the activity of the enzyme. 
The agreement in the fold stimulation by cGMP between the PDE2 holoenzyme, which 
hydrolyses cAMP, and CyaB1 AC, which cyclizes ATP to cAMP, would suggest the 
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possibility of physical interaction between the GAF domain and the catalytic domain. In order 
to prove or disprove this possibility, the assay of PAS/catalytic activity in the presence of 
different isolated GAF domains ± cNMP would be one way. 
In CyaB2GAF, the presence of two hydrogen bonds between Q252 residues of the two chains 
represents an important interaction for the dimerization interface of the two monomers. 
Mutation of this aa residue may severely affect dimerization as this strong interaction is 
localized at the middle of the helix.  
Furthermore, the project of the PAS domain was not completed, and further experiments are 
required to shed light on the signaling of this unique PAS domain.  
The trials to crystallize the CyaB1 GAF (D42-389) domain have produced only small needles 
and all attempts to optimize did not succeed. Applying the sequence of the crystallized 
construct to the protean program showed the presence of an α-helix which starts 9 amino 
acids before (S33). The recloning of this construct with this beginning could be worthy if it is 
interesting to elucidate the crystal structure of another GAF to have a clearer idea about this 
group of SMBDs. 
The efforts spent to solve the crystal structure of the CyaB1 PAS domain were not enough 
and a diploma student for 4 weeks doesn’t have the time and the experience to elucidate a 
crystal structure. Further work is required to reveal not a crystal structure of a PAS domain 
but a new mechanism in signal transduction. 
And lastly, trials by Dr. J.Linder to express CyaB2 holoenzyme and my trials to express the 
PAS/catalytic of this enzyme didn’t succeed. I cloned and expressed the CyaB2 catalytic 
domain for crystallization purposes in this project but its purity was not enough for 
crystallization. The expression can be further optimized and the catalytic domain can be 
characterized with different divalent metals similar to CyaB1.  
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6 Conclusion 
The human cGMP-stimulated PDE2 has a long proline-rich N-terminus while the hPDE5 
had a glutamine-rich hydrophilic N-terminus ahead of the respective tandem GAF. The 
swapping of any of them in front of hPDE2/CyaB1 chimera had inhibitory effect. In 
rPDE2/CyaB1 chimera, CyaB1 N-terminus had a regulatory effect on the enzyme by either 
reducing the binding of cGMP to the GAF domain or reducing the signal transduction from 
the GAF domain to the catalytic domain. 
The CyaB2 GAF linker was important with regard to the length and its amino acid 
sequence. Shortening the length of the connecting helix reduced signalling represented by 
fold stimulation and increased the cAMP-EC50. The difference in the fold stimulation 
between the different mutants can be due to a shift in the dimerization or the differences in 
the exposed and embedded amino acids in the helix which affect dimerization. In the 
constructs with three inserted aa, the effect on fold stimulation and cAMP-EC50 was less 
dramatic but the mutant with 4 aa inserted was unstable which indicates the importance of 
this linker not only for the proper signalling but also for the stability of this domain. The 
cooperativity was lost in all deletion and insertion mutants. The loss of the cooperativity 
may be due to the interruption of signalling between GAFa and GAFb motifs. Mutations of 
the Met/Leu couple in the α1-helix or the two methionines in the connecting helix partially 
disrupted dimerization leading to dramatic reduction in the fold stimulation, decrease in the 
affinity toward cAMP and reduction in the Hill coefficient for most constructs. A quadruple 
mutation in the four amino acids reduced the fold stimulation more than 100 times, in 
addition to the need of high concentrations of protein to achieve steady state. Unlike CyaB2 
GAF α-helices, the mutation in any of the helices preceding the GAF motifs in hPDE5 
increased the basal activity and the cGMP-affinity. The quadruple mutation in leucines of 
both helices led to complete loss of regulation and increase in the basal activity. Mutations 
of the α1-helix to serines in PDE2 GAFs increased the fold stimulation without affecting 
cGMP affinity while the mutations in the connecting helix caused little reduction in the 
fold-stimulation with an 28-fold increase in the cGMP affinity. The quadruple mutation in 
both helices and the truncation of the N-terminus showed loss of regulation and a 25-fold 
increase in the basal activity. The disruption of dimerization of the GAF in three enzymes 
had different effects on regulation of each of them. This indicates that each GAF domain has 
a unique structure and drugs may be targeted toward it without cross-inhibition between 
different GAF domains.  
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The PAS domain of CyaB1 was shown to be important for the proper and efficient 
signalling from the GAF domain to the catalytic domain. The exchange of the PAS domain 
by the hPDE5 linker showed that it is required between the GAF and catalytic for 
signalling. This applies also to the exchange by PAS domain of CyaB2 which was able to 
transduce the signal. Regarding the mechanism of signalling between the different domains, 
the situation was highly complicated. I expect that the N-terminus of hPDE2 was only for 
anchoring the enzyme to the membrane but PDE5 N-terminus had physical interaction with 
the GAF domain that regulates the binding of cGMP. The GAF domain tandems are 
responsible for dimerization and the allosteric activation by cNMP, the binding of the cyclic 
nucleotide to one of the GAF motifs is changing the conformation of that GAF leading to 
rotation of the connecting helix which will loosen the dimerization interface in the other 
GAF motif and cause further conformational changes in the other GAF that will be 
transferred to the catalytic domain by  rotational mechanism that will cause the change in 
the conformation of the catalytic domain and affect the Km or the Vmax for that enzyme 
accordingly. 
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7. Appendix 
A. kinetic parameters of PDE2A 
Isoform 
substrate 
Km 
(µM) 
Vmax 
(unit/mg 
protein) 
stimulation 
(x)* 
Hill 
coefficient 
Ref. 
rPDE2A1 (Cytosolic) 
cAMP 
cAMP + 2µM cGMP 
cGMP 
 
40 ± 2 
20 ± 2  
25 ± 2 
 
4.8 ± 0.25 
4.2 ± 0.13 
1.6 ± 0.12 
 
 
2-fold 
 
1.6 ± 0.05 
1.0 ± 0.1 
1.0 ± 0.05 
[110] 
rPDE2A2 (Particulate) 
cAMP 
cAMP + 2µM cGMP 
cGMP 
 
34 ± 2 
20 ± 2 
31 ± 3 
 
4.0 ± 0.2 
3.8 ± 0.1 
2.1 ± 0.15 
 
 
4-fold 
 
1.5 ± 0.05 
1.0 ± 0.05 
1.0 ± 0.05 
[110] 
 
Isoform cGMP cAMP stimulation 
(x)* 
inhibitors Ref. 
hPDE2A3 28.5 
nmol/mg.min 
20.5 
nmol/mg.min 
3-fold EHNA [111] 
hPDE2A catalytic domain 
(579-921) 
in vitro translated 
bacterially expressed 
 
 
43 ± 7 
34 ± 4 
 
 
34 ± 6 
32 ± 8 
 
 
- 
- 
 [53] 
* Allosteric stimulation of cAMP hydrolysis by cGMP 
 
Affinity toward cyclic nucleotide  
IC50 (nM) 
Ref. 
mPDE2A cAMP cGMP [127] 
GAFa ND ND  
GAFb 146 ± 10 7 ± 1  
GAF a + b 247 ± 14 25 ± 2  
GAF a + b +C 400 ± 20 20 ± 2  
Holoenzyme 598 ± 47 22 ± 1  
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B. DNA and protein sequences of the enzymes used in this study 
B-1 CyaB2 (all1904) 
gi: 1754639 
Acc no.: D89624 
GeneID: 1105496  Protein ID: BAA13999.1 
 
              bp aa 
atg tca ttg caa cag cgt aat ttt ggg gag act ggc gat ttg 42  
M S L Q Q R N F G E T G D L  14 
atc tta ggt acg caa aac caa gag caa aac ttg cca gaa act 84  
I L G T Q N Q E Q N L P E T  28 
tcg gct cct gtc ggc aca cta gcc cgc aga aaa ggt act att 126  
S A P V G T L A R R K G T I  42 
tcg aca ttt ctt gct ccc tta act cag gat act ttt aaa caa 168  
S T F L A P L T Q D T F K Q  56 
gtt gtt aca gaa gtc gag caa aaa ctc caa att gtg cat caa 210  
V V T E V E Q K L Q I V H Q  70 
acc ctg tca atg ttg gat tct cac ggg ttt gaa aat atc ctg 252  
T L S M L D S H G F E N I L  84 
caa gag atg ttg cag tca att acc tta aaa act ggg gaa ttg 294  
Q E M L Q S I T L K T G E L  98 
ttg ggg gca gat cgg acg act ata ttt ttg cta gat gaa gaa 336  
L G A D R T T I F L L D E E  112
aaa caa gaa ttg tgg tcg att gtc gcc gcc gga gga ggc gat 378  
K Q E L W S I V A A G E G D  126
cgc tcc cta gaa att cgc atc ccc gcc gac aag ggg att gcc 420  
R S L E I R I P A D K G I A  140
ggt gaa gtc gct act ttt aaa caa gta gtt aat ata ccc ttt 462  
G E V A T F K Q V V N I P F  154
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              bp aa 
gac ttt tat cac gat cct cgg tcg ata ttt gcc caa aaa caa 504  
D F Y H D P R S I F A Q K Q  168
gag aaa atc act ggc tac cgc aca tat aca atg ctg gct tta 546  
E K I T G Y R T Y T M L A L  182
ccg cta ttg agt gag caa ggg cga tta gtc gcg gtg gta cag 588  
P L L S E Q G R L V A V V Q  196
tta ctc aac aaa tta aaa cct tac agt cct cct gat gca ctg 630  
L L N K L K P Y S P P D A L  210
cta gca gaa cgg att gat aat caa ggt ttt acc agt gca gat 672  
L A E R I D N Q G F T S A D  224
gag caa ttg ttt caa gaa ttt gcg ccc tca att cgc ttg att 714  
E Q L F Q E F A P S I R L I  238
ttg gag tcg tca cgc tcc ttt tat ata gcg acg caa aaa caa 756  
L E S S T S F Y I A T Q K Q  252
agg gcg gcg gcg gcg atg atg aag gcg gta aag tct ctg agc 798  
R A A A A M M K A V K S L S  266
caa agt agt ctg gat tta gaa gat acc ctc aaa cgg gta atg 840  
Q S S L D L E D T L K R V M  280
gat gaa gcc aag gaa ctg atg aac gcc gat cgc agt acc tta 882  
D E A K E L M N A D R S T L  294
tgg ctg ata gac cgc gat cgc cat gaa tta tgg acg aaa att 924  
W L I D R D R H E L W T K I  308
act caa gat aat ggt tct act aag gag ttg cgc gtt ccc ata 966  
T Q D N G S T K E L R V P I  322
ggt aaa ggt ttt gcc ggg atc gtc gcc gca tcc ggt caa aaa 1008  
G K G F A G I V A A S G Q K  336
ctc aac atc cct ttt gat tta tac gac cat cca gac tcg gca 1050  
L N I P F D L Y D H P D S A  350
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              bp aa 
act gcc aaa caa atc gac cag caa aat ggc tac cgc acc tgt 1092  
T A K Q I D Q Q N G Y R T C  364
agt tta tta tgt atg cct gta ttt aac ggc caa gaa caa tta 1134  
S L L C M P V F N G D Q E L  378
att ggt gtg acc caa ctg gta aat aaa aag aaa acc gga gag 1176  
I G V T Q L V N K K K T G E  392
ttc ccc ccc tat aat cca gaa act tgg ccg ata gcg ccc gaa 1218  
F P P Y N P E T W P I A P E  406
tgc ttc caa gcg agt ttt gac cgc aac gac gaa gaa ttc atg 1260  
C F Q A S F D R N D E E F M  420
gaa gct ttt aat att caa gcc ggg gtg gct tta caa aat gct 1302  
E A F N I Q A G V A L Q N A  434
cag ttg ttt gcc aca gtc aag caa caa gag caa atg caa cgg 1344  
Q L F A T V K Q Q E Q M Q R  448
gat att ctg cgg agt ttg tcc aac ggt gtg att tcc aca gat 1386  
D I L R S L S N G V I S T D  462
aag tct ggg aca att att gca gcg aat gaa agc gcc cag cgt 1428  
K S G T I I A A N E S A Q R  476
ttg ttg ggg ctg gaa tca gaa gat cgt ttg gaa ggt aaa ctc 1470  
L L G L E S E D R L E G K L  490
atc agt gag gcg atc gcc att aaa gaa ggc gat ttt agc aaa 1512  
I S E A I A I K E G D F S K  504
tgg tgt caa gat gcc tta cat ggg aca gac ctc aaa ggc cgc 1554  
W C Q D A L H G T D L K G R  518
cag caa tat tac cca gac cgc aca cta gta agc act gaa gca 1596  
Q Q Y Y P D R T L V S T E A  532
gca caa aat agc att aac cta tcg att aat acc att gcc gat 1638  
A Q N S I N L S I N T I A D  546
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              bp aa 
gct agc gat ccc cag caa gtc tgc ggc gcg ttg gtg gtg atg 1680  
A S D P Q Q V C G A L V V M  560
gaa gat att agc gat gag aag cgc ctc aag agt acg atg tat 1722  
E D I S D E K R L K S T M Y  574
cgc tac atg act cag gaa tta gcc gag gaa ttg ctg aaa tta 1764  
R Y M T Q E L A E E L L K L  588
gac gat gct aaa ctg gga ggc gat cgc aaa gaa gtt tcc atc 1806  
D D A K L G G D R K E V S I  602
ctc ttt tcg gat att cgc ggt tac acc act ttg acg gaa aat 1848  
L F S D I R G Y T T L T E N  616
ctg gaa gcc gaa gaa gtc gta agt atg ctc aat gaa tat ttt 1890  
L E A E E V V S M L N E Y F  630
gag tcg atg gta gag gct gta ttc aaa cac aaa ggc act ctg 1932  
E S M V E A V F K H K G T L  644
gat aaa tac atc ggt gat gcg att atg gcc gtg ttt ggt tca 1974  
D K Y I G D A I M A V F G S  658
cct ttg ccc tta gaa gaa cac gct tgg atg gct gta aaa aca 2016  
P L P L E E H A W M A V K T  672
tct ata gaa atg cgt cat cgc tta caa gaa ttt aat caa aaa 2058  
S I E M R H R L Q E F N Q K  686
cgt tat gca gct aat aaa ccc cga atc aat atc ggt att ggc 2100  
R Y A A N K P R I N I G I G  700
atc aat tcc gac acc gta att agt ggc aac att ggc tct agt 2142  
I N S D T V I S G N I G S S  714
aaa cgt atg gaa ttt aca gct att ggt gat ggt gtg aat ctg 2184  
K R M E F T A I G D G V N L  728
ggt tcc cgc tta gaa agt gtg agt aag cag tat ggt tgc gac 2226  
G S R L E S V S K Q Y G C D  742
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              bp aa 
att att ctc agt gat aat act ttt aaa cca tgc cag gaa aat 2268  
I I L S D N T F K P C Q E N  756
att tgg gct aga gaa cta gat ttt atc cgt gtt aaa ggc aga 2310  
I W A R E L D F I R V K G R  770
aat gag cca gta tct ata tac gag tta att ggt tta cgt tct 2352  
N E P V S I Y E L I G L R S  784
gac ccc att gct agt gaa aaa ttg cag gta att gag cat tat 2394  
D P I A S E K L Q V I E H Y  798
cac aag gga cgg gaa tat tac ctg caa cgt caa ttt tcc tta 2436  
H K G R E Y Y L Q R Q F S L  812
gca aga gca gaa ttt gcc aat gtt tta gca gtt gat aaa cat 2478  
A R A E F A N V L A V D K H  826
gac aaa gcc gcg atg ttg cat ctg cta cgc tgt cag cat tgg 2520  
D K A A M L H L L R C Q H W  840
tta caa tca cct cca aca gat tca gaa tgg gat gaa ggg gtg 2562  
L Q S P P T D S E W D E G V  854
tgg acg ttt cag gag aag tga        2583  
W T F Q E K .         860
 
B-2 Human PDE2A3: N-terminus with GAF-A and –B 
gi: 4505657 
chromosome: 11 Location: 11q13.4 
Acc. No.: NP_002590.1 
GeneID (PDE2A): 5138 
              bp aa 
atg ggg cag gca tgc ggc cac tcc atc ctc tgc agg agc cag 42  
M G Q A C G H S I L C R S Q  14 
cag tac ccg gca gcg cga ccg gct gag ccg cgg ggc cag cag 84  
Q Y P A A R P A E P R G Q Q  28 
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              bp aa 
gtc ttc ctc aag ccg gac gag ccg ccg ccg ccg ccg cag cca 126  
V F L K P D E P P P P P Q P  42 
tgc gcc gac agc ctg cag gac gcc ttg ctg agt ctg ggc tct 168  
C A D S L Q D A L L S L G S  56 
gtc atc gac att tca ggc ctg caa cgt gct gtc aag gag gcc 210  
V I D I S G L Q R A V K E A  70 
ctg tca gct gtg ctc ccc cga gtg gaa act gtc tac acc tac 252  
L S A V L P R V E T V Y T Y  84 
cta ctg gat ggt gag tcc cag ctg gtg tgt gag gac ccc cca 294  
L L D G E S Q L V C E D P P  98 
cat gag ctg ccc cag gag ggg aaa gtc cgg gag gct atc atc 336  
H E L P Q E G K V R E A I I  112
tcc cag aag cgg ctg ggc tgc aat ggg ctg ggc ttc tca gac 378  
S Q K R L G C N G L G F S D  126
ctg cca ggg aag ccc ttg gcc agg ctg gtg gct cca ctg gct 420  
L P G K P L A R L V A P L A  140
cct gat acc caa gtg ctg gtc atg ccg cta gcg gac aag gag 462  
P D T Q V L V M P L A D K E  154
gct ggg gcc gtg gca gct gtc atc ttg gtg cac tgt ggc cag 504  
A G A V A A V I L V H C G Q  168
ctg agt gat aat gag gaa tgg agc ctg cag gcg gtg gag aag 546  
L S D N E E W S L Q A V E K  182
cat acc ctg gtc gcc ctg cgg agg gtg cag gtc ctg cag cag 588  
H T L V A L R R V Q V L Q Q  196
cgc ggg ccc agg gag gct ccc cga gcc gtc cag aac ccc ccg 630  
R G P R E A P R A V Q N P P  210
gag ggg acg gcg gaa gac cag aag ggc ggg gcg gcg tac acc 672  
E G T A E D Q K G G A A Y T  224
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              bp aa 
gac cgc gac cgc aag atc ctc caa ctg tgc ggg gaa ctc tac 714  
D R D R K I L Q L C G E L Y  238
gac ctg gat gcc tct tcc ctg cag ctc aaa gtg ctc caa tac 756  
D L D A S S L Q L K V L Q Y  252
ctg cag cag gag acc cgg gca tcc cgc tgc tgc ctc ctg ctg 798  
L Q Q E T R A S R C C L L L  266
gtg tcg gag gac aat ctc cag ctt tct tgc aag gtc atc gga 840  
V S E D N L Q L S C K V I G  280
gac aaa gtg ctc ggg gaa gag gtc agc ttt ccc ttg aca gga 882  
D K V L G E E V S F P L T G  294
tgc ctg ggc cag gtg gtg gaa gac aag aag tcc atc cag ctg 924  
C L G Q V V E D K K S I Q L  308
aag gac ctc acc tcc gag gat gta caa cag ctg cag agc atg 966  
K D L T S E D V Q Q L Q S M  322
ttg ggc tgt gag ctg cag gcc atg ctc tgt gtc cct gtc atc 1008  
L G C E L Q A M L C V P V I  336
agc cgg gcc act gac cag gtg gtg gcc ttg gcc tgc gcc ttc 1050  
S R A T D Q V V A L A C A F  350
aac aag cta gaa gga gac ttg ttc acc gac gag gac gag cat 1092  
N K L E G D L F T D E D E H  364
gtg atc cag cac tgc ttc cac tac acc agc acc gtg ctc acc 1134  
V I Q H C F H Y T S T V L T  378
agc acc ctg gcc ttc cag aag gaa cag aaa ctc aag tgt gag 1176  
S T L A F Q K E Q K L K C E  392
tgc cag gct ctt ctc caa gtg gca aag aac ctc ttc acc cac 1218  
C Q A L L Q V A K N L F T H  406
ctg gat gac gtc tct gtc ctg ctc cag gag atc atc acg gag 1260  
L D D V S V L L Q E I I T E  420
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              bp aa 
gcc aga aac ctc agc aac gca gag atc tgc tct gtg ttc ctg 1302  
A R N L S N A E I C S V F L  434
ctg gat cag aat gag ctg gtg gcc aag gtg ttc gac ggg ggc 1344  
L D Q N E L V A K V F D G G  448
gtg gtg gat gat gag agc tat gag atc cgc atc ccg gcc gat 1386  
V V D D E S Y E I R I P A D  462
cag ggc atc gcg gga cac gtg gcg acc acg ggc cag atc ctg 1428  
Q G I A G H V A T T G Q I L  476
aac atc cct gac gca tat gcc cat ccg ctt ttc tac cgc ggc 1470  
N I P D A Y A H P L F Y R G  490
gtg gac gac agc acc ggc ttc cgc acg cgc aac atc ctc tgc 1512  
V D D S T G F R T R N I L C  504
ttc ccc atc aag aac gag aac cag gag gtc atc ggt gtg gcc 1554  
F P I K N E N Q E V I G V A  518
gag ctg gtg aac aag atc aat ggg cca tgg ttc agc aag ttc 1596  
E L V N K I N G P W F S K F  532
gac gag gac ctg gcg acg gcc ttc tcc atc tac tgc ggc atc 1638  
D E D L A T A F S I Y C G I  546
agc atc gcc cat tct ctc cta tac aaa aaa gtg aat gag gct 1680  
S I A H S L L Y K K V N E A  560
cag tat               
Q Y              562
 
 
B-3 Rat PDE2A:  GAF-A and –B 
gi: 13592021 
chromosome: 1 ; Location: 1q32 
Acc.no.: NM_031079.1 
GeneID: 81743 ProteinID: NP_112341 
GAF domain from E207-546 
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              bp aa 
gaa aag gga tac acc gcc cat gac cga aag atc ctg caa ctg 660  
E K G Y T A H D R K I L Q L  220 
tgt gga gaa ctc tat gac ttg gat gcc act tct ctg cag ctc 702  
C G E L Y D L D A T S L Q L  234 
aaa gtc ctt cga tat ctt cag cag gag aca cag gcc act cac 744  
K V L R Y L Q Q E T Q A T H  248 
tgc tgc ctc ctg ctg gtg tca gag gac aac ctg cag ctt tcc 786  
C C L L L V S E D N L Q L S  262 
tgc aag gtc att gga gag aaa gtg ctg gga gaa gag gtc agc 828  
C K V I G E K V L G E E V S  276 
ttt cca ttg acc atg gga cgc ctg ggc cag gtg gtg gag gac 870  
F P L T M G R L G Q V V E D  290 
aaa cag tgt atc cag ttg aag gac cta acc tct gac gat gtg 912  
K Q C I Q L K D L T S D D V  304 
caa cag cta caa aac atg ttc ggg tgt gag ctt cgg gct atg 954  
Q Q L Q N M L G C E L R A M  318 
cta tgt gtc cct gtc atc agt cga gcc act gac cag gtg gtg 996  
L C V P V I S R A T D Q V V  332 
gcc ctg gct tgc gcc ttc aac aag ctt gga gga gac ttc ttc 1038  
A L A C A F N K L G G D F F  346 
aca gat gag gat gaa cgt gcg atc caa cac tgc ttc cac tac 1080  
T D E D E R A I Q H C F H Y  360 
aca ggc acg gtg ctc acc agt acc ttg gcc ttc cag aag gag 1122  
T G T V L T S T L A F Q K E  374 
cag aag ctc aag tgg tga tgc cag gct ctt ctc caa gtg gca 1164  
Q K L K C E C Q A L L Q V A  388 
aag aac ctc ttc acc cac ctg gat gac gtc tct gtc ctg cta 1206  
K N L F T H L D D V S V L L  402 
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              bp aa 
cag gag atc atc aca gag gcc aga aac ctc agc aac gca gag 1248  
Q E I I T E A R N L S N A E  416 
atc tgc tcc gtg ttc ctg ctg gat cag aat gag ctg gtt gcc 1290  
I C S V F L L D Q N E L V A  430 
aag gtg ttc gat ggc ggt gta gtg gac gat gag agt tat gag 1332  
K V F D G G V V D D E S Y E  444 
atc cgc atc cct gcg gac caa ggc atc gcg ggc cac gtg gcg 1374  
I R I P A D Q G I A G H V A  458 
acc acg ggc cag atc ctg aac atc cca gat gca tac gcc cat 1416  
T T G Q I L N I P D A Y A H  472 
ccg ctt ttc tat cgc ggc gta gac gac agc act ggc ttc cgc 1458  
P L F Y R G V D D S T G F R  486 
acg cgc aac att ctc tgc ttc cct atc aag aac gag aac caa 1500  
T R N I L C F P I K N E N Q  500 
gag gtc atc ggt gtg gct gag cta gtg aac aag atc aat ggg 1542  
E V I G V A E L V N K I N G  514 
cca tgg ttc agc aaa ttt gat gag gac ctg gcc aca gcc ttc 1584  
P W F S K F D E D L A T A F  528 
tcc atc tac tgt ggc att agc atc gct cac tct ctc cta Tac 1626  
S I Y C G I S I A H S L L Y  542 
aaa aag gtg aat           1638  
K K V N            546 
 
 
B-4 Human PDE5A1: N-Terminus with GAF-A and -B 
gi: 61744435 
Chromosome no.: 4 Location: 4q25-q27 
Acc. no.: NM_001083.3 
GeneID (PDE5A): 8654 
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              bp aa 
atg gag cgg gcc ggc ccc agc ttc ggg cag cag cga cag cag 42  
M E R A G P S F G Q Q R Q Q  14 
cag cag ccc cag cag cag aag cag cag cag agg gat cag gac 84  
Q Q P Q Q Q K Q Q Q R D Q D  28 
tcg gtc gaa gca tgg ctg gac gat cac tgg gac ttt acc ttc 126  
S V E A W L D D H W D F T F  42 
tca tac ttt gtt aga aaa gcc acc aga gaa atg gtc aat gca 168  
S Y F V R K A T R E M V N A  56 
tgg ttt gct gag aga gtt cac acc atc cct gtg tgc aag gaa 210  
W F A E R V H T I P V C K E  70 
ggt atc aga ggc cac acc gaa tct tgc tct tgt ccc ttg cag 252  
GE E R G H T E S C S C P L Q  84 
cag agt cct cgt gca gat aac agt gtc cct gga aca cca acc 294  
Q S P R A D N S V P G T P T  98 
agg aaa atc tct gcc tct gaa ttt gac cgg cct ctt aga ccc 336  
R K I S A S E F D R P L R P  112
att gtt gtc aag gat tct gag gga act gtg agc ttc ctc tct 378  
I V V K D S E G T V S F L S  126
gac tca gaa aag aag gaa cag atg cct cta acc cct cca agg 420  
D S E K K E Q M P L T P P R  140
ttt gat cat gat gaa ggg gac cag tgc tca aga tct ttg gaa 462  
F D H D R G D Q C S R L L E  154
tta gtg aag gat att tct agt cat ttg gat gtc aca gcc tta 504  
L V K D I S S H L D V T A L  168
tgt cac aaa att ttc ttg cat atc cat gga ctg ata tct gct 546  
C H K I F L H I H G L I S A  182
gac cgc tat tcc ctg ttc ctt gtc tgt gaa gac agc tcc aat 588  
D R Y S L F L V C E D S S N  196
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              bp aa 
gac aag ttt ctt atc agc cgc ctc ttt gat gtt gct gaa ggt 630  
D K F L I S R L F D V A E G  210
tca aca ctg gaa gaa gtt tca aat aac tgt atc cgc tta gaa 672  
S T L E E V S N N C I R L E  224
tgg aac aaa ggc att gtg gga cat gtg gca gcg ctt ggt gag 714  
W N K G I V G H V A A L G E  238
ccc ttg aac atc aaa gat gca tat gag gat cct cgg ttc aat 756  
P L N I K D A Y E D P R F N  252
gca gaa gtt gac caa att aca ggc tac aag aca caa agc att 798  
A E V D Q I T G Y K T Q S I  266
ctt tgt atg cca att aag aat cat agg gaa gag gtt gtt ggt 840  
L C M P I K N H R E E V V G  280
gta gcc cag gcc atc aac aag aaa tca gga aac ggt ggg aca 882  
V A Q A I N K K S G N G G T  294
ttt act gaa aaa gat gaa aag gac ttt gct gct tat ttg gca 924  
F T E K D E K D F A A Y L A  308
ttt tgt ggt att gtt ctt cat aat gct cag ctc tat gag act 966  
F C G I V L H N A Q L Y E T  322
tca ctg ctg gag aac aag aga aat cag gtg ctg ctt gac ctt 1008  
S L L E N K R N Q V L L D L  336
gct agt tta att ttt gaa gaa caa caa tca tta gaa gta att 1050  
A S L I F E E Q Q S L E V I  350
ttg aag aaa ata gct gcc act att atc tct ttc atg caa gtg 1092  
L K K I A A T I I S F M Q V  364
cag aaa tgc acc att ttc ata gtg gat gaa gat tgc tcc gat 1134  
Q K C T I F I V D E D C S D  378
tct ttt tct agt gtg ttt cac atg gag tgt gag gaa tta gaa 1176  
S F S S V F H M E C E E L E  392
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              bp aa 
aaa tca tct gat aca tta aca agg gaa cat gat gca aac aaa 1218  
K S S D T L T R E H D A N K  406
atc aat tac atg tat gct cag tat gtc aaa aat act atg gaa 1260  
I N Y M Y A Q Y V K N T M E  420
cca ctt aat atc cca gat gtc agt aag gat aaa aga ttt ccc 1302  
P L N I P D V S K D K R F P  434
tgg aca act gaa aat aca gga aat gta aac cag cag tgc att 1344  
W T T E N T G N V N Q Q C I  448
aga agt ttg ctt tgt aca cct ata aaa aat gga aag aag aat 1386  
R S L L C T P I K N G K K N  462
aaa gtt ata ggg gtt tgc caa ctt gtt aat aag atg gag gag 1428  
K V I G V C Q L V N K M E E  476
aat act ggc aag gtt aag cct ttc aac cga aat gac gaa cag 1470  
N T G K V K P F N R N D E Q  490
ttt ctg gaa gct ttt gtc atc ttt tgt ggc ttg ggg atc cag 1512  
F L E A F V I F C Q L G I Q  504
aac acg cag atg tat gaa gca gtg gag aga gtt ctg tcg tat 1554  
N T Q M Y E A V E R A M A K  518
cat gct tca gca gca gag gaa gaa aca aga gag cta cag tcg 1596  
Q M V T L E V L S Y H A S A  532
tta gcg gct gct gtg gtg cca tct gcc cag acc ctt aaa att 1638  
A E E E T R E L Q S L A A A  546
act gac             1644  
V V              548
 
B-5 CyaB1 (alr2266) 
gi: 15553050 
Acc. no.: D89623.2  
GeneID (CyaB1): 1105863  proteinID: BAA13998 
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              bp aa 
atg act ctt ccc aat cct ggt agc gtt ttg gct tcg tta aca 42  
M T L P N P G S V L A S L T  14 
gaa ctg act caa gtt aat cgt acc cac gct tta ttg cgt cgg 84  
E L T Q V N R T H A L L R R  28 
gtc aaa gac ctt tct gtt aac gaa ttt gtt tgc ttg cta gac 126  
V K D L S V N E F V C L L D  42 
ttt atc act gcc gaa tcc gaa caa ttt ctc aga gca att gaa 168  
F I T A E F E Q F L R A I E  56 
ctc att aat aat gaa gcc cta gaa aat atg ttg gag aaa gtg 210  
L I N N E A L E N M L E K V  70 
ttg gaa gca att aca ctg aaa atc ggt caa att ctc caa gca 252  
L E A I T L K I G Q I L Q A  84 
gaa cat aca gcc att ttc tta gtt gac tat gat aaa tgt caa 294  
E H T A I F L V D Y D K C Q  98 
tta tgg tca aaa gta ccc caa gat aat ggg cag aaa ttt tta 336  
L W S K V P Q D N G Q G F L  112
gaa att cgt act ccc att act gta gga att cct ggt cat Gtt 378  
E I R T P I T V G I P G H V  126
gct agt aca ggt caa tat tta aat atc tca gaa act gct act 420  
A S T G Q Y L N I S E T A T  140
cat cct ttg ttt agc cca gga tta gag aga caa atg ggc tat 462  
H P L F S P E L E R Q M G Y  154
aag att aat aat att tta tgt atg cct gtc gtt agt agc aaa 504  
K I N N I L C M P V V S S K  168
gat cca att gtc gca gta gta caa tta gct aat aag aca gga 546  
D Q I V A V V Q L A N K T G  182
aat ata ccc ttc aat cga aat gat gaa gag tct ttt cgt gat 588  
N I P F N R N D E E S F R D  196
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              bp aa 
ttt gct gct tct att ggg att att tta gaa acc tgt caa tct 630  
F A A S I G I I L E T C Q S  210
ttt tat gtt gca gct cgc aat caa cgg gga gtc aca gca ctt 672  
F Y V A A R N Q R G V T A L  224
tta cgc gct act caa aca cta ggg caa agt cta gat tta gag 714  
L R A T Q T L G Q S L D L E  238
gct act ttg caa ata gtg atg gaa caa gcc cga att ttg atg 756  
A T L Q I V M E Q A R I L M  252
cag gca gac cgc agc aca tta ttt ctg tat cgc aaa gaa atg 798  
Q A D R S T L F L Y R K E M  266
ggc gaa ctc tgg act aaa gta gca gca gca gca gat acc aca 840  
G E L W T K V A A A A D T T  280
cag tta ata gaa att cgg att ccg gcg aat cgc ggt att gtc 882  
Q L I E I R I P A N R G I V  294
ggc tat gtg gca tct aca ggc gat gcg ctg aat atc tct gat 924  
G Y V A S T G D A L N I S D  308
gct tat aaa gac ccc cgg ttt gat cca aca aca gac aga aaa 966  
A Y K D P R F D P T T D R K  322
aca ggc tat ttg acc aga aat att ttg tgt ttg cca gtc ttt 1008  
T G Y L T R N I L C L P V F  336
aat tca gcc aat gaa ttg atc gga gta aca cag tta att aat 1050  
N S A N E L I G V T Q L I N  350
aag caa caa gga agt ttt acg gct tct gat gaa gag ttt atg 1092  
K Q Q G S F T A S D E E F M  364
cgg gct ttt aat att caa gcc gga gtt gct tta gaa aat gct 1134  
R A F N I Q A G V A L E N A  378
cgt tta ttt gaa aat gta tta ctc gag aaa caa tat caa aaa 1176  
R L F E N V L L E K Q Y Q K  392
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              bp aa 
gac att tta caa agc ttg tca gat gct gta att tct aca gat 1218  
D I L Q S L S D A V I S T D  406
atg gcc ggg aga att gtc aca att aat gat gca gcc ttg gaa 1260  
M A G R I V T I N D A A L E  420
tta ctc ggt tgt cct tta ggt gat gct aat cat aaa agt aat 1302  
L L G C P L G D A N H K S N  434
aag ctg ctg tgg gaa caa aat tta att ggt cgc gta gtt tgg 1344  
K L L W E Q N L I G R V V W  448
gaa att gta cca att gaa aat ttg cag atg cgc tta gaa gat 1386  
E I V P I E N L Q M R L E D  462
agt tta aaa agt ggt gct aaa cat tat gtg cca gaa caa agt 1428  
S L K S G A K H Y V P E Q S  476
ttg ata gtg gga att tat caa tta caa atg tct gaa agt cgg 1470  
L I V G I Y Q L Q M S E S R  490
gtt ttg cat gaa act caa gac tac tct att ttg aca gta cgc 1512  
V L H E T Q D Y S I L T V R  504
gat cgc atc aac cca gat att ttt ctc ccc tgg aat tta ccc 1554  
D R I N P D I F L P W N L P  518
caa acc ccc cag tcg caa ttt atc acc ccg gaa gaa gta caa 1596  
Q T P Q S Q F I T P E E V Q  532
atc tta gaa cgc agt att aat ctt acc gtt aat cct ttg acg 1638  
I L E R S I N L T V N P L T  546
aac cca gaa ggc ggt gtc cgt ggt ggt ttg gta gtt ttg gaa 1680  
N P E G G V R G G L V V L E  560
gat att agt caa gag aag cgc ctc aaa act act atg tat cgc 1722  
D I S Q E K R L K T T M Y R  574
tac ctt aca ccc cat gta gct gaa cag gta atg gct tta ggg 1764  
Y L T P H V A E Q V M A L G  588
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              bp aa 
gaa gat gcc tta atg gtt ggt gaa cgc aag gag gtg act gtt 1806  
E D A L M V G E R K E V T V  602
tta ttt tca gat atc cga ggc tac acc aca ctt acg gaa aat 1848  
L F S D I R G Y T T L T E N  616
cta ggt gcg gct gaa gtg gta tca ctc ctg aac caa tat ttt 1890  
L G A A E V V S L L N Q Y F  630
gaa aca atg gtt gaa gca gtt ttc aac tat gaa ggc aca ctg 1932  
E T M V E A V F N Y E G T L  644
gat aaa ttt atc ggt gat gct tta atg gct gtt ttt ggt gcg 1974  
D K F I G D A L M A V F G A  658
cca cta cca ctc aca gaa aat cat gct tgg caa gca gta cag 2016  
P L P L T E N H A W Q A V Q  672
tca gca tta gat atg cgc caa cgc ctg aag gaa ttt aac caa 2058  
S A L D M R Q R L K E F N Q  686
cga cgc atc att cag gca caa cca caa atc aaa atc ggt att 2100  
R R I I Q A Q P Q I K I G I  700
ggt att agt tct gga gaa gta gtt tct ggt aac atc ggt tct 2142  
G I S S G E V V S G N I G G  714
cac aag cgt atg gat tac aca gtc att ggt gat ggt gtg aat 2184  
H K R M D Y T V I G D G V N  728
tta agt tcc cgc ttg gaa act gtc acc aaa gaa tat ggc tgt 2226  
L S S R L E T V T K E Y G C  742
gat att atc ctc agt gag ttt act tac caa tta tgc agc gat 2268  
D I I L S E F T Y Q L C S D  756
cgc att tgg gta cgt cag tta gat aaa atc cga gtc aaa ggg 2310  
R I W V R Q L D K I R V K G  770
aaa cac caa gct gtc aat atc tat gag ttg att agc gat cgc 2352  
K H Q A V N I Y E L I S D R  784
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agt act ccc tta gat gac aac acc caa gag ttc ctc ttt cac 2394  
S T P L D D N T Q E F L F H  798
tat cat aat ggt cgg act gcc tac tta gtc cgc gat ttt acc 2436  
Y H N G R T A Y L V R D F T  812
cag gcg atc gct tgt ttt aac tca gct aaa cat att cga ccc 2478  
Q A I A C F N S A K H I R P  826
aca gac caa gct gct aat att cac cta gaa cgc gcc tac aat 2520  
T D Q A V N I H L E R A Y N  840
tat caa caa act cca cca cct cct cca tgg gac ggc gta tgg 2562  
Y Q Q T P P P P Q W D G V W  854
aca att ttc aca aag tag         2580  
T I F T K .          859
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